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ABSTRACT 
Vaccines remain the most effective medical intervention to disease in 
which effective vaccines are available. Designing vaccines that elicit protective 
immunity while minimizing adverse events is difficult. Exacerbating the 
challenges of vaccine design is the increased emphasis on using pure 
preparation of antigens that alleviate safety concerns but also show decreased 
potency. Therefore the need for safe adjuvants to boost immunity of subunit 
immunizations is great.  This work demonstrates the capability of a novel bio-
erodible polyanhydride particle platform to enhance humoral and cellular 
immunity.  Encapsulation of 25 µg of Ovalbumin (Ova) antigen in 
microparticles elicits humoral immune responses equivalent to 1600, 400, and 
100 µg dosages of Ova.  Characterizing the persistence of the nanoparticle 
platform shows that in vivo persistence and immunomodulatory activity can be 
tailored by altering copolymer chemistry. Polyanhydride nanoparticle vaccines 
against Ova show an increased ability to expand CD8+ T cells as compared to 
Alum and soluble Ova. These same polyanhydride nanoparticle vaccines 
expand CD4+ T cells and promote a T follicular helper (CXCR5high PD-1high) 
cell phenotype important for germinal center formation.  The polyanhydride 
platform designed vaccines against H5N1 using a stabilized trimeric H5 
antigen were evaluated in multiple dose and route regimens and elicit 
neutralizing antibody activity and expanded CD4+ cellular recall responses 
	  	   vi	  
when administered subcutaneously.  These results demonstrate that the 
polyanhydride particle platform can be used to effectively enhance immune 
responses in subunit immunizations.   
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CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW 
Introduction 
Vaccinology 
Preventive immunizations remains the most effective therapeutic intervention 
to disease [1]. In 1742, the modern era of immunization began with crude 
preparations of cowpox from lesions administered by Edward Jenner to individuals 
to prevent smallpox. This process was initially termed variolation and this milestone 
in health history both led to insight into mechanism of the evolved mammalian 
immune system as well as establishing immunization as a preventive therapy. Using 
an attenuated cowpox organism to prevent infection by a more virulent smallpox 
organism was the first designed vaccine and the same basic principle for vaccine 
design is used today.  Attenuated whole organisms replicate in vivo, establish low 
levels of infection, and train the adaptive immune system to respond to a more 
virulent version of the attenuated organism. Attenuating organisms present many 
problems however.   
Establishing attenuated organisms can be very difficult due to unforeseen 
genetic mutations of the organism, safety concerns associated with attenuating the 
organism in production, reversion to wild-type, and shedding of organisms into the 
environment [2]. Compounding the difficulties associated with attenuated vaccine 
strains one must consider the complications presented when using whole cell 
organisms or lysates as vaccine preparations.  For example, whole cell lysates 
contain a myriad of phlogistic components in addition to the target immunogen 
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creating problems with purity with the preparation and adverse reactions after 
administration. Whole cell preparations, whether viable or killed, contain components 
of the organism that may lead to undesired inflammatory reactions because of 
conserved microbe associated molecular patterns (MAMPS) that ligate pattern 
recognition receptors (PRRs) of the innate immune system, masking 
immunodominant epitopes, and replicating mechanisms that may incorporate into 
the genome in the cases of attenuated viruses [3-5].  
The subsequent 200 years in vaccine design has evolved. Many of the same 
challenges persist in attempting to recapitulate a low level infection to prevent a 
more detrimental infection later but at the same time not cause overwhelming harm 
to the host as a consequence of immunizations. Inactivation of pathogenic 
organisms was an initial alternative to producing attenuated organisms.  Inactivation 
of organisms leads to complications with antigenic structures, complications of 
inactivating chemicals (i.e. reactive carbonyl groups on proteins), as well as being 
unable to alleviate the MAMPS of an organism that cause detrimental inflammation 
and adverse reactions [6].  
There is a trade off in the benefits of whole cell antigenic preparations. Whole 
cell preparations have the benefit of containing multiple MAMPS that specifically and 
non-specifically act to activate the innate immune system augmenting downstream 
adaptive immune responses [7]. Those same ligands may also lead to detrimental 
non-specific side-effects including inflammation and pain at the site of 
administration. Whole cell antigen preparations also benefit in activation of the 
immune system by providing particulate structure for phagocytic antigen presenting 
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cells (APCs) to uptake the antigen and process for antigen presentation. Finally, 
whole cell preparations also allow for multiple epitopes to be served up as antigenic 
targets.   
Examining alternatives to the use of crude whole cell antigen preparations led 
to methods in which pathogenic organisms were essentially lysed or broken apart 
and components were purified for the purposes of antigenic preparations [8]. These 
lysed antigenic preparations led to increases in purity, which help to alleviate non-
specific adverse events associated with whole cell vaccines as well as focusing 
immune responses towards the antigens of interest.   
Advances in recombinant technology have led to relative ease in production 
of highly purified proteins. This advance in ability to produce and purify proteins of 
interest based on sequence has pushed vaccine antigens to be highly purified, 
essentially having vaccine antigenic preparations consisting of only the antigen of 
interest and not blanketed with other epitopes as would be the case with whole cell 
vaccines.  These vast improvements in purity, and the subsequent reduction in 
adverse events associated with the vaccine, have consequently resulted in less 
robust immune responses because of the elimination of the non-specific immune 
stimulation provided by MAMPs and limiting the number of epitopes to which the 
host can respond.   
Understanding the immunological mechanisms that elicit lifelong protection 
following administration of efficacious vaccines like the highly successful yellow 
fever vaccine or polio virus vaccine [9-11], as well as the vaccine-induced 
mechanisms that cause deleterious effects following immunization with the 
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respiratory syncytial virus incidences of increased disease after administration of a 
formalin inactivated vaccine [12], will pave the road for understanding mechanisms 
to design next generation vaccines using highly pure antigenic preparations.  
 
History of efficacious vaccines 
 As stated earlier, vaccines and the subsequent immune responses elicited by 
them are dependent on different factors in the vaccine preparation (e.g. antigen(s) 
and adjuvant) as well as the route of immunization and genetics/health of the 
vaccinee. The earliest vaccine developed was the attenuated smallpox variolation by 
Edward Jenner, essentially using an attenuated version of a smallpox virus that 
elicited protection from the lethal smallpox virus [13]. The whole cell Bordetella 
pertussis vaccine against whooping cough best exemplifies the classic structure of 
many vaccines discovered and employed in the early to mid twentieth century 
(commonly referred to as first generation vaccines). In 1933, isolated whole cell B. 
pertussis was administered as a preventive and therapeutic treatment against 
whooping cough and provided a modicum of protection and treatment indicating 
efficacy [14]. Many adaptations to the whole cell preparation were tested afterwards 
and the consensus antigenic preparation of the pertussis vaccine consisted of 
washed, concentrated, and inactivated (either by heat of chemical) whole B. 
pertussis [15]. The pertussis vaccine is now commonly administered in conjunction 
with toxoids (DTP) prepared from the toxins from Corynebacterium diphtheriae and 
Clostridium tetani and the immunization regimen consists of three treatments within 
the first year of life with booster immunizations recommended at 2 and 4-6 years of 
	  	   5	  
age [16]. This relatively simple vaccine preparation where a pathogenic organism is 
isolated from a diseased individual, grown, attenuated or inactivated, and 
administered as vaccine antigen was, and is, employed for many of the vaccines 
(influenza virus, polio virus, hepatitis A virus, Measels, Mumps, Rubella, Varicella, 
Rotavirus, Salmonella typhimurium, Yellow fever virus, and Bacillus of Calmette and 
Guerin (BCG)) used today [17].   
 The pertussis vaccine also presents a great allegory into how our increased 
understanding of the immune system and the parallel increased emphasis on drug 
safety has led to a refined focus in next generation vaccine design. Whole cell 
pertussis vaccines (as would all whole cell bacterin vaccines) contained endotoxin 
which would induce adverse vaccine events such as fever (and earlier febrile 
seizures in children), arthus reactions, and pain at the injection site in some people 
[15, 18]. First occurrences of epileptic seizures is hastened by whole cell pertussis 
vaccine administration to epileptic children (often times diagnosed after 
immunization) [19]. These adverse events led to a shift towards use of an acellular 
pertussis vaccine consisting of purified bacterial components of B. pertussis. A 
randomized controlled trial in Sweden demonstrated increased efficacy with an 
improved safety profile of a five B. pertussis component (glutaraldehyde-inactivated 
pertussis toxin, filamentous hemagglutinin, 2 and 3 combined, and pertactin) 
acellular DTP vaccine as compared to a two component acellular DTP and a whole 
cell DTP vaccine [20]. 
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Next generation vaccine design 
 First generation vaccine design was relatively simple: isolate pathogenic 
organism, culture pure organism, attenuate or kill organism, and make a vaccine 
[21]. We now know that the “crude” method will not continue to fulfill the standards of 
safety that public and the regulatory agencies governing medical interventions 
expect and rightly so. The shift in focus towards vaccines of increasing purity to 
improve safety directs the design of next generation vaccines [22]. The increasing 
advancements in recombinant technology also push vaccinology to new heights by 
allowing for manufacture of purified antigens to be used in immunization. This 
increase in purity often leads to decreases in efficacy of the vaccine as compared to 
the traditional whole cell formulations. This decrease in efficacy indicates a need for 
adjuvants (non-specific immune stimulators) and booster immunizations to increase 
potency and efficacy.  
 Adjuvants are commonly referred to as immunologists “dirty little secret” 
because of their use in many first generation vaccine formulations, as well as tools in 
research, without the knowledge defining the exact mechanisms as to how adjuvants 
augment an immune response [23]. Many elegant reviews have now outlined 
general principles of adjuvants and how their use in vaccine design leads to 
enhanced immune responses [21, 22, 24-26]. Here, we outline the general principles 
of what adjuvants can do to improve vaccine efficacy.   
 
Particulate antigen 
 Recombinant technology allows for production of large quantities of purified 
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proteins from a pathogen that are known, or suspected, to be important for the 
induction of a protective immune response. The raison d’être of immunization is to 
capitulate an infection to “train” the adaptive immune response (i.e. cellular and 
humoral immunity) so that there is immunological memory to respond to a much 
more serious pathogenic infection at a later time. This process is dependent on the 
antigen(s) and the ability of the antigens to engage with the phagocytic APCs of the 
innate immune system.  
Innate immunity serves as the initial barrier to protect the host from infection.  
Anatomical and physiologic barriers such as skin, cilia, hair, and degradative 
enzymes found on mucosal surfaces all serve protective functions of exclusion of 
pathogens from the host [23, 27]. The cellular component of the innate immune 
system consists of leukocytes that circulate throughout the host to monitor and 
maintain homeostasis. These leukocytes consist of mast cells, natural killer cells, 
basophils, and eosinophils with specialized effector functions which will not be 
discussed here. The other major components of the innate leukocyte population of 
interest in vaccine design are the phagocytic macrophages, neutrophils, and 
dendritic cells. The phagocytic cell populations fulfill varying levels of antigen 
presentation functions for initiating adaptive immune responses in the secondary 
lymphoid tissues with the most professional antigen presentation being performed by 
the dendritic cells (with varying subsets), then the macrophages and some 
presentation by neutrophils [28-31].  
For the initial purpose of targeting the antigen towards these critically 
important cell populations, it is key for vaccines to have a particulate structure [32, 
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33]. Recombinant antigens are quite miniscule in scale as compared to the 
corresponding whole cell or virion that the antigens are derived from. By having the 
antigen delivered in the context of a particulate structure, the APCs of the innate 
immune system can phagocytose the antigen similar to the process the APCs would 
use to clear viruses or bacteria.  
Common adjuvants used for many years in immunological research, as well 
as some current vaccines, do provide a particulate structure when adjuvanting 
protein antigens. Liposomes, virosomes, synthetic particles (nano, micro), 
immunostimulatory complexes (ISCOMs), aluminum salts (Alum), water-in-oil 
emulsions (Freund’s adjuvant), and oil-in-water emulsions (MF59) all create a 
particular structure when combined with antigen that is larger than soluble antigens 
as well as mimicking the size of the pathogens being targeted against [24]. 
APCs (dendritic cells (DCs) and macrophages) bridge the chasm between 
innate and adaptive immunity by continued immune surveillance in the tissues and 
phagocytosing foreign substances [34]. APC interaction with antigen, whether in the 
form of the pathogen or particulate structure, can be directly affected by the size.  
Rettig et al found that particles containing the same Toll-like receptor (TLR) ligand 
that activates plasmactyoid dendritic cells (pDCs) to mature and secrete pro-
inflammatory cytokines show different cytokine profiles when particles are ~220 µm 
compared to ~1200 µm particles [35]. The smaller particles led to more IFN-α, a 
typical anti-viral inflammatory cytokine response, and larger particles led to a more 
TNF-α indicating a more pleiotropic inflammatory response.   
Phagocytosis of antigens by APCs leads to intracellular trafficking towards a 
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phagolysomal compartment where the antigens can be broken down for 
presentation to the adaptive immune system by lysomal degradative enzymes [36]. 
The interaction of the phagosome compartment containing the phagocytosed 
materials and the subsequent lysosome fusion may be effected by the particle size 
phagocytosed [37]. The optimal size for phagocytosis of particles and antigenic 
particles is < 500 µm as compared to larger materials [38-42]. Particles of < 200 nm 
are able to directly drain to secondary lymphoid tissue by lymphatic vessels and 
arrive in the lymph nodes within minutes while particles 200 to 500 nm in diameter 
do so less efficiently [43]. In contrast, particles of 200 nm to 2 µm in diameter require 
APC trafficking for optimal delivery to lymph tissue arriving approximately 24 hours 
after administration [41].  
Particulate antigen also benefits from controlled presentation to T cells and B 
cells in the secondary lymphoid tissue. The conduit system transfers and shuttles 
soluble antigen to initiate early primary immune responses (i.e., expansion and 
differentiation of naïve antigen specific T cells and B cells) in the secondary 
lymphoid tissue [44-46]. Particulate antigens, while being phagocytosed and 
trafficked to secondary lymphoid tissues through the traditional APC maturation 
pathway as well as being captured by macrophages in the medulla, benefit from 
sustained presentation to follicular B cells by subscapular sinus macrophages [47]. 
Subscapular sinus macrophages provide a sustained presentation of particulate 
antigens to follicular dendritic cells, a specialized cell in the secondary lymphoid 
follicles that retains immune complexes on the surface via complement receptors 
[48]. These follicular dendritic cells can then retain immune complexes on their 
	  	   10	  
surface for continued antigen presentation resulting in retention of B cells in the 
germinal center and generation of affinity matured memory B cells and plasma cells 
[49, 50]. 
Creating a particulate antigen for design of vaccines produces a larger 
surface area of the particle for receptor or membrane interaction with the APC(s).  
Particulate antigens also present charge differences that dictate APC interaction with 
the particle. Protein opsonins or humoral pattern recognition molecules (PRMs) such 
as innate natural IgM, complement protein components, pentraxins, and serum 
amyloid proteins all bind to repetitive structures in vivo which lead to subsequent Fc 
or complement receptor based interaction and phagocytosis by APCs [51-53]. 
Particulate antigens provide this repetitive structure. Hydrophobicity of the 
particulate antigens plays an important role in the binding of the protein opsonins as 
well [54, 55]. Many of the protein opsonins are thought to be evolutionarily early 
forms of antibodies, or innate antibodies in the case of natural IgM, that function to 
bind to hydrophobic residues for targeting to phagocytes for degradation or antigen 
presentation [43, 56-58]. 
 
Repetitive structure 
Pathogens, especially viruses, often contain a highly ordered surface 
structure of proteins, carbohydrates and/or lipids. These highly ordered surface 
structure are important for engaging the conserved ‘danger’ signaling mechanisms 
of the innate immune system as the host does not often exhibit such order [59]. 
Particulate antigens that exploit the repetitive structure show a strong induction of 
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IgM because they are able to engage B cell receptors directly leading to T cell 
independent antibody responses solely based on antigen repetition at approximately 
5-10 nm apart [60]. All vaccines adjuvanted to create particulate antigens most likely 
exhibit some antigen repetitiveness as compared to soluble antigens.   
 Virus-like particles (VLPs) are the most efficient particulate antigen system at 
achieving this 5 to 10 nm particulate spacing [26]. Translation of the capsid protein in 
conjunction with the surface proteins, or antigens, of interest results in a virus 
particle devoid of nucleic acid material making it effectively neutered from replication 
[61]. Many different VLP constructs have been produced and using molecular 
genetics techniques allows for many proteins to be expressed on the VLP surface 
[61, 62].   
Emulsion based adjuvants are used to create particulate of varying sizes 
based on differences in oils and techniques used. Oil based adjuvants have long 
been used in vaccines with complete Freund’s adjuvant (CFA) consisting of a water 
in mineral oil emulsion with dried and inactivated Mycobacteria added as an 
immunopotentiator. Incomplete Freund’s (IFA) is the water in oil (W/O) emulsion 
without the Mycobacteria. Presumably the antigen would be ordered in the emulsion 
particles especially in W/O adjuvants that retain the antigen in the particle for up to 3 
weeks in vitro compared to water-oil-water (W/O/W) and oil in water (O/W) 
(equivalent of MF59) emulsions [63].  
 Biodegradable particle adjuvant systems could provide the same repetitive 
antigenic structure. Antigens are often encapsulated into biodegradable materials 
such as poly(dl-lactic-co-glycolic acid) (PLGA), poly(amino acid)s, and 
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polyanhydrides all effectively augment the induction of an immune responses [64, 
65]. Many different size ranges can effectively be created by altering fabrication 
processes with these biomaterials thus leading to antigen dispersal within the 
particle. Small amounts of antigen in a large diameter particle may lead to large 
gaps between antigens on the surface of the particles while that same amount of 
antigen in smaller diameter particle will lead to tighter spacing of antigens thus 
effectively poising the particle for B-cell receptor ligation.   
Jegerlehner et al demonstrate that IgG, but not IgM, can be enhanced with 
this structured spacing of antigen using nanoparticles expressing 60 epitopes at 5 to 
10 nm spacing [66]. Structured antigen of inactivated vesicular stomatitis virus 
glycoprotein (VSV-gP) was able to break tolerance in a mouse model expressing 
VSV-gP as a self protein while administration of soluble VSV-gP induced no immune 
activation [60, 67, 68]. Complement activation is enhanced by repetitive antigen 
structures thus leading to more efficient CD19-21 complex ligation on B cells [69].  
The increased ligation of CD19-CD21 decreases the amount of BCR ligation needed 
to activate transcription factors crucial for plasma cell generation [70-72]. These 
benefits appear largely T cell independent but as stated earlier, protein opsonins 
such as complement and natural IgM enhance particulate antigen uptake to APC’s.  
Repetitive antigen structure facilitates enhanced opsonin binding leading to greater 
uptake of antigen by phagocytic APC’s, thus leading to greater T cell activation 
indicating the benefits of repetitive antigen structure on T cell activation. 
Complement components C3b and C4b have also been attributed to T cell activation 
through receptor interactions between T cell co-receptors CD46, CD55, and CD59 
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again indicating how repetitive antigenic structures can function to enhance cellular 
immune responses [73].  
 
Innate pathogen recognition receptors  
Repetitive structures contributing to immune activation via receptor linking 
and innate opsonin ligation leading to uptake demonstrate important factors in the 
host determining non-self components. A burgeoning area of research into initiation 
of immune responses has been the repetitive structures of pathogen associated 
molecular patterns (PAMPs) and how these conserved components of pathogens 
lead to activation of innate immune APCs via evolutionarily conserved intra and 
extracellular pattern recognition receptors (PRRs). The most familiar PRRs are the 
Toll-like receptors (TLRs) first described in drosophila [74] but also include the 
nucleotide oligomerization domain (NOD) like receptors (NLRs), C-type lectin 
receptors (CLRs), retinoic acid-inducible gene (RIG-I) like receptors (RLRs) [75].   
These PRRs sense the cellular environment and, when ligated, begin a cascade of 
intracellular signaling leading to transcription of inflammatory mediators such as 
Type I interferons, proinflammatory cytokines like tumor necrosis factor (TNF), IL-1ß, 
IL-6, and other cytokines and chemokines. These conserved danger receptors of the 
innate immune system are not only expressed by phagocytic APCs but are also 
located on the cell surface of T and B cells and non-myeloid epithelial cells, 
endothelial cells, and fibroblasts. 
The PRRs serve to recognize conserved, and most times highly structured, 
components of pathogens that are relatively static. PRRs also have a self-sensing 
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component in recognizing damage associated molecular patterns (DAMPs) of cell 
death leading to immune activation. TLRs remain the most characterized forms of 
PRRs. TLRs contain a Toll/IL-1R homology (TIR) domain that extends into the 
cytoplasm from the membrane allowing for downstream signaling after sensing 
extracellular or intracellular pathogens within membrane bound compartments [76].  
TLR2 forms heterodimers on the plasma membrane with either TLR1 or TLR6 
recognizing different forms of lipoproteins on bacteria, viruses, and parasites as well 
as some self components. TLR4, TLR5, and TLR11 are the other extracellular TLRs 
and recognize lipopolysaccharide (LPS), bacterial flagellin, and a profilin-like protein 
of protozoa, respectively. Endolysosomal TLRs recognize structural components of 
viral replication such as dsRNA, ssRNA, and CpG-DNA that ligate TLR3, TLR7 
(mouse) or TLR8 (human), and TLR9, respectively. TLR10 is another endolysomal 
sensor found in humans but is yet uncharacterized as far as ligands recognized but 
is up-regulated by reactive oxygen species in a human monocyte cell line [77]. The 
compartmentalization of the endosomal TLRs serves to protect the host from 
aberrant inflammatory responses to self components that resemble the ligands of 
those TLRs [78]. TLR ligation leads to signaling cascades dictated by the adaptor 
molecules recruited to the TIR domains. The major adaptor molecule recruited to 
most TLRs with the exception of TLR3 is MyD88. MyD88 recruitment leads to an 
intracellular signaling cascade that concludes with translocation of the transcription 
factor NF-κB leading to pro-inflammatory cytokine transcription. Type I IFN 
transcription is also dependent on MyD88 via the translocation of interferon 
regulatory factor (IRF) 1 and 7 via TLR7 and TLR9 ligation [79]. TIR domain 
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containing adaptor inducing IFN-β (TRIF) is the other major adaptor protein recruited 
to TLR3 and TLR4. Recruitment of TRIF leads to a signaling cascade resulting in 
translocation of NF-κB, IRF3, and IRF7 [79, 80].  
 The RLR family are intracellular PRRs located in the cytoplasm that are up-
regulated by type I IFNs and recognize genomic double stranded RNA (dsRNA) and 
dsDNA from viral replication [81]. RIG-I, melanoma differentiation-associated gene 5 
(MDA5), and LGP2 make up the RLR family and recognize short dsRNA (up to 1kb) 
and dsDNA, long dsRNA (greater than 2 kb), and modified viral RNA (speculative), 
respectively [75, 82]. RLR structurally contain a C-terminal regulatory domain, which 
binds dsRNA ligands, as well as two N-terminal caspase recruitment domains 
(CARDs) (except in the case of LGP2) and a central DEAD box helicase/ATPase 
domain. The CARD domain triggers the signaling cascades resulting in transcription 
of type I IFNs via IRF3 and IRF7 transcription factors and NF-κB.  
 NLRs are also cytoplasmic PRRs that exhibit leucine rich repeat (LRRs) 
regions responsible for binding and make up portions of larger signaling complexes 
termed signalosomes and the inflammasome [83].  The signalosome and 
inflammasome are part of large inflammatory cytokine regulatory unit used to control 
inflammatory caspases needed to cleave pro IL-1β into the mature active IL-1β form 
for subsequent release [84]. There have been 14 genes identified with NALP 
receptors, non CARD carrying NLRs, and six genes identified with NOD receptors, 
CARD carrying NLRs, in humans [85]. Much like extracellular surface TLRs, NOD1 
and NOD2 recognize conserved structures of the gram positive bacterial cell wall 
peptidoglycan, specifically g-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and 
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muramyl dipeptide (MDP) which are often degraded components of the bacteria 
after phagocytosis. The NOD signalosome essentially consists of NOD receptors 
engaged with kinases through CARD domain interactions leading to activation of 
NF-κB [86]. Similarly NALPs provide a framework for the high molecular weight 
signaling complex termed the inflammasome. Inflammasomes are subsequently 
responsible for recognizing bacterial toxin components as well as cell wall 
components similar to NODs. Inflammasome signaling has also been associated 
with danger associated molecular patterns (DAMPs) of self, indicating cellular 
damage such as uric acid, extracellular ATP, and reactive oxygen species [87-89].  
 Finally, CLRs are transmembrane receptors capable of binding conserved 
carbohydrate sequences of pathogens [90]. CLRs are generally divided into 
mannose receptor families and the asialoglycoprotein receptor family. CLRs are 
responsible for signaling uptake by the phagocytic antigen-presenting cell as well as 
downstream signaling leading to pro-inflammatory cytokine secretion. Signaling 
mechanisms of CLRs are vague but most CLRs contain an immunoreceptor 
tyrosine-based activation motif (ITAM) similar to what is found on B cell and T cell 
receptors that eventually leads to NF-AT and NF-κB dependent transcription of pro-
inflammatory cytokines.  
 A major action of adjuvants is to interact with these innate immune receptors 
to activate APCs leading to presentation of antigen and initiating a robust adaptive 
immune response against the antigen of interest by influencing the T cells and B cell 
polarizations through antigen presentation and cytokine secretion. The interactions 
with the conserved PRRs to the ligands, either from the pathogen or the host danger 
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signals, are not exclusively single events but rather elegant events of multiple 
interactions and thus multiple synergistically signaling events, as evidenced by 
common vaccine formulations being able to elicit robust immune responses in the 
absence of TLR signaling mechanisms [91]. Formulations of vaccines, either 
adjuvanted or non-adjuvanted, interact with these conserved receptors to activate 
and get past the hurdles of the innate immune system barrier to activate adaptive 
immunity. Obviously, whole cell vaccines maintain the integrity of the microbe thus 
interacting with the host (i.e., APCs) in a similar manner as would the target 
pathogen. As stated before, subunit or purified vaccine preparations lack many of 
the immune stimulating ligands of the whole cell and, thus, adjuvants are utilized. 
Documented adjuvant interactions with these conserved PRRs explained earlier are 
outlined in Table 1 adapted from Takeuchi et al and Coffman et al [33, 75]. 
Table 1. Pattern recognition receptors and the adjuvants that exploit their 
mechanism  
PRRs Ligand Adjuvant Output 
TLR1/2 Triacyl lipoprotein (bacteria) Pam3CSK4 (synthetic lipoprotein)[92, 93], alkane 
polymeric particles [94] 
Ab, CD8+ (DNA 
priming) 
TLR2/6 Lipoprotein (bacteria, virus, 
parasites, self) 
Macrophage-activating lipopeptide-2 (MALP-2) [95], 
alginate biomaterials [96], modified vaccinia virus 
Ankara (MVA) [97] 
Ab 
TLR3 dsRNA (virus) Polyriboinosinic:polyribocytidylic acid (Poly I:C) [98]  Ab, CD4+ 
TLR4 LPS (bacteria, virus, self) MPL, AS04 (MPL + Alum) [99], Ribi.529 [100], 
alginate biomaterials [96], hydroxyapatite [101] 
Ab, CD4+ 
TLR5 Flagellin (bacteria) FliC [102] Ab, CD4+, CD8+ 
TLR7 ssRNA (virus, bacteria, self) Imidazoquinoline [103], SM360320 [104] Ab, CD4+, CD8+ 
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Table 1 (continued) 
TLR9 CpG-DNA (virus, bacteria, 
protozoa, self) 
CpG ODN, CpG 7909 [105], IC31 [106] Ab, CD4+, CD8+ 
 
TLR11 Profilin-like molecule 
(protozoa) 
Eimeria tenella profilin-like protein [107] Ab 
RIG-I Short dsRNA, 5’ triphosphate 
dsRNA (virus) 
DNA vaccine vectors alone or expressing RNA [108] CD8+ 
MDA5 Long dsRNA (virus) MVA [97], Poly I:C [109]  
LGP2 (virus) Inactivated WNV vaccines [110]  
NOD1 and NOD2 Peptidoglycan components 
(bacteria) 
iE-DAP, MDP [111]  
NALP3 β-Glucan alkane polymeric particles [94], poly(lactide-co-
glycolide) (PLG) [112], MVA [97], Alum [113] 
 
Dectin-1 β-Glucan (fungi) Curdlan [114] CD8+ 
Dectin-2 β-Glucan (fungi) Ara h 1 [115]  
MINCLE SAP130 (self, fungi) CFA (trehalose dimycolate (cord factor) of 
Mycobacteria [33], CAF01 [116]  
Ab 
 
Antigen exposure kinetics 
 The final hallmark of next generation vaccine design is to recapitulate the 
kinetics of antigen exposure similar to a pathogenic infection. Killed, attenuated, or 
subunit vaccines face the greatest hurdle in this arena because the antigen does not 
replicate resulting in an antigen exposure curve where the peak amount of antigen 
presented to the immune system occurs very quickly and then rapidly wanes (Figure 
1). For soluble antigens, that antigen exposure is lost very quickly as the antigen is 
Table 1. 
Table outlines common PRRs, the ligands they bind of pathogens, the adjuvants that exploit the 
receptors, and the enhanced immune phenotype.  
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cleared from the system often resulting in the induction of poor protective immune 
responses. Replicating pathogens provide a sustained antigen exposure resulting in 
a continued training regimen for the immune response to establish quality immune 
memory. A major mechanism of adjuvants in vaccines is to provide a controlled 
release of antigen either through depot effect or mechanisms of antigen exclusion. 
The prolonged antigenic exposure curve (Fig. 1, red line) is a major mechanism 
associated with establishing and maintaining protective immunity to viral infections 
[117, 118]. Low dose injections of a total fixed 125 µg dose of antigen amount given 
in daily dosing regimen of increasing amount of antigen, thus, replicating a 
replicating pathogenic infection, has been shown to be more effective in eliciting T 
cell responses compared to injections involving the same amount of antigen at each 
time [119]. These extended antigen exposures also lead to improved T cell memory 
that can overcome the need for T cell co-stimulation [120, 121].  
Immunization schedules involving multiple injections to replicate this antigen 
exposure are often not feasible because of decreased patient compliance and 
increased cost. Single dose vaccines that are able to provide protective immunity 
through alteration of these antigen release kinetics are ideal. The feasibility of single 
dose immunizations is dependent on the ability of the adjuvant to provide particulate 
and repetitive structure, immunomodulatory activity of innate immune receptors and 
altering in vivo antigen kinetics, as well as the immunogenicity of the antigen, 
protective epitopes being targeted, and immune phenotypes elicited by the vaccine.  
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 The designing of next generation vaccines, using the principles outlined 
above, will be driven by the need to develop efficacious vaccines against eminent 
pandemic pathogens.  One pandemic pathogen that is heavily studied and 
speculated to become the next pandemic is the highly pathogenic influenza A virus 
H5N1 emerging from Asia. The following review outlines the pathogenesis of H5N1 
and how the potential pandemic potential of the virus has led to innovation in 
vaccine and post-exposure therapeutic design deviating from traditional seasonal 
influenza.  
 
 
 
 
 
Figure 1. Antigen exposure kinetics of vaccines and how similar those kinetics can be 
altered with adjuvants to mimic a replicating pathogen infection. A theoretic table outlining 
the kinetics of soluble antigen vaccine (green curve) in which the peak amount of antigen is 
exposed immediately after administration.  A mechanism of adjuvants allows for sequestration 
of antigen for continued exposure altering the kinetics of clearance by the immune system.  This 
shift comes closer to the kinetics of antigen exposure of a pathogen in which replication occurs 
allowing for a continued antigen exposure until the immune system can eliminate the infection. 
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CHAPTER 2: THE REQUISITE OF PREPAREDNESS DRIVING INNOVATION IN 
PANDEMIC H5N1 INFLUENZA VACCINES AND PREVENTIVE THERAPIES 
A review paper to be submitted to Vaccine 
Lucas Huntimer, Kathleen Ross, Balaji Narasimhan, and Michael Wannemuehler 
 
Abstract 
The potential human pandemic resulting from highly pathogenic avian 
influenza (HPAI) H5N1 has been rigorously studied since the identification of the 
virus in the Guangdong province of China. The majority of research has focused on 
the unique and severe tissue damage induced by the viral infection. These severe 
pathological lesions have also prompted investigators to evaluate various 
immunological approaches to induce protective immunity against HPAI, which will be 
discussed in this review. 
 
Introduction 
Influenza A virus is a single strand negative sense RNA virus of the 
Orthomyxoviridae family.  The genome of influenza contains eight segmented RNA 
strands. The negative sense orientation of the RNA in the genome leads to 
replication dependence on a low fidelity RNA polymerase allowing a myriad of 
mutations contributing to antigenic diversity, which is called genetic drift [122]. The 
segmented genome also allows for re-assortment of the segments to take place 
between different viruses infecting the same host cell leading to genetic shift [123]. 
Genetic shift is the basis for the sub-classification of the influenza virus based on the 
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sixteen subtypes of hemagglutinin (HA) surface proteins, which bind the sialic acid 
(SA) receptors on epithelial cells of the host’s respiratory tract, and the nine 
subtypes of neuraminidase (NA) surface proteins, which cleave the SA of the host 
cell allowing release of the virus. These surface proteins are the primary neutralizing 
antigens towards which host antibody responses are directed.   
A distinct classification of avian H5N1 influenza viruses based on their 
pathogenicity in chickens was first identified from a geese population in the 
Guandong province of China in 1996 [124]. This lineage of highly pathogenic avian 
influenza (HPAI) H5N1 viruses has since been detected in over 60 countries. 
Because of the genetic drift of influenza viruses, genetic sub-classifications of clades 
of HPAI viruses have been created based upon their hemagglutinin sequence [125, 
126]. The evolution of the HPAI viruses has led to classification of a particular HPAI 
genotype into clades of heterogeneity.  
The avian H5N1 influenza binds preferentially to SA linked to galactose with α 
2-3 linkages that are characteristic of avian cells in comparison with α 2-6 SA 
linkages to galactose in the upper human respiratory tract (that bind typical seasonal 
H3N2 and H1N1 viruses) and both α 2-6 SA and O-linked α 2-3 SA linkages that 
bind both human and avian influenza viruses [127-129]. Because of the preferential 
binding of avian SA, HPAI H5N1 has not been able to efficiently spread from human 
to human although suspected human to human transmission has been reported 
[130]. The swine respiratory tract contains both α 2-3 and α 2-6 SA making the pig a 
potential mixing vessel for genetic re-assortment [131]. Because of the ability of 
influenza to mutate very quickly, there are concerns that the mutations needed to 
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change binding preferences for SA linkages from the avian α 2-3 to the human α 2-6 
could lead to a global pandemic, similar to the global spread of the H1N1 pandemic 
of 2009 [129]. Recent work with serial passage of the wild type virus in ferrets, the 
preferred animal model for recapitulating human responses to influenza because of 
sialic acid receptor distribution and pathological similarities, has demonstrated that 
the virus will adapt to airborne transmission albeit with a loss in pathogenicity [132-
134].  These studies, while generating controversy within the scientific community, 
are essential to the understanding of the virus and the capabilities of the HPAI H5N1 
to evolve and adapt if sufficient selective pressure is placed on the virus.   
HPAI H5N1 influenza infection in humans is attributed to extended viral 
replication in tissue sites beyond the respiratory tract as well as increased host 
inflammatory responses as compared to seasonal influenza infections [135-137]. 
Mutations in the HA viral sequence leading to multiple basic amino acids at the HA 
cleavage site of HPAI viruses skews the ability of the virus to replicate in multiple 
tissue sites as compared to other influenza viruses being restricted to the respiratory 
Figure 2.  
The H5N1 virion capsid encloses an eight segmented, negative sense RNA genome. The 
virion also contains a lipid envelope with several major glycoproteins: hemagglutinin (HA), 
neuraminidase (NA), and ion channels (M2 proton channels).  
	  	   24	  
tract [138, 139]. The multibasic cleavage site leads to an increased ability for 
cleavage needed for viral attachment. The ubiquitous distribution of replicating HPAI 
virus contributes to an overabundant antiviral immune response. Human peripheral 
blood derived macrophages infected in vitro with H5N1 exhibited increased release 
of the cytokines TNF-α, IL-6, IL-1β, IL-10, and IFN α and β as well increased release 
of the chemokines RANTES, MCP-1, MCP-3, MIP-1α, and MIP-1β [140-142].  In 
vitro infection of bronchial alveolar epithelial cells showed an increase in IFN-β, 
RANTES, and CXCL10 early in infection as compared to a seasonal H1N1 virus 
[143]. These detrimental inflammatory responses were attributed to the increased 
cytokine (IL-6, IL-8, and IL-10) and chemokine responses (CXCL10 and MCP-1) 
measured in the plasma of patients with increased viral load [91, 136, 137]. 
Approximately half of the cases of human H5N1 infections demonstrated the wide 
tissue tropism of viral replication [144]. Primate studies have disputed the wide 
tissue tropism of H5N1 replication seen in the liver and intestines of human patients 
in that the virus was only demonstrated to replicate in the lung but little in other 
tissue sites [145]. Nevertheless, the increased systemic viral loads as well as the 
hypercytokinemia and hyperchemokinemia in the respiratory tract are believed to be 
root cause of the severe tissue damage associated with H5N1 infection compared to 
seasonal influenza.    
The histopathological changes associated with H5N1 influenza infection are 
characteristic of acute respiratory distress syndrome (ARDS) in which there is 
pulmonary congestion caused by cellular infiltrate of innate and activated adaptive 
immune cells as well as alveolar epithelial cell apoptosis [127]. Leukopenia, 
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gastrointestinal symptoms, renal dysfunction, and liver dysfunction have also been 
reported [144, 146, 147]. Traces of virus sequence and antigens have also appeared 
in brain and cerebrospinal fluid [136, 139]. Evidence of HPAI infecting the placenta 
and subsequently the virus is able to be vertically transmitted [139, 148].   
Immune surveillance is still lacking concerning the prevalence of H5N1 in the 
human population. Recent epidemiological surveillance studies suggested that 9.1% 
of rural Thai villagers have antibodies against one of two H5N1 viruses suggesting 
subclinical prevalence [149]. Although the severity of disease associated with H5N1 
human infections can be disputed based on this limited evidence of subclinical 
infections, it is very important to be prepared against a pandemic due to the 
unfamiliarity of the H5 HA to the human population.   
 The severe tissue damage associated with H5N1 infections in humans, the 
increased risk of secondary infections due to subsequent immunocompromise, as 
well as the high frequency of mutation of influenza virus which could lead to human 
to human transmission, have motivated research in the realm of preventive 
therapeutic approaches against HPAI. This section will focus on the traditional 
seasonal influenza vaccines and the possibility of using those approaches for 
pandemic preparedness to H5N1 as well as emerging vaccine and anti-viral 
technologies being explored to which may facilitate pandemic preparedness. 
 
Inactivated viral vaccines 
The traditional seasonal influenza vaccine consists of formaldehyde or β-
propiolactone inactivated virus propagated in embryonated hen eggs [150], and 
	  	   26	  
more recently, propagation of influenza virus in Vero cell cultures to replace hen egg 
propagation [151]. The antigenic components of the vaccine are either administered 
as whole inactivated virion, purified subunit of surface glycoproteins, or chemically 
split virus vaccine consisting of viral components. These different formulations of 
seasonal influenza vaccines may, therefore, be applied towards stockpiling H5N1-
specific vaccines for pandemic preparedness. Production and distrubution of 
seasonal influenza vaccines are based on epidemiological studies to closely match 
antigenic profiles and previous exposure to influenza [152]. With respect to HPAI 
H5N1, the human population will be immunologically naive due to the fact that 
seasonal influenza A virus vaccines contain H1 and H3 (and not H5) HA [4].  
Inactivated influenza virus vaccines can result in rubor and tumor at injection 
sites with frequency of incidence dictated by age but no differences from placebo 
were observed [153-155]. People with egg albumin allergies are also not able to be 
administered the traditional mass-produced inactivated vaccines because of hen egg 
virus propagation. The main conundrum of using traditional seasonal inactivated 
influenza virus vaccine technologies to produce pandemic vaccines is the time 
needed for production of the virus and manufacturing of the vaccines. Typical mass 
production timelines are estimated to be 6-9 months [156]. A dominant pandemic 
strain would need to be identified prior to vaccine production which would delay 
when the vaccine could make it to clinics and undermine the benefits of prophylactic 
immunization programs.    
The immune response elicited by inactivated influenza virus vaccines is 
predominately humoral. Antibody responses are typically directed towards the 
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surface glycoproteins HA and NA. Systemic antibody specific for HA and NA is 
predominately IgG1 with some IgM and IgA being identified and protective antibody 
responses being elicited within two weeks post-vaccination [157]. IgG and IgA 
specific antibody secreting cells have been identified in peripheral blood following 
vaccination [158]. The IgG isotypes associated with these humoral responses can 
be attributed to the prime/boost benefits provided by the previous year’s 
vaccinations [159]. Combinations of antiviral NA inhibitors with inactivated virus 
vaccines may also be an effective treatment regimen during an influenza pandemic 
disease outbreak due to little interference with the humoral response in clinical 
studies [160]. Inactivated viral vaccines can also elicit stronger influenza antigen-
specific proliferative responses of T cells isolated from the palatine tonsils or 
peripheral blood, although this may also be attributed to the prime/boost responses 
subsequent to either natural seasonal influenza infection or previous vaccinations 
[157, 161-163].  
Studies with inactivated HPAI H5N1 prepared and administered similarly to 
licensed seasonal vaccines still present the most viable option for pandemic 
formulations due to the vaccine not having to undergo licensure but rather be 
considered a new strain of influenza added to an existing licensed product to 
alleviate regulatory delays. Inactivated subvirion (chemically split measured by HA 
units) H5N1 virus vaccines were shown to provide virus neutralization titers in 54 
percent of individuals receiving two doses of 90 µg of HA units, which is 
approximately six times the dose of seasonal influenza vaccines [164, 165]. A TLR7 
dependent mechanism associated with increased immunogenicity of inactivated 
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H5N1 vaccines, because of residual viral RNA in the preparation, has been identified 
[166]. Aluminum salt adjuvanted inactivated split virion H5N1 vaccines were able to 
elicit 67% HA inhibition in patients after two doses of 30 µg HA [167]. After 
vaccination, immunological responses to split virion H5N1 were greater in infants 
and children [168]. Additionally, inactivated, whole virion H5N1 vaccines were able 
to produce 78 % seroconversion when administered in a two dose regimen with 
aluminum salts at a dosage of 10 µg of HA [169]. Vero cell derived and inactivated 
H5N1 vaccines induced similar humoral immune responses with and without Al(OH)3 
adjuvant [170].    
 
Cold adapted attenuated viral vaccines 
Influenza vaccine options were expanded by the licensure of a cold adapted 
live seasonal influenza vaccine (Flumist®, Aviron Gaithersberg, MD). Cold adapted 
live influenza viruses are based on the master strain A/Ann Arbor/6/60 (H2N2) being 
attenuated by passaging the virus through decreasing temperatures in embryonated 
hen eggs. The continuous passage through decreasing temperatures allows for 
mutational adaptations in the polymerase (PA), PB1, PB2, and M genes of influenza 
leading to the cold adapted phenotype in which replication is restricted to 33oC in the 
upper respiratory tract [171]. The cold adapted virus expressing the HA and NA of 
interest, either the seasonal influenza strains or pandemic strains, is produced by 
genetic reassortment [172]. The modified live cold adapted influenza virus allows for 
an intranasal vaccination that mimics the natural infection in both site and mode of 
infection but under the virus replicative constraints of the upper respiratory tract. The 
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upper respiratory replication of the virus allows for lower doses of influenza antigen 
to be administered in order to induce an effective immune response.   
The cold adapted influenza virus seasonal vaccines have shown cross-
reactive immune responses to other antigenically drifted H1N1 and H3N2 strains 
[173-175]. This cross reactivity could prove extremely beneficial in the stockpiling of 
pandemic influenza vaccines because prediction of the antigenically drifted strain of 
influenza will be difficult [176]. The intranasal route also allows for ease of 
administration by individuals with minimal professional training during a pandemic 
situation.   
Cold adapted H5N1 virus vaccines were able to provide incomplete protection 
after single dose vaccinations with homologous and heterologous viral challenge but 
two dose regimens (prime/boost) provided heterologous cross protection in 
laboratory models [177]. Safety and toxicological profiles of the cold adapted H5N1 
vaccines were favorable in the ferret model [178]. Clinical evaluations of a cold 
adapted influenza vaccine containing the H5 and N1 outer glycoproteins of two 
H5N1 isotypes A/Vietnam/1203/2004 and A/Hong Kong/213/2003 on the A/Ann 
Arbor/6/60 show limited viral replication leading to nominal neutralizing humoral 
immune response [176]. Immune responses were elicited using a low pathogenicity 
avian influenza A/Duck/Potsdam/1402-6/86 (H5N2) genetically reassorted to a cold 
adapted A/Leningrad/134/17/57(H2N2) that show cross reactivity to an H5N1 strain 
in a HA inhibition test [179]. Interestingly, a cold adapted vaccine consisting of HA 
and NA of the 2009 pandemic H1N1 was able to protect mice from lethal H5N1 
challenge [180, 181]. 
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Reverse genetics derived virus 
The traditional method of genetic re-assortment of influenza virus for vaccines 
in embryonated hen eggs can be inefficient and variable. Recent advances in 
molecular biological techniques have allowed for the formation of infectious influenza 
A virus completely from plasmid cDNA expression of the viral RNA segments 
transfected in human embryonic kidney cells (293T) or Madin-Darby canine kidney 
(MDCK) cells [182, 183]. The reverse genetics system of creation and propagation 
of influenza virus allows for molecular manipulation of the genetic elements to 
decrease pathogenicity, a more targeted approach for creation of genetically 
reassorted viruses, and alleviation of propagation validation issues associated with 
production of virus for vaccine purposes.   
The initial reverse genetics systems demonstrated the rescue of seasonal 
influenza variants containing the HA and NA of A/New Caledonia/20/99 (H1N1), 
A/Panama/2007/99 (H3N2), A/teal/HK/W312 (H6N1), and A/quail/HK/G1/97 (H9N2) 
and the six internal genes of PR8, a high growth lab strain of influenza [184].  
Subsequently, reverse genetics derived strains containing the HA and NA of H5N1 
were created [185, 186] and adapted for expression in Vero cells, which have been 
previously validated for the production of polio vaccine [187-189]. The reverse 
genetics derived system for production of re-assorted viruses verified the decreased 
timeline needed for reverse genetics derivation compared to the traditional 
embryonated hen egg re-assortment method. Vero cells present difficulties in 
transfection efficiency compared to non-production validated cell lines such as 293T 
cells. Adenovirus vectors that, when transduced in Vero cells, produce the viral RNA 
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needed for creation of the viral ribonucleoprotein complex by transfecting the same 
cells with plasmids encoding the PB1, PB2, and PA subunits of the viral polymerase 
increased the viral production efficiency from the traditional eight plasmid method 
[190].  
Reverse genetics derived inactivated virus was used for immunization and 
elicited cross neutralization to several H5N1 strains isolated from human infections 
in a guinea pig model and protection from challenge with three different H5N1 
viruses in mice vaccinated with a prime/boost regimen [191]. A H5N3 reverse 
genetics derived virus was used for an inactivated vaccination challenge model in 
ducks and chickens that provided protection in a single dose and a two dose 
regimen [192].  Finally, a formalin inactivated reverse genetics derived H5N1 oil 
emulsion vaccine also showed protection 43 weeks post vaccination in chickens 
[193].   
The reverse genetics platform allows for a more targeted approach towards 
generation of cold adapted influenza virus with the A/Ann Arbor/6/60 (H2N2) 
backbone and the H5N1 glycoproteins of HPAI H5N1 as well. Reverse genetics 
derivation of cold adapted influenza virus for modified live vaccines have shown 
potential in two dose intranasal administrations in reducing wild type virus replication 
[194]. Protection from homologous and heterologous virus challenge in mice, ferrets, 
and macaques has also been reported when boosted with a second immunization 
[177, 195].   
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DNA vaccines 
DNA vaccination, in general, refers to the initiation of an immune response 
against an antigen introduced via purified DNA in supercoiled plasmids that encode 
for the antigen (poly)peptide sequence [196]. The plasmid DNA incorporates into the 
host cells via direct gene transfer and the host cells produce the protein antigen. 
Mass production of plasmid DNA is less labor intensive than protein antigens and 
DNA storage conditions are less intense when proper techniques are used, 
providing advantages in stockpiling pandemic vaccines [197].   
The immune response elicited to DNA vaccines is primarily skewed to the 
Th1 type of immune response, in which cell-mediated immunity (CMI) to the DNA 
encoded antigen is more prevalent with IFN-γ and IL-12 being the predominant 
cytokines reported in the vaccine response [198]. Although the entirety of the 
plasmid DNA in the vaccine is non-immunogenic, the plasmid DNA can be a non-
specific immunostimulatory component through pattern recognition receptors (PRRs) 
thus providing an innate adjuvant response [199, 200].  The proposed mechanism of 
DNA vaccines mimics the cellular pathogenesis of viruses. The post-transcriptional 
and -translational proteins are split into smaller peptides by intracellular 
proteasomes of either muscle, epithelial, or APCs [201, 202]. The peptides are 
presented by MHC class I molecules after trafficking through the endoplasmic 
reticulum of the host cell. The MHC class I molecule containing the peptide then 
elicits the appropriate CD8+ T cell responses.  
The stability and ease of manipulation of plasmid DNA allows for encoding of 
additional immunostimulatory components to be transcribed and translated by the 
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host cell.  Some components that have been encoded to be co-expressed with the 
antigen of interest include the cytokines IFN-γ, IL-2, IL-12, and/or GM-CSF, co-
stimulatory molecules such as B7 (CD80 and CD86) and CTLA4-Ig, as well as DNA 
sequences that are specifically immunostimulatory [203-208].    
The molecular techniques developed in the last decade and the antigenic drift 
associated with influenza have provided resources to enable fast production of a 
pandemic H5N1 vaccine. Protection from lethal challenge of heterologous strains of 
H5N1 influenza with DNA vaccines encoding HA proteins as well as protection from 
homologous strains encoding for NA, NP, or M2 have been demonstrated [209-211].  
Dependency on the HA protein needing to be encoded in the formulation for humoral 
and cellular immunity is evident when combinations of all of the antigenic targets are 
used [212-214]. Addition of a virus induced signaling adaptor (VISA) molecule in the 
DNA antigenic preparation of an H5 HA peptide was able to convey protection from 
lethal challenge in a mouse model [215]. Heterotypic immunity against different 
clades of HPAI viruses has been reported thus validating the approach [216]. 
Clinical trials of H5N1 DNA vaccines have begun [217]. 
 
Virus like particles (VLPs) 
Responding to the need for enhanced immunity and novel approaches for 
potential pandemics, VLPs present viral antigens in a more native and, therefore, 
immunogenic fashion [218, 219]. VLPs are self-assembled virion shells containing 
relevant viral proteins such as HA, NA, nucleoprotein (NP), and matrix protein 1 and 
2 (M1, M2) [220-222]. The presented proteins are active and remain in their native 
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structures similar to live virions.  
VLPs are immunogenic due to their ability to mimic live virions at the cellular 
level [220]. Due to the lack of the viral genome, VLPs are non-replicating and non-
infectious and, therefore, remain immunogenic and safe to those in high-risk groups 
such as the elderly, even after several administrations [218, 220, 221, 223]. 
Immunogenicity of VLPs can be further enhanced due to the particle’s adjuvant 
properties to stimulate both humoral and cellular immune responses, including 
cross-reactive antibodies that protect against the variability of influenza strains [218, 
221, 222, 224]. 
VLP proteins are commonly recombinant based, produced by the baculovirus 
system in yeast, insect, or mammalian cells [219, 220, 222]. Independence from 
egg-derived vaccines is especially important for an avian influenza vaccine, due to 
the limited egg supply and the H5N1’s ability to kill egg embryos [224]. Egg 
independence also eliminates the need for live viruses during production and 
manufacturing, and is, therefore, very favorable for production without the need for 
chemical inactivation or biosafety containment. 
VLP’s against H5N1 have been successful in eliciting cross-reactive 
responses between subtypes [218, 219, 224, 225]. H1N1 VLP intranasal 
vaccinations in mice and ferrets induced high levels of cross-reactive IgG and IgA 
and had two to three fold greater amounts of IL-2, IL-9, IL-10, and IL-17 than other 
vaccinations, while remaining protective against a heterologous H5N1 challenge 
[218]. VLPs using HA and NA surface proteins, while internalizing the conserved 
epitopes of the M1 protein, stimulated the activation and proliferation of CD8+ T cells 
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that increase production of IFN-γ, TNF-α, and IL-2 when compared to recombinant 
protein subunit vaccines [219, 223]. Although the HA protein is mainly responsible 
for inducing H5N1 specific antibodies, the M1 protein’s conserved epitopes are 
generally accountable for cellular immunity and cross-protection [219, 223]. This 
increase in cellular immunity was also apparent in the ratios of antibodies found with 
H5N1 VLP vaccine responses. Post-vaccination, IgG2a and IgG2b titers were 
largely increased resulting in a balanced IgG1:IgG2 ratio [224, 226]. H5N1 vaccines 
using VLP technology showed long lasting memory responses in challenge with 
single does as low as 0.4 µg [219, 227] and utilized needle-free technologies for 
inoculation [219, 226-228]. Protective efficacy of VLP vaccines against H5N1 have 
been shown in poultry and a computationally optimized broadly reactive antigen 
(COBRA) H5 VLP vaccine showed protection from challenge in a non-human 
primate model challenged with clade 2.2 A/Whooper Swan/Mongolia/244/05 
(WS/05) [229, 230]. 
 
Subunit vaccines  
Recombinant subunit protein-based vaccines, using a single protein antigen, 
have also been examined due to the increased purity and safety profiles [220, 231-
233]. Using this system, individual viral proteins, most commonly HA and NA, are 
recombinantly synthesized in mammalian or insect cells that support post-
translational modifications such as glycosylation, allowing the production of correctly 
folded proteins [220, 232-234].  
While the baculovirus technology allows rapid production of recombinant 
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proteins, there is some debate on using insect or mammalian cultures [220, 231-
233]. During translation of recombinant H5 HA protein, mammalian cells commonly 
produced a high-molecular weight oligomer or trimer form of HA [231-233]. Insect 
cells have been more likely to produce cleaved or monomer forms of the HA protein, 
although some studies have shown stable production of trimer HA in insect cultures 
[231-233]. In most cases, the immunogenicity of the H5 HA protein was highly 
dependent on its oligomer and trimer forms showing that in a weakly immunogenic 
protein it is optimal to present it in its natural trimeric state [231-233]. 
Besides the challenges associated with the protein’s production, H5 HA is a 
weak antigen that degrades quickly in the body. Therefore, several large doses (up 
to 90 µg) are needed to achieve suitable protection. However, with the help of novel 
adjuvants and/or protein carriers, the immunogenicity of HA can be greatly improved 
to reduce both the number and size of vaccine doses [220, 232, 235, 236]. H5 HA 
has been shown to be the dominant protein for subunit immunizations for the 
obvious reasons of inducing H5N1 specific neutralizing antibodies, however other 
proteins that have not shown to be protective on their own, such as NA, are also 
included in protein-based vaccinations. When used in tandem with HA protein, NA 
enhances cross-reactive protection between H5N1 clades [231, 232, 234, 235]. 
Like DNA vaccines and VLPs, recombinant proteins can be produced quickly 
in mass quantities without the dependence on a limited egg supply [231, 233]. Large 
scale production of recombinant proteins is feasible because no live viruses are 
required, eliminating the need for bio-containment facilities [231, 233].  Novel 
recombinant production techniques that use plant-based systems are being 
	  	   37	  
developed for influenza HA antigens [237]. Likewise, recombinant proteins can be 
highly purified and don’t utilize chemicals to inactivate the antigen, reducing 
contamination and adverse effects on patients [231].   
Oral and intranasal vaccinations of baculovirus produced H5 HA led to 
effective, long-lived production of IgA in mucosal tissues, as well as protection in 
mice [233, 235]. Likewise, H5N1 proteins such as M2, NP, and NA have also been 
used to induce cross-protection between clades of avian influenza [234, 238, 239]. 
As mentioned previously, HA is the primary antigen that stimulates neutralizing 
antibody in H5N1 [238] . However, by using more conserved proteins, studies have 
shown an increase in HA-specific neutralizing antibodies, as well as IFN-γ producing 
CD8+ T cells, especially in the presence of an adjuvant [234, 238-240].  
Recombinant production of HA proteins of H5 allows for manipulation of the antigen, 
specifically in the creation of stabilized trimeric forms of the antigen that increase the 
immunogenicity of the protein [241-243]. Licensure of a recombinant HA vaccine, 
FluBlok, grown in insect cells has been a recent advancement in this area [244]. 
 
Immune refocusing  
Immune refocusing, also termed as deceptive imprinting or epitope masking, 
is a new advance in influenza vaccine technology. Immune refocusing targets class 
II pathogens, such as influenza, or pathogens that have immune responses to strain 
specific epitopes, yet high rates of mutation within these epitopes [245]. Tobin et al. 
theorize that pathogens, such as H5N1 avian influenza, have immunodominant 
epitopes, such as the globular head of the HA trimer, and subdominant epitopes, or 
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more conserved proteins [245]. These dominant epitopes are distractions to obstruct 
the immune system from recognizing and manufacturing antibodies against more 
protective or cross-reactive epitopes [246]. This concept arises from the theory of 
original antigenic sin [247]. For example, a secondary influenza infection containing 
epitopes previously recognized from a former strain as well as new epitopes will only 
produce antibodies against the previous epitopes, eliminating the infection quickly 
during a memory response [247]. However, in the cases of HPAI, strain specific 
epitopes dominate the immune response and block reactions to epitopes that appear 
from strain to strain. In this case, the immune system must respond to each infection 
as a primary infection, with no memory response [247]. 
Recent evidence has identified wide cross reaction of the influenza HA 
immune responses by constructing a headless HA molecule that retains the correct 
conformation of the stalk structure [248]. The HA protein has two subunits: the 
globular head and immunodominant HA1, and the more conserved and cross-
reactive HA2 [35]. By removing a portion of the HA1 globular head, the most variable 
and strain specific subunit, the remaining portion of HA1 and conserved HA2 is 
retained and exposed to the immune response allowing cross-reactive antibodies to 
form [248]. Immunizations with the headless HA allowed complete protection and 
partial prevention of weight loss during a lethal homologous challenge and cross-
reactive antibodies to different HA subtypes.  This advancement could be exploited 
for a prospective pandemic platform for cross-reactive influenza vaccines [248]. 
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Vectors 
An increasing focus on utilizing vectors (i.e. bacteria or viruses) to deliver 
antigen to the appropriate cellular compartments has been identified with emphasis 
on production in poultry medicine. A commercially available fowlpox vectored avian 
influenza vaccine administered parenterally has demonstrated extensive efficacy in 
poultry against HPAI although administration requires handling of each individual 
bird [249, 250]. Subsequent studies looked at improving efficacy by overcoming 
immune suppressive effects of the fowlpox vector by including genes encoding for 
the cytokine IL-18 [251]. Modified Vaccinia virus Ankara (MVA) encoding H5 HA 
showed protective efficacy in mice [252]. Vaccinia virus, smallpox and fowlpox viral 
vector vaccines encoding A/chicken/Indonesia/7/03 H5 hemagglutinin were 
examined in a swine model of vaccination and elicited protection from challenge with 
low pathogenic H5N1 virus [253]. Replication defective human adenovirus vectors 
effectively delivered DNA encoding influenza antigens to host cells while being well 
tolerated in human trials [254]. The adenovirus technology ensures a targeted 
approach towards delivery of the H5 HA DNA over the intramuscular injection of 
DNA discussed earlier and demonstrated protection in mouse and poultry models of 
HPAI challenge [255-257]. A poultry specific attenuated live vaccine strain of 
Newcastle Disease Virus (NDV) was genetically modified to express HA of HPAI and 
showed protection from lethal challenge of both HPAI and NDV in poultry [258]. 
Wang et al. have demonstrated that a common poultry Lactobacillus that colonizes 
the gut of poultry delivered H5 antigen to mucosal tissues and elicited specific IgA 
and cell mediated immune responses [259].  
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Table 2. Clinic trials of H5N1 vaccines 
Vaccine Unique 
Clinical 
Trial 
Identifier 
Phase 
Clinical 
Trial 
Route Dose Regimen 
Inactivated (A/Vietnam/1194/2004 
HA and NA or 
A/Vietnam/1203/2004 x A/PR/8/34) 
grown in embryonated hen’s egg 
adjuvanted with or without MF59 
[260-267] 
 
20 
 
I, II, III IM 3.75, 7.5, 
15, 30, or 
45 µg 
Prime/Boost 1, 2, 3, 
4, or 6 weeks post-
primary 
immunization 
DNA plasmid encoding H5 
A/Indonesia/05/2006 with CMV/R 
promotor [268] 
4 
 
I, II, III ID (w/ or 
w/o needle 
free 
technology) 
500 and 
1000 µg 
Prime/boost 4 
weeks and 8 weeks 
post-primary 
immunization 
Inactivated H5N1 
(A/Vietnam/1194/2004 or 
A/Vietnam/1203/2004 HA and NA x 
A/PR/8/34 (NIBRG-14)) grown in 
embryonated hen’s egg adjuvanted 
with or without Alum [164, 168, 169, 
262, 269-275] 
36 
 
I, II IM or ID 1.25, 2.5, 
3, 5,  7.5, 
9, 10, 15, 
45, 90 , or 
300 µg 
Prime/Boost 28 
days post-primary 
immunization 
Third dose 6 
months post second 
dose 
*Up to 4 doses with 
in 4 weeks of 
primary 
immunization 
Purified recombinant  H5 HA 
A/Vietnam/1203/2004 produced 
using  baculovirus expression 
system in insect cells adjuvanted 
with  or without Alum 
2 
 
I, II IM 45, 90, or 
135 µg 
Prime/Boost 21 
days post-primary 
immunization 
Purified recombinant  H5 HA 
A/Indonesia/05/2006 produced 
using  baculovirus expression 
system in insect cells adjuvanted 
with  or without Glucopyranosyl 
Lipid A (GLA-SE) 
3 
 
I, II IM 3.8, 7.5, 
15, 45, 
90, or 135 
µg 
Prime/Boost 21 
days post-primary 
immunization 
Inactivated split virion 
A/Indonesia/5/05 
adjuvanted  grown in embryonated 
hen’s egg with tocopherol (AS03) 
[268, 273, 276-278] 
11 
 
I, II, III IM 3.75, 7.5, 
15, 45, or 
90 µg 
Prime/Boost 21 or 
28 days post-
primary 
immunization 
Inactivated split virion 
A/Vietnam/1194/2004-like strain 
grown in embryonated hen’s egg  
adjuvanted with tocopherol 
(AS03(A) 11.86 mg) [278-280] 
10 
 
III IM 3.75 µg of 
HA 
Prime/Boost 21 
days post-primary 
immunization 
Inactivated pre-pandemic H5N1 
Vero cell derived 
A/Vietnam/1203/2004 adjuvanted 
with or without Alum [151, 170, 281] 
 
11 
 
I, II, III IM or SC 3.75, 7.5, 
15, or 45 
µg 
Prime/Boost 21 or 
28 days post-
primary 
immunization 
Third dose 6 
months, 12 months, 
or 24 months 
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Table 2 (Continued). 
Inactivated pre-pandemic H5N1 
Vero cell derived 
A/Indonesia/05/2005 unadjuvanted 
Baxter Healthcare Corp. 
2 
 
I, II IM 3.75, 7.5, 
15, or 45 
µg 
Prime/Boost 21 
days post-primary 
immunization 
 
      
Inactivated split virion 
A/Vietnam/1194/2004  grown in 
embryonated hen’s egg adjuvanted 
with proprietary oil-in-water 
emulsion  (AS) [282] 
2 
 
I, II, III IM 3.8 or 15 
µg 
Prime/Boost 21 
days post-primary 
immunization 
 
Inactivated split virion 
A/Indonesia/5/2005  grown in 
embryonated hen’s egg adjuvanted 
with proprietary oil-in-water 
emulsion  (AS) [282] 
1 
 
I IM 3.8 or 15 
µg 
Prime/Boost 21 
days post-primary 
immunization 
 
Inactivated subvirion 
A/Indonesa/5/05 grown in 
embryonated hen’s eggs 
adjuvanted with or without MF59 
3 
 
I, II IM 3.75, 7.5, 
15 or 90 
µg 
Prime only or 
Prime/Boost 28 
days post-primary 
immunization 
Recombinant H5 HA 
A/Indonesia/5/2005 produced in 
plant based expression system 
assembled into VLP adjuvanted 
with glucopyranosyl lipid adjuvant 
(GLA-AF) or Alhydrogel® or without 
adjuvant [283] 
3 
 
I IM or ID 5, 10, 15, 
20, 45, or 
90 µg 
Prime/Boost 21 
days post-primary 
immunization 
Replication competent Adenovirus 
expressing H5 HA 
A/Vietnam/1194/2004  adjuvanted 
with or without dsRNA 
4 
 
I Oral, IN,  or 
tonsillar 
(mouth 
spray) 
10^7, 
10^8, 
10^9 
10^10, 
10^11 
Prime/boost 56 
days post 
primary/boost 112 
post primary 
immunization 
HA and NA of 
A/Vietnam/1194/2004 (H5N1) x 
A/Puerto Rico/8/34, purified and 
coupled with phospholipids to 
create virosomes with or without 
Matrix M™ adjuvant [284] 
1 
 
I IM 1.5, 7.5, 
or 30 µg 
of HA 
Prime/Boost 21 
days post-primary 
immunization 
Cold adapted live attenuated HA 
and NA of A/Vietnam/1203/2004 or 
A/HongKong/213/2003 x 
A/AnnArbor/6/60/ca [176] 
2 
 
I IN 10^3, 
10^5, or 
10^7 
TCID50 
Prime/Boost 4-8 
weeks post-primary 
immunization 
Inactivated cell based H5 
A/Vietnam/1203/2004 vaccine 
adjuvanted with GelVac™ a plant 
polysaccharide gel that 
encapsulates the antigen 
1 
 
I IN 30 µg Primary 
Inactivated H5N1 
(A/Vietnam/1194/2004 HA and NA 
x A/PR/8/34) grown in embryonated 
hen’s egg adjuvanted with or 
without oil-in-water emulsion [285] 
1 
 
I IM 1.9, 3.8, 
7.5, or 15 
µg 
Prime/Boost 21 
days post-primary 
immunization 
Inactivated H5N1 
A/Vietnam/1194/2004 Madin-Darby 
canine kidney (MDCK) cell derived 
unadjuvanted 
Baxter Healthcare Corp. 
1 
 
I IM 7.5, 15, or 
30 µg 
Prime/Boost 21 
days post-primary 
immunization 
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Adjuvants 
HPAI vaccines are confronted with the same problems that hinder seasonal 
influenza vaccines in that the immunogenicity of the antigens is mediocre [286].  
Including adjuvants with immunostimulatory compounds in vaccine formulations has 
long been a proven technique for increasing the immune response towards the 
antigens of interest [23]. However, the use of adjuvants heighten safety concerns as 
vaccinologists and immunologists attempt to balance between sufficiently engaging 
the immune system to mount a robust response without crossing the line into a 
Table 2 (Continued).      
Recombinant H5 HA 
A/Indonesia/5/2005 produced in 
baculovirus/insect cell expression 
system assembled into VLP 
3 
 
I, II IM 15, 45, of 
90 
Prime/Boost 21 or 
28 days post-
primary 
immunization 
Globular head domain of H5 
hemagglutinin A/Indonesia/5/2005 
fused with Salmonella typhimurium 
flagellin type 2 (STF2) TLR5 
agonist 
2 
 
 
I IM 1, 2.5, 4, 
6, 8 or 12 
µg 
Prime/Boost 21 
days post-primary 
immunization 
DNA plasmid encoding H5 protein 
VGX-3400X 
3 
 
I IM, or ID + 
electroporat
ion Day 0 
and 1 
month 
0.6,  0.9, 
2, or 6 mg 
of 
DNA/dose 
Prime/Boost 28 
days post-primary 
immunization 
Live attenuated H5N2 
A/17/Turkey/05/133 
1 
 
I IN  Prime/Boost 21 
days post-primary 
immunization 
Replication competent Adenovirus 
expressing H5 HA 
A/Vietnam/1194/2004  adjuvanted 
with or without dsRNA 
Ad4-H5-Vtn for delivery to the ileum 
by a radio controlled capsule 
(ND1.1) 
1 
 
I Oral   
Inactivated H5N1 vaccine 
adjuvanted with 50 µg of E. coli 
heat-labile toxin (LT) patch at 
immunization site 
3 
 
I, II IM + LT 
Patch 
15 or 30 
µg 
Prime/Boost 21 
days post-primary 
immunization 
Table 2.   
Pandemic preparedness leading to design of standard (based on seasonal influenza 
vaccines) and novel vaccines has led to 131 unique clinical trial identifiers at 
clinicaltrials.gov.   
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deleterious immune event. Because of the potential for adverse events associated 
with adjuvants, very few vaccines containing adjuvants have been approved for use 
in humans [287, 288]. Seasonal as well as pandemic influenza vaccine research has 
led to significant advances in adjuvant development, leading to novel adjuvants like 
MF59, an oil-in-water emulsion, being approved for human use in the European 
Union [289].   
As mentioned in earlier sections, many vaccine formulations for HPAI under 
investigation contain adjuvants. Here, we highlight the advances in adjuvant 
research in the context of HPAI vaccines. Alum remains the principal adjuvant 
studied because of its approval for human use while maintaining favorable safety 
profiles [290-292]. MF59 and AS03 (another oil-in-water emulsion) appear to more 
effectively increase efficacy as compared to Alum, although vaccines using these 
adjuvants are limited in their approval for use world-wide [293-297]. Evidence has 
pointed to the induction of serum antibody recognizing more epitopes of H5N1 
following immunization with a MF59 adjuvanted H5N1 vaccine versus non-
adjuvanted vaccines providing insight into a basis for vaccine efficacy [298].   
The pandemic possibility of HPAI has pushed other avenues of adjuvant 
research. Inactivated whole virus adjuvanted with CoVaccine HTTM, a mixture of 
squalene, polysorbate 80, sucrose fatty acid sulphate ester in water, demonstrated 
favorable HA inhibition titers in ferrets and macaques with a single dose regimen 
[299, 300]. A purified derivative of the saponin from Quillaja saponaria, QS-21, has 
been identified as another potential adjuvant in pandemic HPAI vaccines [195]. The 
addition of QS-21 along with Alum in H5N1 vaccines greatly increased antibody 
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responses to the M2 protein in rhesus monkeys [195]. Immune stimulating 
complexes (ISCOMs) are 40 nm structures containing glycosides from Quillaja 
saponaria and lipids for which immunogens can attach via hydrophobic interactions. 
These compounds have shown promising protection data upon lethal challenge in 
avian models [301, 302]. Platycodin D, another saponin derived from Platycodon 
grandiflorum, has shown adjuvant potential when combined with recombinant H5 
[303]. 
Recent advances in molecular and structural biology have led to targeted 
approaches to stimulate innate immune cells through pattern recognition receptors 
(PRRs) such as Toll-like receptors (TLRs), RIG-1-like receptors, NOD-like receptors, 
and C-type lectin receptors (CLRs) [304, 305]. Stimulating PRRs with ligands in 
conjunction with delivering antigens enhances immune responses [306]. Stimulation 
of endosomal TLR3 or TLR9 with poly IC:LC or CpG DNA, respectively, during HPAI 
infections led to protection and viral clearance [307]. The adjuvant effect of TLR3 
ligands was also demonstrated in intranasal (IN) HPAI vaccines in primates [308]. IN 
administration of poly I:C with H5N1 HA as well as with using chitin microparticles 
concurrently with poly I:C induced immune protection upon lethal challenge [309, 
310]. PIKA, a dsRNA analog that functions through ligation of TLR3 showed 
adjuvant effects to subunit H5N1 vaccines administered intranasally in mice as well 
as protection from heterologous challenge [311]. Incorporation of monophosphoryl 
lipid A (MPLA), a non-toxic derivative of LPS that signals through TLR4, combined 
with Alum induced higher HAI antibody responses characterized by a balanced HA-
specific IgG1 and IgG2a isotypes using a dose a 3.8 µg HA combined with a split 
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virion vaccine [312].  
Cholera toxin (CT) has demonstrated mucosal adjuvant capabilities that 
appear to be STAT3 signaling dependent [313]. Recombinant CT demonstrated 
more favorable safety profiles due to engineering the absence of the catalytic 
subunit [314]. Recombinant CT used as an adjuvant in combination with inactivated 
H5N1 viral vaccines showed similar antibody titers to other adjuvanted inactivated 
H5N1 vaccines but with diminished protection [315]. Another bacterially derived 
adjuvant, the heat labile enterotoxin from E. coli (LT) administered, proved to be safe 
and provided enhanced mean HA inhibition (HI) titer in a randomized clinical trial in a 
prime boost immunization regimen [316]. 
Combinations of adjuvants, as alluded to earlier with MPLA and Alum, are 
also an exciting avenue of vaccine research. A synthetic bioresorbable diblock tri-
component copolymer poly(ethylene glycol)-block-poly(lactide-co-ε-
caprolactone)(PEG-b-PLACL) was used to create a novel emulsion delivery system 
(PELC) that when combined with CpG DNA, a TLR9 agonist induced higher 
antibody responses in single dose applications using inactivated H5N1 virus and 
elicited cross reactive antibodies to heterologous virus [317, 318]. These increased 
immune responses with a particulate adjuvant, as well as other studies using 
micelle-based carriers administered orally [319] indicate the importance of size and 
shape in designing adjuvants [24].  
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Anti-viral drugs 
Besides vaccines, stockpiling of anti-viral drugs for use in a possible H5N1 
pandemic is also critical for treatment of infected individuals.  These drugs are 
focused on inhibiting specific functions of viral replication and can be used 
prophylactically or therapeutically against viral infection [320]. Drugs such as 
oseltamivir and zanamivir act as NA inhibitors of influenza virus by binding to the 
Figure 3.   
The looming influence of a possible pandemic of HPAI has pushed research into refining, 
improving and generating novel vaccine approaches. A simplified overview of the immune 
responses generated from the different antigens used in the vaccines discussed in this 
paper.  Arrows are indicative of the route of administration being used for the discussed 
vaccines.  
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functional binding site of NA [321]. Oseltamivir treatments studied in HPAI H5N1 
mouse and ferret models show incomplete virus inhibition when not given early 
(within 4 hours) in the infection cycle [322, 323]. Oseltamivir resistant H5N1 viruses 
have also been identified in clinical studies of infected individuals [91, 324, 325].  
Small animal models studying the effects of therapeutic zanamivir on reducing HPAI 
viral load showed promise in decreasing morbidity and mortality [322, 326].  
Zanamivir when administered prophylactically in a non-human primate model 
showed promising antiviral effects by reducing viral load but therapeutic doses given 
post HPAI infection showed less effect [327].   
Ion channel inhibitors such as amantadine and rimantidine are viable options 
for anti-viral treatment in pandemic HPAI situations. Amantadine and rimantidine 
form a barrier at the M2 influenza viral protein that functions to enable the entry of H+ 
ions [328]. Inhibition of the ion flux hinders viral entry and prevents release of viral 
genome segments from matrix protein. Older HPAI isolates from human infections 
showed resistance to amantadine and rimantidine but new isolates showed 
susceptibility to amantadine, making stockpiling for combination anti-viral therapies 
useful [329, 330].   
Type I IFNs and corticosteroids could also be utilized as broad-spectrum anti-
viral therapies in the case of pandemics. IFNs are cytokines produced by viral 
infected cells that help facilitate resistance to viral replication, increase class I 
antigen presentation, and activate innate antigen presenting cells and natural killer 
cells [23]. Synthetic IFNs have shown efficacy in therapeutic applications of 
influenza infection however only prophylactic treatments have shown efficacy with 
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HPAI [331, 332]. Corticosteroid treatments have also been examined in the context 
of HPAI infection because of the multi-system cytokine storm associated with 
pathogenesis. Corticosteroids provided little improvement from the pathogenic traits 
in animal models and in clinical patients [333-335].  
Prophylactic anti-viral treatment appears to be the most effective anti-viral 
approach in the midst of pandemic influenza.  Speculation has occurred as to what 
may be the most effective combination of therapies for infected individuals, however, 
truly definitive studies examining HPAI may be unable to be performed [330, 335, 
336]. 
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Table 4. An outline of the typical factors needed to be considered towards designing and 
producing a pandemic vaccine against HPAI. 
 
 
Vaccine Potency 
Production 
Speed Purity Safety 
Inactivated Viral 
 ** * * * 
Cold Adapted Attenuated Viral ** * ** * 
Reverse Genetics Derived ** ** * * 
DNA 
 ** *** *** ** 
Virus Like Particles *** ** ** ** 
Immune Refocusing * ** *** *** 
 
   
Discussion 
The 2009 H1N1 influenza pandemic has reinforced the speed and 
aggressiveness of global influenza virus spread. Technological advancements in 
media and virus detection allowed the public to witness the virus distribution in real 
time. This public awareness as to how quickly influenza virus can be transmitted to 
Table 4. 
Efficacy is often the major consideration but production speed, purity, and safety of the vaccines 
are all important aspects of vaccines to undergo and pass aspects of governmental regulations to 
be used in the population.  Safety in the context of this table is considering only the antigen.  
Safety of many of these vaccines can be altered by the use of adjuvants which may present more 
adverse events at the time of or after vaccination. One * represents low value and *** represents 
higher value in the context of the vaccines discussed.  
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different populations globally has emphasized the need for pandemic preparedness 
and preventative therapeutics.   
Highly pathogenic avian influenza H5N1 poses great concern to dense 
human populations because of the disease severity associated with this variant not 
typically associated with seasonal influenza virus. Although the H5N1 influenza has 
yet to acquire the ability to be transmitted from human to human, significant efforts 
have been focused on studying the viral pathogenicity as well as investigating 
prophylactic treatments in case of pandemic spread. 
Traditional seasonal influenza vaccine preparations involving inactivated virus 
have shown efficacy, but are limited by the production constraints associated with 
seasonal influenza vaccines grown in embryonated hen eggs. New techniques using 
viral propagation in cell culture as well as the development of reverse genetics 
systems where an entire virus can be produced from plasmid DNA in vitro can help 
alleviate the production constraints with traditional methods. These inactivated viral 
vaccines from non-egg origins still face licensure scrutiny from the governing 
oversight committees, however, the increased turnaround time of propagating the 
virus as well as the lack of egg products negating the allergic effects observed in 
traditional seasonal vaccines provides these technologies with advantages.   
Cold adapted viral vaccines present another promising option for H5N1 
pandemic vaccines. Because of the restrictive replicative abilities of the modified live 
virus in the upper respiratory tract, low quantities of antigen are needed. Cold 
adapted viral vaccines are also advantageous for pandemic situations because of 
the ease of intranasal administration as well as not being constrained by the need 
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for medical professionals for administration. 
DNA vaccines are an attractive option in vaccine development because of the 
low cost of production of DNA in contrast to protein antigen. DNA vaccines are also 
very stable and are not restricted by cold chain storage when produced, thus 
providing a significant advantage in pandemic situations. However, DNA vaccines 
may suffer from the specialized regimens needed, such as electroporation, which 
may not be readily executable. To get around these specialized regimens, DNA 
vaccines have been examined in the form of viral vectored vaccines encoding genes 
of influenza virus.  Regulatory approval for viral vectored vaccines in humans is still 
a challenge. 
Subunit vaccines for HPAI H5N1 present one of the better safety profiles of 
pandemic influenza vaccines due to the purity of the single or tandem antigens used.  
Efficacy of subunit vaccines remains a consistent hurdle that needs to be overcome 
especially in the context of H5N1 vaccines. The HA trimer is the target of a 
neutralizing antibody response due to the antibody being able to block the binding of 
virus to host epithelial cells. The HA molecules are under constant selective 
pressure to evade adaptive immune responses and as such are one of the most 
rapidly mutagenic proteins of influenza virus that allow the virus to undergo antigenic 
drift or shift precipitously.  
Adjuvants such as aluminum salts, TLR agonists, and MF59TM have been 
commonly used to enhance the immune response to the subunit protein antigens of 
H5N1 [238, 261, 265, 298, 311, 337-339]. Co-administration of HA and NA antigens 
as well as the vaccination of VLPs improves the protective immune responses due 
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to the increased resemblance to an infectious event compared with a single antigen. 
Although protective efficacy associated with the use of recombinant proteins may be 
less than with other immunogen formats, the labor and cost of producing 
recombinant proteins are reducing with technological advances in protein 
engineering.   
Cross protective influenza vaccines against distinct strains remains one of the 
biggest obstacles in influenza vaccine design. Recent insights into examining the 
immunological map of where the immune responses are directed to on the HA are 
raising exciting possibilities in obtaining cross strain protection. Antigens that refocus 
the immune response to more conserved regions in the stalk of the HA molecule of a 
lab strain of influenza have induced antibodies that cross react with other strains 
[248]. Although in its infancy, this technology could prove to be the ultimate fail safe 
in protecting against a pandemic by eliciting protection against both seasonal and 
pandemic strains of influenza.   
Prophylactic or therapeutic anti-viral drugs also need be evaluated when 
examining influenza pandemic preparedness. Prophylactic anti-viral treatments 
appear to be the most effective approach to prevent infection [336]. Combination 
therapies have also been examined to tackle the issues associated with genetic 
resistance to anti-viral drugs.   
 
Polyanhydride particle platform 
The main principle supporting the use of polyanhydrides as biomaterial drug 
delivery vehicles was the ability of these materials to provide a controlled release of 
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a payload encapsulated within the particle by a unique surface erosion mechanism 
[340].  The erosion kinetics can be tailored by purposeful selection of copolymer 
combinations of aromatic polyanhydrides such as 1,6-bis(p-carboxyphenoxy) 
hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) either in 
combination with each other or in combination with sebacic acid (SA) to increase or 
decrease the rate of degradation and thus the release of protein. Combinations 
consisting of CPH and SA erode relatively quicker than combinations of CPH and 
CPTEG [341]. The amount of CPH in copolymer dictates longer erosion kinetics as 
well for example 50:50 CPTEG:CPH erodes quicker than 20:80 CPTEG:CPH. 
Differences in size of proteins and chemistry of particles of particles all lead to 
unique erosion and release kinetics from particles but the principle of controlled 
release is maintained. 
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Using different fabrication techniques allows for manipulation of particle size 
creating ~15 µm diameter particles when using solid/oil/oil emulsion methods or 
cryogenic atomization based methods outlined in Lopac et al [342] and ~300 nm 
diameter particles when using an anti-solvent nanoprecipitation technique outlined in 
Ulery et al [343]. The CPTEG containing polyanhydride particles allow for an 
amphiphilic and an environment that serves to maintain structural integrity and 
immunogenicity of the encapsulated immunogen [344-346] while mimicking 
pathogen sizes (Figure 3). These microparticles or nanoparticles provide a 
particulate context for phagocytic APCs enhance activation markers of antigen 
presenting cells [343, 347]. 
Using these attributes of size optimized for phagocytosis [343, 347], innate 
immunomodulatory activity of APCs [344, 347-349], controlled release of 
encapsulated antigen to continually provide antigen for an extended period of time 
Figure 4. Size comparisons of the synthetic polyanhydride nanoparticle platform compared 
to common pathogens. A continuous size comparison of common pathogen sizes expressed in 
nanometers to microns.   
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post-immunization [340, 342, 345, 350-354], and theoretical repetitive structure of an 
antigen loaded in particles helping to provide crosslinking of B cell receptors, the 
polyanhydride particle platform provides a unique base for vaccine design.   
Efficacy of vaccines designed using the polyanhydride particle platform has 
been characterized by the induction of long-lived antibody responses of high titer 
and high avidity [65, 355, 356]. Fully encapsulating tetanus toxoid into polyanhydride 
microparticles composed of 20:80 CPH:SA or 50:50 CPH:SA was capable of 
inducing high titer IgG1 as well as IgG2a in the case of the 50:50 CPH:SA groups 
indicating presence of IFN-γ elicited post-immunization [357]. Building from that 
information as well as other studies, an intranasal polyanhydride nanoparticle 
vaccine against Yersinia pestis was designed using the F1-V fusion protein, a 
protective antigen consisting of the Fraction 1 capsular antigen (F1) and the V 
protein portion of the type III secretion system [358]. The vaccine regimen consisted 
of a soluble antigen administered along with F1-V encapsulated into 50:50 
CPTEG:CPH polyanhydride nanoparticles. After a single intranasal dose, protective 
immunity from Y. pestis challenge was observed at 26 and 40 weeks post-
immunization that was characterized by the presence of high titer and highly avid 
F1-V-specific IgG1 [65, 356]. 
 
Overview of thesis and project objectives 
 Based on previous studies, elucidating the cellular mechanisms underlying 
the efficacious adjuvant activity of the polyanhydride particle platform was 
warranted. The following chapters of this dissertation attempt to define those 
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mechanisms and to use that knowledge for design of a novel vaccine using the 
polyanhydride particle platform against the H5N1 influenza virus.  Specifically, the 
aims were to (1) provide a proof of concept of encapsulation of antigen into 
polyanhydride particles facilitates antigen sparing and induction of antigen-specific 
IgG1 and IgG2a antibodies, (2) define biocompatibility, reactogenicity, and in vivo 
kinetics of particle persistence after administration, (3) define the CD4+ and CD8+ T 
cell responses after immunization, and (4) test the efficacy of polyanhydride 
nanoparticle designed vaccines to induce neutralizing antibody against the H5N1 
influenza virus. By defining these host response characteristics and tailoring the 
platform to induce neutralizing antibody against a viral pathogen, this will further 
define the host response characteristics needed for translating the polyanhydride 
platform to use in human and veterinary medicine as well as demonstrate the 
capabilities of the platform for other vaccinological applications.   
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CHAPTER 3: SINGLE IMMUNIZATION WITH A SUBOPTIMAL ANTIGEN DOSE 
ENCAPSULATED INTO POLYANHYDRIDE MICROPARTICLES PROMOTES 
HIGH TITER AND AVID ANTIBODY RESPONSES	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Abstract 
 Microparticle adjuvants based on biodegradable polyanhydrides were used to 
provide controlled delivery of a model antigen, ovalbumin (Ova), to mice. Ova was 
encapsulated into two different polyanhydride microparticle formulations to evaluate 
the influence of polymer chemistry on the nature and magnitude of the humoral 
immune response following administration of a suboptimal dose. Subcutaneous 
administration of a single dose of polyanhydride microparticles containing 25 µg of 
Ova elicited humoral immune responses that were comparable in magnitude to that 
induced by soluble doses of 400 to 1600 µg Ova, demonstrating at least a 16-fold 
dose-sparing capability. In contrast, the avidity of the Ova-specific antibodies was 
greater in mice administered the microparticle formulations in comparison to the 
higher soluble doses. The increased avidity was maintained throughout the 12 week 
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time period. Finally, the microparticle delivery system primed an anamnestic immune 
response as evidenced by the significant increases in Ova-specific antibody when 
mice were administered an antigenic challenge of 25 µg of Ova at 12 weeks post-
vaccination. Together, these results indicate that encapsulation of antigens into 
polyanhydride microparticles facilitates isotype switching, establishes immunologic 
memory and the humoral response provides a dosage sparing benefit as 
characterized by a higher quality antibody response. 
 
1. Introduction 
Many current subunit vaccine formulations consist of poorly immunogenic 
recombinant proteins that require adjuvants to induce humoral and cellular immune 
responses. Although beneficial, vaccine adjuvants do pose a risk of adverse 
reactions, which may, in part, explain why only three formulations (the aluminum 
salts Al(OH)3 and AlPO4, oil-in-water emulsion, and monophosphoryl lipid A) are 
currently licensed for human use in the United States [1]. Recombinant proteins are 
also often costly to produce. Reducing the amount of antigen needed to elicit 
protective immune responses could help eliminate vaccine production shortages 
similar to those observed during the 2009 H1N1 influenza pandemic [2]. 
Immunization with subunit vaccines can also fail to induce robust humoral immune 
responses in which naïve B cells differentiate into antigen-specific, long-lived plasma 
cells and memory B cells. While these vaccines elicit measurable antibody titers, the 
quality (i.e., avidity) and kinetics of the antibody response may be less than optimal. 
Successful vaccines must induce antigen specific memory B cells capable of rapidly 
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proliferating upon antigen stimulation [3, 4]. In addition, an avid antibody response 
must be developed through somatic hypermutation and positive selection of high 
affinity B cell clones. These attributes are all essential factors in determining the 
quality of antibody-mediated protection against a subsequent pathogen challenge. 
To overcome many of the limitations associated with traditional vaccine 
regimens, antigens have been encapsulated into synthetic, biodegradable polymer 
micro- and nanoparticles [5-8]. The most extensively studied formulations include 
the polyesters poly(glycolic acid), poly(lactic acid) and their copolymers (i.e., 
poly(lactide-co-glycolide) or PLGA). Unfortunately, particles made of PLGA degrade 
by a bulk erosion mechanism that may negatively affect the stability of proteins 
susceptible to moisture-induced aggregation [9, 10]. In addition, the acidic 
microenvironment created by PLGA degradation products (i.e., lactic or glycolic 
acids) can lead to protein instabilities [11, 12]. Polyanhydrides, another class of well-
studied biodegradable polymers, present an alternative for drug and vaccine delivery 
[13]. These materials exhibit surface erosion characteristics and possess 
hydrolytically labile anhydride bonds [14]. The most commonly studied 
polyanhydrides are based on the aliphatic sebacic acid (SA) and the aromatic 1,6-
bis(p-carboxyphenoxy)hexane (CPH). Encapsulation of proteins into CPH:SA 
copolymers has been shown to preserve protein and antigenic epitope stability [9, 
15, 16]. These surface-erodible polymers also provide sustained protein release [15-
17] and possess immune-modulatory capabilities [18-21].  
In this present work, we extend our studies of polyanhydride particle-based vaccines 
by exploring the ability of this platform to enhance the immunogenicity of ovalbumin 
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(Ova), a model vaccine antigen. We found that a single subcutaneous (SC) 
administration of a suboptimal dose of Ova encapsulated into polyanhydride 
microparticles induced an antibody response that was comparable in magnitude to 
that induced by 16-fold higher doses of soluble Ova or that induced by multiple 
doses of Alum-adjuvanted OVA [22]. Moreover, this microparticle vaccine regimen 
successfully primed the humoral immune response for an anamnestic immune 
response. Together, these results indicate that encapsulation of vaccine antigens 
into polyanhydride microparticles provides a dosage sparing effect by providing a 
platform delivery system that can eliciting a mature humoral memory response 
following a single administration. 
 
2. Materials and Methods 
2.1  Materials and polymer synthesis 
The chemicals needed for CPH monomer synthesis, 4-p-hydroxybenzoic 
acid, 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, and sebacic acid (99%), were 
purchased from Sigma Aldrich (St Louis, MO); acetic anhydride, methylene chloride, 
and ethanol were purchased from Fisher Scientific (Fairlawn, NJ). CPH diacid was 
synthesized as described previously [23, 24]. Prepolymers of SA and CPH were 
synthesized by the methods described by Shen et al. [25] and Conix et al [23]. 
CPH:SA copolymers were synthesized by melt polycondensation as described 
previously [14]. The purity and degree of polymerization of the copolymers was 
analyzed using 1H nuclear magnetic resonance (NMR) spectroscopy obtained from a 
Varian VXR-300 MHz NMR spectrometer (Varian Inc., Palo Alto, CA). NMR spectra 
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were consistent with previously published data and confirmed the synthesis of the 
desired copolymer compositions [24]. In addition, polymer molecular weight was 
determined using gel permeation chromatography (GPC, Waters HPLC System, 
Milford, MA) using Varian Inc. GPC columns.  
 
2.3  Microparticle fabrication 
To eliminate the endotoxin contamination of the Ovalbumin (Ova; Sigma 
Aldrich) and to prevent unintended enhancement of the immune response caused by 
contaminating endotoxin, affinityPak Detoxi-Gel endotoxin removal columns 
(Thermo Scientific, Rockford, IL) were used according to manufacturer’s instructions. 
The recovered Ova contained <10 EU/mg protein and was lyophilized and stored at -
20oC. Ova-loaded microparticles were fabricated using cryogenic atomization [5, 9, 
26]. The parameters used for each copolymer chemistry were previously specified 
by Torres et al. [16] and Lopac et al [17]. The obtained microparticles were collected 
by vacuum filtration and dried under vacuum. Using four replicative samples for each 
microparticle preparation, microparticle morphology and size distribution were 
analyzed by using images obtained by scanning electron microscopy (SEM) (JEOL 
840 A, JEOL, Peabody, MA), and ImageJ image analysis software (National 
Institutes of Health, Bethesda, MD). An average of 200 particles per image was 
analyzed. 
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2.4  In vitro antigen release 
In vitro Ova release kinetics were measured by suspending 15 mg of the Ova-
loaded microparticles in 1 mL of phosphate buffered saline (0.1 M, pH 7.4) with 
0.01% w/v sodium azide, and incubating at 37°C on a shaker platform at 100 rpm. 
Aliquots of 750 µL were taken at prescribed time intervals and replaced with fresh 
buffer. Aliquots were stored at 4°C to measure protein concentration using micro-
bicinchoninic acid (BCA) analysis at an absorbance of 570 nm. At least three 
replicates of each sample were analyzed. After 25 days, the remaining encapsulated 
protein was extracted by degrading the remaining particles in 17 mM NaOH. Protein 
concentration was determined with a microBCA assay. Total protein encapsulated in 
the particles was determined by calculating the protein released at each timepoint as 
described by Torres et al [16]. 
 
2.6  Mice and immunization procedures 
Female C3H/HeNHsd (C3H) mice were purchased from Harlan Sprague 
Dawley (Frederick, MD). All animal procedures were conducted with the approval of 
the Iowa State University Institutional Animal Care and Use Committee. To evaluate 
the serum antibody response to non-adjuvanted Ova, twenty milligrams of 
endotoxin-free Ova was suspended in pyrogen-free saline and diluted to the 
indicated concentrations. Mice were subcutaneously (SC) immunized with soluble 
Ova alone at doses of 1600, 400, 100, or 25 µg in 100 µL pyrogen-free saline with 7 
mice per treatment group (n=7). Control animals received 100 µL saline alone (n=6). 
Blood samples were collected from the left saphenous vein prior to immunization 
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and every four weeks thereafter. Serum was collected after centrifugation and stored 
at -20°C until assayed for Ova-specific antibody as described below. 
Mice were immunized SC with 25 µg of Ova encapsulated into 0.5 mg of either 
20:80 CPH:SA or 50:50 CPH:SA microparticles suspended in pyrogen-free saline 
with 8 mice per treatment group (n=8). Prior to administration, microparticles were 
sonicated briefly to generate a uniform suspension. A total volume of 100 µL was 
administered at the injection site. For the antigenic challenge studies, mice that had 
been immunized 12 weeks prior were immunized SC with 25 µg of endotoxin-free 
Ova suspended in pyrogen-free saline. Serum samples were collected five days 
later in order to measure the anamnestic antibody response.  
 
2.7  ELISA for Ova-specific antibody titer and avidity 
ELISA plates (Costar Catalog # 3590, EIA/RIA high binding) were coated 
overnight with 0.5 µg/well Ova. Plates were washed with phosphate buffered saline 
containing 0.5% Tween 20 at a pH of 7.4 (PBST). Plates were blocked for two hours 
with 2% gelatin (Difco) in PBST. Plates were washed and serial dilutions of 
individual serum samples in PBST with 1% heat inactivated normal goat serum 
(GIBCO) were incubated overnight at 4oC. Plates were washed again with PBST 
and alkaline phosphatase-conjugated goat anti-mouse IgG (H&L), IgG1, or IgG2a 
(Jackson ImmunoResearch Laboratories, West Grove, PA) diluted 1:1000 in 1% 
heat inactivated normal goat serum in PBST was incubated for 2 h. Plates were 
washed and p-nitrophenyl phosphate (Sigma) substrate (1 mg/mL) in 50 mM 
Na2CO3 and 2 mM MgCl2 buffer (pH 9.3) was added to each well. Changes in optical 
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density (OD) were measured at 405 nm using a spectrophotometer (Spectra Max 
190, Molecular Devices, Sunnyvale CA). Antibody avidity ELISA was performed as 
described previously to determine antibody binding strength in the presence of a 
chaotropic agent that disurpts antibody-antigen binding interactions [18]. The molar 
concentration of NaSCN corresponding to the to 50% percent loss of absorbance 
was designated as the relative avidity value reported. 
 
2.8  Statistical analysis 
Longitudinal data were analyzed using repeated measure analysis of variance 
(ANOVA) models (with SAS version 9.2). Treatment and time were fixed effects in 
the statistical model, whereas mouse was the subject of repeated measures. Cross-
sectional data were analyzed using one-way ANOVA models with treatment as the 
explanatory variable. Differences in mean responses among treatments were 
compared by using Tukey’s T-test. Log10 transformation was applied to responses 
with skewed distributions before analyses. Statistical tests with p ≤ 0.05 were 
regarded as significant. 
 
3. Results 
3.1 Single, soluble doses of Ova require 100 mg or more to elicit significant antibody 
titers and prime the humoral response to respond to an antigenic challenge. 
In order to demonstrate the dose sparing advantages associated with 
capabilities of a single dose immunization regimen employing a suboptimal dose of 
Ova encapsulated into polyanhydride microparticles, we first examined the kinetics 
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of the IgG antibody response of mice immunized subcutaneously once with varying 
doses of soluble Ova (Figure 1A). Groups of mice that were administered 1600 µg, 
400 µg or 100 µg of Ova elicited significantly higher antibody titers in contrast to 
mice immunized with 25 µg of Ova. The kinetics of the IgG response induced by a 
single, soluble dose of Ova demonstrated that the peak titer was obtained four 
weeks post-injection and then began to wane. 
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Figure 1. Single doses of soluble 
ovalbumin (Ova) required 100 mg 
or more to elicit significant 
antibody titers and prime the 
humoral response to respond to 
an antigenic challenge. Separate 
groups of C3H mice were immunized 
with a titrating dosage of soluble 
Ova: 1600 µg (open diamonds), 400 
µg (open squares), 100 µg (open 
circles), 25 µg (open triangles), or 
saline alone ( x ). Ova-specific serum 
antibody titers (A) and antibody 
avidity (B) were measured over 12 
weeks. (C) At 12 weeks post-
immunization, the Ova-specific 
serum antibody titer was measured 
prior to (open histograms) and five 
days after (closed histograms) an 
antigenic challenge administered 
subcutaneously in the form of 25 µg 
Ova. All data are presented as the 
mean ± SEM and are representative 
of three independent experiments. 
For panel A, * represents a 
statistically significant difference from 
the 25 µg group at p < 0.05. For 
panel C, * indicates a statistically 
significant difference from treatments 
prior to boost at p < 0.05. Treatments 
with different letters are significantly 
different from one another at p < 
0.05. 
	  	   101	  
 
Antibody avidity was also assessed as a surrogate marker of vaccine efficacy. 
Serum samples from the mice immunized with a single dose of 100 µg, 400 µg or 
1600 µg of soluble Ova developed a peak antibody avidity at four weeks post-
vaccination that was stable through 12 weeks post-immunization (Figure 1B). Serum 
samples from mice vaccinated with 25 µg of soluble Ova alone did not induce a 
sufficient antibody titer to measure antibody avidity. To ascertain the generation of 
antigen-specific memory responses, a 25 µg “antigenic challenge” was administered 
at 12 weeks post-vaccination. A measurable increase in the secondary humoral 
antibody response was observed in mice that had received 25 µg or more antigen at 
the initial vaccination (Figure 1C). A soluble dose of 25 µg of Ova was not sufficient 
to induce a primary serum antibody (Figure 1C, open bar) response but was able to 
prime the mice for a secondary immune response (Figure 1C, closed bar), indicating 
that 25 µg was a suboptimal dose of immunogen. 
 
3.2  Controlled antigen release by polyanhydride microparticles in vivo results in a 
primed humoral response while sparing antigen. 
Ova-loaded 20:80 and 50:50 CPH:SA microparticles were characterized by 
SEM after fabrication (Figure 2A). Morphologies of the Ova-loaded microparticles 
were consistent with previous work describing blank microparticles [16, 17]. The 
diameter of the microparticles ranged between 5 and 21 µm for both 20:80 CPH:SA 
and 50:50 CPH:SA. While there was a greater initial burst release from the 20:80 
CPH:SA formulation (Figure 2B), the release profile of Ova from the two 
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polyanhydride formulations was shown to be sustained and is consistent with 
previous work [9, 16, 17]. 
 
 
 
 
Using the polyanhydride microparticle vaccine delivery platform, we sought to 
demonstrate that a significant humoral response could be induced when a 
suboptimal dose of Ova (25 µg) was encapsulated into one or both of the 
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Figure 2. Morphology and in vitro release kinetics of Ova-loaded 
polyanhydride microparticles. Scanning electron photomicrographs of Ova-
loaded 20:80 CPH:SA (mean diameter ± SD, 10 ± 5 µm) and 50:50 CPH:SA (12 ± 
7 µm). (A) Scale bar: 20 µm. (B) Release kinetics of Ova from 20:80 CPH:SA and 
50:50 CPH:SA microparticles. Data are presented as the mean ± SEM and are 
representative of two independent experiments with duplicate samples analyzed 
in each experiment. 
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microparticle formulations evaluated in this study. The IgG response induced by the 
administration of 500 µg of either 20:80 CPH:SA or 50:50 CPH:SA containing 25 µg 
of Ova (i.e., 5% wt/wt) was evaluated for 12 weeks following administration (Figure 
3A). Both polyanhydride formulations tested elicited similar Ova-specific antibody 
titers. Compared to mice receiving 25 µg of soluble Ova, significant antibody titers 
were demonstrable in microparticle vaccinated groups beginning at week four and 
were maintained through 12 weeks post-vaccination. Compared to the mice 
receiving the larger soluble doses (i.e., ≥ 100 µg) of Ova, the anti-Ova serum 
antibody response of the microparticle vaccinated mice peaked four weeks later 
(Figure 3A versus Figure 1A). Mice receiving either Ova-encapsulated microparticle 
vaccine formulation developed a more avid Ova-specific antibody response than did 
mice receiving much larger doses of soluble Ova (Figure 3B). These more avid 
antibody responses were sustained over the 12 weeks of the experiment (Figure 
3B). After the antigenic challenge (i.e., booster immunization), greater Ova-specific 
serum antibody responses (i.e., titers ≥ 100,000) were observed in mice 
administered the Ova-loaded microparticles as compared to the antibody responses 
(i.e., titers ≤ 10,000) induced by the soluble doses of Ova (Figure 3C compared to 
Figure 1C). Statistical comparisons of the antibody responses induced after the 
antigenic challenge (Figures 1C and 3C, solid histograms) demonstrated an 
adjuvant effect associated with the administration of the microparticles that was 
consistent with the elevated titers and avidity presented in Figures 3A and 3B. 
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3.3  Isotype switching of the serum 
antibody responses suggests immunological memory. 
Characteristics of an immune response can be determined by examining the 
antibody isotype produced. For mice immunized with Ova-loaded microparticles, the 
secondary serum antibody response was characterized by the presence of both 
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Figure 3. Enhanced serum 
antibody response in mice 
immunized with Ova-loaded 
polyanhydride microparticles. 
Ova-specific serum antibody titers 
(A) and antibody avidity (B) for 
C3H mice immunized with 20:80 
CPH:SA Ova-loaded 
microparticles (closed circles), 
50:50 CPH:SA Ova-loaded 
microparticles (closed squares), 
25 µg soluble Ova (open 
triangles) or saline alone ( x ). (C) 
At 12 weeks post-immunization, 
the anamnestic Ova-specific 
serum antibody titer was 
measured prior to (open 
histograms) and five days after 
(closed histograms) a 
subcutaneously administered 
dose of 25 µg Ova(i.e., antigenic 
challenge). All data are presented 
as the mean ± SEM and are 
representative of three 
independent experiments. For 
panel A, * represents a 
statistically significant difference 
from the 25 µg soluble Ova group 
at p < 0.05. For panel C, * 
indicates a statistically significant 
difference from treatments prior to 
boost at p < 0.05. Treatments 
with different letters are 
significantly different from one 
another at p < 0.05. 
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Ova-specific IgG1 and IgG2a (Figure 4A and 4B, respectively). For mice immunized 
with single doses of soluble Ova (100 to 1600 µg), there was no demonstrable Ova-
specific IgG2a detected after the antigenic-challenge (data not shown). Together, 
these results indicate that a mature, antigen-specific memory response was 
obtained with a priming dose of only 25 µg when encapsulated into polyanhydride 
microparticles. 
 
 
4. Discussion 
Biodegradable polymers exhibit adjuvant properties, making them ideal 
delivery platforms for single dose vaccine regimens [27-29]. Specifically, vaccine 
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Figure 4. Mice immunized with Ova-loaded polyanhydride microparticles 
develop an anamnestic humoral response characterized by IgG1 and 
IgG2a, indicating antibody isotype switching. Ova-specific (A) IgG1 and 
(B) IgG2a serum antibody titer in mice administered a subcutaneous antigenic 
challenge of 25 µg Ova in saline 12 weeks after initial immunization with Ova-
loaded polyanhydride microparticles. Data are presented as the mean ± SEM 
and are representative of three independent experiments. Treatments with 
different letters are significantly different from one another at p < 0.05. 
	  	   106	  
formulations based on PLGA, PLA or PGA have been shown to induce immune 
responses to a variety of immunogens [30, 31]. Several of these studies 
incorporated monophosphoryl lipid A, a known adjuvant, into the polymer delivery 
device along with the immunogen, thereby complicating the ability to determine 
whether or not the polymer itself provides any immune enhancing activity [13, 29, 
31]. Other studies have included excipients and/or stabilizers to enhance the 
immunogenicity of encapsulated proteins [27]. In the current study, no additional 
immune-enhancers were included during the fabrication of our polyanhydride 
microparticles loaded with endotoxin-free Ova or administered at the time of 
immunization. Therefore, any immuno-modulatory properties observed were the 
direct result of the polymers themselves. 
Previously, we have demonstrated that polymer chemistry differentially effects 
in vitro antigen presenting cell (APC) cytokine production, particle uptake, and cell 
surface marker expression [20, 32]. In contrast to these differential effects 
demonstrated in vitro on APCs, in vivo administration of Ova-loaded 20:80 or 50:50 
CPH:SA microparticles induced similar serum antibody titers (Figure 3A), avidity 
(Figure 3B), and recall responses (Figure 3C and 4). A robust antigen-specific 
humoral response to Ova, a weakly immunogenic protein, was induced using 16- to 
64-fold less protein when encapsulated into polyanhydride microparticles as 
compared to soluble Ova alone (Figure 1 compared to Figure 3). The present 
studies were performed to demonstrate that immune responses could be induced 
with a single, suboptimal dose of an immunogen, not to compare the adjuvant 
capabilities of the microparticles to other adjuvants. However, these studies do infer 
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that polyanhydride delivery devices provide the adjuvant properties essential for 
effective implementation of subunit vaccines. Indeed, when a sub-immunogenic 
dose (e.g., 25 µg) of Ova was encapsulated into the microparticles, both co-polymer 
formulations were able to induce a robust immune response comparable to that 
induced by 400 to 1600 µg of soluble Ova. Furthermore, the titers of mice 
immunized with single dose microparticle formulations were similar to those reported 
for mice immunized multiple times with Alum-adjuvanted Ova over a range of doses 
comparable to the 25 µg dose used in this study [22, 33-38]. For example, Pollock et 
al. reported mean IgG1 titers of 40,000 after two administrations of 100 µg Ova 
adjuvanted with Alum [22]. In another study, a single immunization with 50 µg Ova 
adjuvanted with Alum in C57BL/6 mice induced an IgG1 titer of approximately 100, 
which increased to approximately 10,000 after a second immunization [36]. Sun et 
al. observed similar antigen-specific IgG titers following administration of 100 µg Ova 
adjuvanted with Alum [38]. In the present work, the titer values (approximately 
1,000) obtained by immunizing mice once with 25 µg of Ova encapsulated in 
polyanhydride microparticles are similar to those induced by multiple doses of Alum-
adjuvanted Ova described in the literature [22, 33-38]. Moreover, these titers 
increased to approximately 100,000 by boosting with only 25 µg of non-adjuvanted, 
endotoxin-free Ova (Figure 3C). 
Recombinant protein antigens provide excellent purity and safety profiles for 
vaccines, but may sacrifice potency of the vaccine and lead to less than efficacious 
immune responses. The peak antibody response of microparticle vaccinated mice 
appeared four weeks later than in mice vaccinated with large amounts of soluble 
	  	   108	  
antigen. This observation indicates that microparticle controlled antigen release 
provides a unique microenviroment in vivo where antigen persistance facilitates a 
more avid antibody response . In this regard, the avidity of the antibody response 
induced by the microparticle formulations was greater than that induced by any of 
the soluble doses of Ova used in this study. These observations demonstrate the 
importance of evaluating the magnitude (i.e., titer) and the quality (i.e., avidity) of the 
antibody response in order to fully appreciate the benefits of novel vaccine delivery 
platforms. 
Persistence of antigen is also known to be critical for inducing long-lived 
plasma cells and memory B cells [39]. Companion studies from our laboratory 
indicate the persistence of polyanhydride particles at injection sites up to 12 weeks 
post-administration (manuscript in preparation). In the present study, the 
encapsulation, controlled release and subsequent persistence of Ova in vivo likely 
contributed to the induction of long-lived plasma cells and induction of a more avid 
humoral immune response than that induced by higher doses of soluble Ova. It may 
be speculated that the increased avidity of the serum antibody response in mice 
vaccinated with the Ova-loaded microparticles results specifcially from persistence 
of antigen in germinal centers, possibly mediated by follicular dendritic cells, in 
secondary lymphoid tissue [40]. An optimal immunization regimen employing both 
soluble and particle encapsulated antigen likely induces a robust humoral response 
more rapidly after immunization as well as promotes a sustained antibody response . 
The single dose of 25 µg Ova encapsulated into the microparticles was sufficient to 
induce a demonstrable antibody response and to prime the host for a more robust 
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secondary antibody responses following an antigenic challenge 12 weeks later 
(Figures 3 and 4). In contrast, there was little evidence of a recall response in mice 
initially administered 1600 µg Ova. Bioerodible microparticles may be performing 
similar actions as traditional emulsification vaccine adjuvants by providing an 
antigenic depot and creating particulate antigen that is more readily recognized by B 
cells and taken up by APCs [41]. Experimental models employing micro- or 
nanoparticle vaccination regimen incorporating recombinant immunogens followed 
by pathogen challenge will demonstrate the full potential of this polymer delivery 
platform to induce protective immune responses [42].  
 
5. Conclusions 
In this work, we demonstrated that robust, long-lived immune responses can 
be induced by a single, suboptimal dose of a weak immunogen by encapsulation 
into surface eroding polyanhydride microparticles. Administration of Ova-loaded 
microparticles facilitated the induction of a more robust humoral immune response 
with 16- to 64-fold less immunogen than the amount of soluble Ova required to 
induce a comparable titers. The use of these polymer delivery devices to immunize 
mice induced an anamnestic antibody response and generated isotype switching, as 
evidenced by the induction of antigen-specific IgG2a, an antibody isotype indicative 
of memory T cell development). Lastly, the avidity (i.e., quality) of the serum 
antibody induced by 25 µg of Ova encapsulated into microparticles was greater than 
that induced by 1600 µg of soluble Ova. Collectively, the data demonstrate that the 
use of surface erodible polyanhydride microparticles as a vaccine delivery platform 
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may enhance the magnitude and quality of the immune response to subunit or 
recombinant proteins, and thus broaden the arsenal of recombinant immunogens 
that can be safely, efficaciously, and cost effectively employed in vaccine 
formulations. 
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CHAPTER 4: EVALUATION OF BIOCOMPATIBILITY AND ADMINISTRATION 
SITE REACTOGENICITY OF POLYANHYDRIDE PARTICLE-BASED PLATFORM 
FOR VACCINE DELIVERY 
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Katherine A. Walz, Chong Wang, Jesse Hostetter, Balaji Narasimhan, and Michael J. 
Wannemuehler 
 
Abstract 
Efficacy, purity, safety, and potency are important attributes of vaccines. 
Polyanhydride particles represent a novel class of vaccine adjuvants and delivery 
platforms that have demonstrated the ability to enhance the stability of protein 
antigens as well as elicit protective immunity against bacterial pathogens. This work 
aims to elucidate the biocompatibility, inflammatory reactions, and particle effects on 
mice injected with a 5 mg dose of polyanhydride nanoparticles via common 
parenteral routes (subcutaneous and intramuscular). Independent of polymer 
chemistry, nanoparticles more effectively disseminated away from the injection site 
as compared to microparticles, which exhibited a depot effect. Using fluorescent 
probes, the in vivo distribution of three formulations of nanoparticles, following 
subcutaneous administration, indicated migration away from the injection site. Less 
inflammation was observed at the injection sites of mice administered nanoparticles 
as compared to Alum and incomplete Freund’s adjuvant. Furthermore, histological 
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evaluation revealed minimal adverse injection site reactions and minimal 
toxicological effects associated with the administration of nanoparticles at 30 days 
post-administration. Collectively, these results demonstrate that polyanhydride 
nanoparticles do not induce inflammation as a cumulative effect of particle 
persistence or degradation and are therefore a viable candidate for a vaccine 
delivery platform. 
 
1. Introduction 
Next generation vaccine design aims to recapitulate the positive effects of 
enhancing immune responses to the immunogen of interest while avoiding the 
detrimental side-effects often caused by adjuvants [2].  While efficacy is an essential 
outcome of vaccine design, biocompatibility is critical for ensuring patient 
compliance and ultimately developing protective immunity [3]. Adverse injection site 
reactions that cause either pain or tissue damage are major hurdles in the 
development and licensure of vaccines containing immunostimulatory adjuvants. 
These adjuvants are often necessary vaccine components, as they enhance 
immune responses against poorly immunogenic antigens. Specifically, adjuvants 
often comprise particulate material that is readily taken up by antigen presenting 
cells, activates innate immunity, and provides an antigenic depot to sustain immune 
responses [4]. The most common adjuvants used in human and veterinary medicine 
consist of aluminum salts, modified Toll-like receptor ligands, oil-water emulsions, or 
combinations thereof [5]. The majority of adjuvanted vaccines approved for human 
use contain potassium aluminum sulfate (Alum), MF59 (a squalene oil-in-water 
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emulsion), or ASO4 (monophosphoryl lipid A and Alum). Unfortunately, 
administration of vaccines containing these adjuvants often induces clinical signs of 
pain, redness, rash, swelling, and fever [6-8]. 
Polyanhydrides are a class of biodegradable polymers that have been studied 
for more than three decades as carriers for drugs, proteins, and vaccines [9]. The 
degradation products of polyanhydrides are metabolized and either released as 
carbon dioxide or excreted through urine and feces as carboxylic acids and were 
found to have no significant impact on kidney or liver functions [10, 11]. Additionally, 
polyanhydride wafer implants comprised of 1,3-bis-(p-carboxyphenoxy)pentane 
(CPP) and sebacic acid (SA) have been successfully used in humans to deliver 
chemotherapeutic drugs to treat glioblastoma multiforme [12-15]. Recently, 
amphiphilic polyanhydride nanoparticles based upon copolymers of SA, 1,6-bis-(p-
carboxyphenoxy)hexane (CPH), and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) have been explored as a vaccine delivery platform with inherent adjuvant 
and antigen stabilization properties [16, 17]. These particles provide amphiphilic 
environments for release of conformationally and functionally stable protein antigens 
[17, 18] and demonstrate a combination of bulk and surface erosion kinetics that 
create a controlled release of encapsulated payload, making them ideal candidates 
for delivery of single-dose vaccines. Recent studies have shown that these 
polyanhydride nanoparticles exhibit pathogen-mimicking properties in terms of their 
effect on immune activation, cellular uptake, and cellular persistence [19-23]. 
Moreover, single dose vaccination with these particles has induced long-lasting, high 
titer, and avid antibody responses against multiple immunogens. For example, 
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administration of a single-dose of CPH:SA microparticles encapsulating tetanus 
toxoid to mice created antibody titers that persisted for at least 26 weeks post-
vaccination [24]. Additionally, immunization of mice with a single dose of ovalbumin-
loaded polyanhydride microparticles elicited humoral responses comparable to those 
induced by a 40-fold greater dose of soluble ovalbumin [25]. We have also 
demonstrated the ability of the polyanhydride nanoparticle vaccine platform to 
induce, in a single intranasal administration, long-lived protective immunity in mice 
for up to 280 days after an otherwise lethal challenge by Yersinia pestis, the 
causative agent of pneumonic plague [21, 23]. 
However, the toxicological effects of these novel polyanhydride nanoparticles, 
especially when administered via various routes, need to be determined. To 
complement our previous findings of efficacy, we demonstrate here that 
polyanhydride nanoparticles result in deposition characteristics similar to those of 
traditional adjuvants. However, in contrast to traditional adjuvants, immunization with 
polyanhydride nanoparticles induced minimal inflammatory reactions and little to no 
tissue damage at sites of injection. Together with previous results, these data 
demonstrate the biocompatibility and limited reactogenicity of this nanoparticle 
delivery platform. 
 
2. Materials and Methods 
2.1 Synthesis and characterization of copolymers 
 CPH and CPTEG monomers were synthesized using the chemicals listed: 4-
p-hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, and tri-
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ethylene glycol. All these chemicals and sebacic acid (99%) were purchased from 
Sigma Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile was obtained from Apollo 
Scientific (Cheshire, UK); potassium carbonate, dimethyl formamide, toluene, 
sulfuric acid, acetic acid, acetonitrile, acetic anhydride, methylene chloride, and 
petroleum ether were purchased from Fisher Scientific (Fairlawn, NJ). Synthesis of 
CPH and CPTEG diacids was performed as previously described [17, 26] and pre-
polymers of SA and CPH were synthesized using previously described methods [26, 
27]. Copolymers (20:80 and 50:50 CPH:SA and 20:80 and 50:50 CPTEG:CPH) were 
synthesized using a melt polycondensation process as detailed by Kipper et al. and 
Torres et al., [17, 24] respectively. The degree of polymerization, molecular weight, 
chemical structure, and polymer purity were determined using 1H nuclear magnetic 
resonance (NMR) spectroscopy (Varian VXR-300 MHz, Palo Alto, CA).  
 
2.2 Fabrication and characterization of particles 
Microparticles were fabricated using a cryogenic atomization method as 
described in Kipper et al [24]. Blank and dye-loaded (Kodak X-Sight 640 LSS Dye, 
NHS Ester Carestream Health, Rochester, NY) nanoparticles (0.5% w/w loading) 
were fabricated using the anti-solvent nanoencapsulation method outlined in Ulery et 
al [20]. Briefly, the copolymer was dissolved in methylene chloride at a concentration 
of 25 mg/mL at 4˚C. The dye was added to the dissolved copolymer and the solution 
was sonicated for uniform dispersal of the dye within the copolymer. The dissolved 
dye and copolymer (dye-loaded) or copolymer (blank) solution was rapidly 
transferred into chilled pentane (-20°C) at a non-solvent to solvent ratio of 80:1, and 
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this solution was vacuum filtered to recover the nanoparticles. Shape and size of the 
resulting nanoparticles were characterized using scanning electron microscopy 
(SEM) (JEOL 840 A, JEOL, Peabody, MA). The particle size distribution was 
obtained from SEM images using Image J version 1.44 image analysis software [28]. 
An average of 200 particles per image was analyzed.  
 
2.3 Mice 
 Female BALB/c mice were purchased from Harlan Laboratories (Indianapolis, 
IN). Female SKH1-E (hairless) mice were purchased from Charles River 
Laboratories (Wilmington, MA). All mice were housed under specific pathogen-free 
conditions where all bedding, caging, water, and feed were sterilized prior to use. 
Animal procedures were conducted with the approval of the Iowa State University 
Institutional Animal Care and Use Committee. 
 
2.4 Mouse treatments 
2.4.1 Microparticle and nanoparticle biodistribution  
Separate groups of BALB/c mice received a subcutaneous (SC) injection of 
either 0.5 mg of microparticles or 0.5 mg nanoparticles loaded with LSS 640 in 250 
µL of saline at the nape of the neck (Figure 1). 
 
2.4.2 Nanoparticle and adjuvant in vivo imaging  
To avoid the auto-fluorescence often associated with animal fur, 
immunocompetent, hairless SKH1-E mice were employed for these studies and 
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assigned to one of six treatment groups: 1.5 mL of sterile saline, 5 mg of 
nanoparticles (of three different chemistries) loaded with LSS 640 suspended in 1.5 
mL of sterile saline, 200 µL of 1:1 sterile saline batched with Imject® Alum (Pierce 
Rockford, IL) or 200 µL of 1:1 sterile saline emulsified in incomplete Freund’s 
adjuvant (IFA). To administer the same amount of fluorescent dye as present in the 
polyanhydride particles, LSS 640 was solubilized in saline (6.25 µg/mL). Each 
mouse was injected SC at the nape of the neck with 2.5 mg of particles in 330 µL 
saline, 1.75 mg of particles in 230 µL of saline in the left rear flank intramuscularly 
(IM) and 0.75 mg in 100 µL of saline IM in the right rear flank. The three nanoparticle 
formulations used for these studies were 20:80 CPH:SA, 50:50 CPTEG:CPH, and 
20:80 CPTEG:CPH. IFA and Alum injections consisted of 100 µL SC at the nape of 
the neck, 75 µL IM in the left rear flank, and 25 µL IM in the right rear flank. The 
regimen for the administration of sterile saline with LSS 640 employed the same 
volumes as the nanoparticle injections. Rotational image capture was performed 
daily for 7 days after the injection with a Multimodal Animal Rotation System 
(Carestream Multispectral FX, Rochester, NY). In vivo images were captured while 
mice were anesthetized with 2% isoflurane in 100% O2, at 2.5 L/min. Images were 
captured using 60-second exposures with an excitation filter of 630 nm and emission 
filter of 790 nm. Rotational images consisted of exposures taken every 25o from 0° 
to 400o to provide sufficient overlap and create a full 360o rotational image of each 
mouse. All image analysis was performed using Image J software version 1.44.[27] 
Raw images were inverted and background subtracted via a rolling ball radius of 150 
pixels. The ImageJ lookup table “thal” was applied to the data in Figures 1 and 2. A 
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region of interest (ROI) was constructed and used to analyze mean fluorescence 
intensity (MFI) at the injection site of all mice for every image. The MFI of the ROI at 
the injection site of mice receiving particles was compared to the MFI of the ROI at 
the injection site measured immediately after administration of nanoparticles and the 
data is expressed as percent of initial fluorescence intensity. 
 
2.4.3 Nanoparticle and adjuvant inflammation  
SKH1-E mice were injected with blank nanoparticles as outlined in the 
treatment groups described above. To evaluate the in vivo inflammatory response, 
mice were intravenously administered 2 nmol of ProSense® 750 (VisEn Medical, 
Woburn, MA) 8 h prior to imaging on days 3 and 7 after the administration of the 
nanoparticles. ProSense® 750 is an activatable fluorescent reagent that is optically 
visible when the dye is cleaved by degradative enzymes, including cathepsin B, L, S, 
or plasminogen, that are common at sites of inflammation [29]. After 8 h, in vivo 
images were captured while mice were kept under anesthesia with 2% isoflurane in 
100% O2, at 2.5 L/min. Images were captured using 30-second exposures with an 
excitation filter of 730 nm and an emission filter of 790 nm. All image analysis was 
performed using ImageJ version 1.44 [28]. Raw images were inverted and 
background subtracted via a rolling ball radius of 150 pixels. The ImageJ lookup 
table “smart” was applied to the data in Figure 3. ROI analysis of injections sites was 
performed and mean fluorescence intensity (MFI) was quantified.   
 
2.4.4 Nanoparticle and adjuvant histological and biomarker examination 
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BALB/c mice were injected with a total of 5 mg of nanoparticles as described 
above. Other treatments included mice injected with Alum, IFA, or saline. Serum 
samples were collected from all mice prior to the administration of the nanoparticles 
and on days 3, 7, and 28 after administration. Serum samples were obtained via 
saphenous vein bleeds. Serum, tissue, and urine samples were collected at 
necropsy. 
 
2.5 Serum cytokine analysis 
Serum samples obtained from BALB/c mice were analyzed using a 22-plex 
chemokine and cytokine antibody array (Millipore, Billerica, MA) measuring the 
following analytes: G-CSF, GM-CSF, IFN-γ, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-
1α, IL-1β, IL-2, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC, MCP-1, MIP-1α, RANTES, 
and TNF-α. Assays were performed according to the manufacturer’s 
recommendations; data were acquired and analyzed using a Bio-Plex 200 (Bio Rad, 
Hercules, CA). 
 
2.6 Biomarker analysis 
Serum and urinary biomarkers of kidney and liver function were analyzed 
using Vitros 5.1 Chemistry Analyzer. Toxicological biomarker values were compared 
to those reported in Mazzaccara et al [1]. 
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2.7 Histological evaluation 
Formalin-fixed tissues from BALB/c mice were embedded, sectioned, stained 
with hematoxylin and eosin (H&E), and blindly evaluated by a board-certified 
veterinary pathologist (JM Hostetter) for indications of toxicity in liver and kidney and 
adverse injection site reactions in muscle as well as in the epidermal and dermal 
tissue. A twenty-point histopathological scoring system for adverse reactions at 
injection sites was created in which scores of 0-5 were assigned to four independent 
parameters: inflammation, distribution of inflammatory cell infiltrate, muscle 
degeneration, and fibrosis. A fifteen-point histopathological scoring system for 
toxicological damage in liver and kidneys was created in which scores of 0 to 5 were 
assigned to three independent parameters: inflammation, distribution of 
inflammatory cell infiltrate, and tissue necrosis. 
 
2.8 Statistical analysis 
Repeated measured cytokine variables were log10 transformed and analyzed 
using repeated measure Analysis of Variance (ANOVA) models. Treatment and time 
were fixed effects in this model, while mouse was the subject of repeated measures. 
Histological, weight, and biomarker data were analyzed using one-way ANOVA 
models with treatment as an explanatory variable. Differences in mean responses 
among treatments were tested with an overall F-test followed by a post-hoc Tukey’s 
t-test. Statistical tests with p values ≤ 0.05 were regarded as significant. 
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3. Results 
3.1 Nanoparticles disseminated away from the injection site whereas microparticles 
formed a depot 
 The estimated mean diameter of the LSS 640 fluorophore-loaded 
microparticles was 10 µm (± 400 nm) (Figure 1A) and that of the LSS 640 
fluorophore-loaded nanoparticles was 400 nm (± 100 nm) (Figure 1B). These sizes 
were consistent between particles of all chemistries and with previously published 
studies [21-24, 30-34]. The polymers were characterized by 1H NMR and the 
molecular weights were determined to be within published ranges [30]. 
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Figure 1. Nanoparticles disseminated away from the injection site 
whereas microparticles formed a depot.  Scanning electron 
photomicrographs of 50:50 CPH:SA (A) micro- (scale bar 20 µm) or (B) 
nanoparticles (scale bar 2 µm). (C) Representative three-dimensional 
surface plot for a BALB/c mouse 4 days after SC administration of 500 µg of 
50:50 CPH:SA micro- (left) or nanoparticles (right) graphed as a function of 
platform location (X- and Y- axes) and fluorescent intensity (Z-axis).  X- and 
Y- axes represent size (in millimeters) of field of view; Z-axis represents 
fluorescence intensity. 
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The effect of size on particle biodistribution was investigated following SC 
administration of 50:50 CPH:SA nanoparticles or microparticles using live animal in 
vivo imaging. At four days post-administration, nanoparticles were more widely 
disseminated in contrast to the microparticles (Figure 1C). Specifically, three 
dimensional image analysis revealed a single, more intense peak of fluorescence at 
the injection site of mice receiving microparticles (Figure 1C). In contrast, multiple 
sites of discrete fluorescence were detected at tissue sites distal to the site of 
administration for mice receiving nanoparticles. This pattern of distribution observed 
following administration of the nanoparticles is not associated with the release of 
the tracer dye because at no time point after administration of the soluble tracer dye 
was a discrete pattern of fluorescence detected. 
 
3.2 In vivo persistence of nanoparticles mimicked that of traditional adjuvants when 
administered via parenteral routes  
 Traditional vaccine adjuvants, including Alum, are thought to elicit immune-
enhancing effects partly by forming antigenic depots [4]. In these studies, live animal 
in vivo imaging was employed to compare the deposition and persistence of 
polyanhydride nanoparticle adjuvants to those of traditional adjuvants. SKH1-E mice 
were administered a total of 5 mg of nanoparticles at three different injection sites as 
outlined in the methods (Figure 2A). Control mice were administered saline 
containing the fluorescent dye (LSS 640), and other mice were administered the 
LSS 640 dye adsorbed onto Alum or emulsified into IFA. Rotational images of mice 
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were captured at 7-day intervals; a representative image of a mouse from each 
treatment group is shown in Figure 2B. Mice administered Alum or IFA exhibited 
depot effects as demonstrated by the focal fluorescence present at the injection site 
after 7 days (Figure 2B). Each of the nanoparticle formulations provide a depot, 
however, there were lower amounts of fluorescence emanating from the injection 
sites, suggesting dissemination and/or erosion of the nanoparticles. Image analysis 
of injection site regions of interest (ROI) revealed chemistry-dependent effects on 
particle persistence (Figure 2C). Fluorescence intensity diminished most rapidly (by 
2 weeks post-injection) for 20:80 CPH:SA nanoparticles. Based on the fluorescence 
intensity, 50:50 CPTEG:CPH nanoparticles persisted for 6 weeks post-injection, 
while the fluorescent signal was detectable at the injection site for 12 weeks post-
administration for the 20:80 CPTEG:CPH nanoparticle formulation. 
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Figure 2. In vivo persistence of nanoparticles mimicked that of 
traditional adjuvants when administered via parenteral routes. (A) 
Schematic of dosing regimen for mice injected with either polyanhydride 
nanoparticles or traditional adjuvants. (B) In vivo imaging of mice injected 
with a total of 5 mg of 20:80 CPH:SA, 20:80 CPTEG:CPH, or 50:50 
CPTEG:CPH nanoparticles loaded with fluorescent dye or administered with 
the fluorescent dye adsorbed onto Alum or emulsified into incomplete 
Freund’s adjuvant (IFA). Images were captured at 7 days post-injection. 
Fluorescence intensity calibration bar is located in bottom right corner. (C) 
Fluorescence extinction of dye at injection sites. Data depict the percent of 
fluorescence intensity of the SC region of interest (ROI) at the nape of the 
neck as compared to the fluorescence intensity of the initial image taken 
immediately after administration. n = 2 mice per group. 
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3.3 Polyanhydride nanoparticle formulations did not induce deleterious injection site 
reactions 
To assess the biocompatibility and phlogistic properties of polyanhydride 
nanoparticles, the magnitude of the host inflammatory response to each nanoparticle 
formulation was compared to that induced by Alum or IFA. Local tissue inflammation 
was visualized in SKH1-E mice using ProSense® 750, a fluorescent probe activated 
by enzymes released by inflammatory cells [35]. At 3 days post-injection, the 
magnitude of the inflammation induced at the SC (nape of the neck) site of 
administration was significantly greater in IFA treated mice than in mice 
administered Alum or any formulation of polyanhydride nanoparticles (Figure 3). The 
IM injection of Alum (left flank) induced a  more severe inflammatory reaction than 
that induced by nanoparticles or IFA. At 7 days post-injection, the relative intensity of 
the local inflammatory reactions at sites of nanoparticle administration was 
significantly lower (p ≤ 0.05) than that observed in mice receiving Alum or IFA. 
These results indicate that the nanoparticles did not induce inflammation as a 
cumulative effect of particle persistence or degradation (Supplemental Figure 1). 
Furthermore, there was little to no evidence of local inflammation at 30 days post-
injection for any of the treatment groups, even though the nanoparticles persisted in 
vivo for up to twelve weeks post-injection (data not shown).  
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Figure 3. Polyanhydride nanoparticles induced less inflammation-
associated enzymatic activity than traditional adjuvants. At 3 days post-
injection, mice were administered ProSense® 750, a protease activatable 
fluorescent imaging agent activated by cathepsins B, L, S and Plasmin at sites 
of inflammation. ProSense® 750 is optically silent in its inactivated state and 
becomes highly fluorescent following protease-mediated activation. Images 
were captured 8 hours after ProSense® 750 administration. Data depict the 
mean of the  fluorescence intensity of the ROI’s of the three injection sites. n = 
2 mice per group.  
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The systemic inflammatory response of mice administered Alum, IFA, or 
nanoparticles was examined by assaying for inflammatory chemokines and 
cytokines in the serum at 3, 7, and 30 days post-injection. At 3 days post-injection, 
levels of the monocyte-recruiting chemokines IP-10 and MCP-1 were elevated in the 
serum of mice administered CPTEG:CPH nanoparticles, Alum, or IFA compared to 
saline controls (Figure 4A-B). Of note, the MCP-1 and IP-10 levels remained 
elevated in mice administered Alum on day 7 post-injection while the levels for mice 
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Supplemental Figure 1. Polyanhydride nanoparticles induce less 
inflammation-associated enzymatic activity than traditional 
adjuvants. At 7 days post-injection, mice were administered ProSense® 
750, a protease activatable fluorescent imaging agent activated by 
cathepsins B, L, S and Plasmin at sites of inflammation. ProSense® 750 
is optically silent in its inactivated state and becomes highly fluorescent 
following protease-mediated activation. Images were captured 8 hours 
after ProSense® 750 administration.  n = 2  
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receiving other treatments were similar to the saline controls (Figure 4 C-D). At 30 
days post-immunization, all cytokine levels were basal (data not shown). 
 
 
 
 Because polyanhydride nanoparticles persist in vivo, tissues from SC and IM 
injection sites were harvested at 30 days post-injection and evaluated for 
microscopic evidence of tissue damage and inflammation.  The highest dosages of 
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Figure 4. Increased levels of the monocyte-recruiting chemokines IP-10 and 
MCP-1 in the serum of mice administered either nanoparticles, Alum, or IFA. 
Concentrations of (A-B) IP-10 and (C-D) MCP-1 in the serum of mice 
administered a 5.0 mg dose of 20:80 CPH:SA, 20:80 CPTEG:CPH, or 50:50 
CPTEG:CPH nanoparticles, Alum, IFA or saline at 3 (A and C) or 7 days post-
injection (B and D). Treatment groups marked with # are significantly different 
from  those mice treated with Alum at p < 0.05. n = 6-7 mice per group. 
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adjuvant were administered at the SC immunization site, and it was observed that 
the tissue response induced by Alum was histopathologically more severe than that 
induced by the nanoparticles or IFA (Figure 5A). Statistical differences were 
observed in only the 20:80 CPH:SA groups for both IM tissues sites indicating more 
inflammation associated with CPTEG:CPH chemistries (Figure 5B-C). Mice 
immunized with Alum had marked injection site reactions, characterized by muscle 
degeneration, inflammatory cell infiltrate, and fibrosis. Macrophage infiltrate was 
observed in all groups at the SC injection site; however, polymorphonuclear cell 
infiltrate was only noted in tissue recovered from mice treated with Alum, IFA, or 
50:50 CPTEG:CPH nanoparticles. Granuloma formation was recorded in five of the 
six Alum treated mice at the SC injection site. In contrast, only one mouse (50:50 
CPTEG:CPH) was found to have granuloma formation across all the nanoparticle-
treated mice. 
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3.4 Minimal toxicological effects on kidney and liver function following immunization 
with polyanhydride nanoparticles 
 Although enhanced tissue distribution of polyanhydride nanoparticles may 
provide immunological benefits, accumulation of CPTEG:CPH or CPH:SA 
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Figure 5. 
Polyahnhydride 
nanoparticle 
formulations did not 
induce deleterious 
injection site reactions. 
Composite 
histopathological scores 
of injection site 
subcutaneous tissue (A), 
left muscle (B), and right 
muscle (C) from mice 
administered 20:80 
CPH:SA, 20:80 
CPTEG:CPH, 50:50 
CPTEG:CPH 
nanoparticles, Alum, IFA, 
or saline at 30 days post-
administration. 
Treatments with # are 
significantly different from 
Alum at p < 0.05. n = 6-
13 per group. 
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nanoparticles in the liver or kidney could prove detrimental to normal physiological 
processes. Therefore, separate groups of mice were administered one of the three 
nanoparticle formulations, Alum or IFA and the appearance of serological 
biomarkers of liver or kidney damage was subsequently evaluated. 
 To measure liver function, total bilirubin, alanine aminotransferase (ALT) 
aspartate aminotransferase (AST) ratios, albumin, and lactate dehydrogenase were 
assayed using serum from mice at seven and 30 days post-treatment. Kidney 
function was evaluated by measuring changes in blood urea nitrogen (BUN), serum 
creatinine, and albumin in serum samples. For all parameters evaluated, no 
statistical differences were observed between nanoparticle treated mice in 
comparison to saline controls (Table 1). Similar results were  
observed at both 7 and 30 days post-injection, indicating that there was no evidence 
of adverse responses at acute or chronic times post-treatment (Supplementary 
Table 1). 
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Table 1. No elevated biomarkers of liver or kidney damage in serum of mice 30 
days after injections with polyanhydride nanoparticles. 
 
 
 
 
 
 
 
 
 
 
 
Test Synopsis Normal 
Range* 
Treatment 
Results (Mean ± 
SEM) 
     Units 
   20:80 CPH:SA 20:80 
CPTEG:CPH 
50:50 
CPTEG:CPH 
Alum IFA Saline  
Liver Function          
Total Bilirubin High levels of total bilirubin indicated 
diminished liver function due to liver 
being incapable of sufficiently removing 
bilirubin.    
0.1-0.9 0.46 ± 0.08 0.44 ± 0.09 0.42 ± 0.07 0.32 ± 
0.06 
0.54 ± 
0.16 
0.52 ± 0.07 Milligrams 
per 
deciliter 
(mg/dL) 
Alanine 
Aminotransferase 
(ALT) 
Used to detect liver injury and/or 
diagnose liver disease.  Elevation of ALT 
levels may be elevated when exposed to 
substances that are toxic and/or 
decrease blood flow.   
29-191 36.2 ± 6.50 37.73± 3.89 30.88 ± 3.10 31.67± 
3.35 
30.33 
± 3.13 
38.0 ± 6.87 Internation
al Units 
per Liter 
(IU/L) 
Albumin Low albumin levels suggest liver disease. 2.5-4.8 2.49 ± 0.13 2.43 ± 0.09 2.30  ± 0.11 2.15  ± 
0.08 
2.40  ± 
0.10 
2.5 ± 0.05 gm/dL 
Aspartate 
Aminotransferase 
(AST/)ALT Ratio 
Used in conjunction with ALT 
measurement for diagnosis of diminished 
liver function.  AST/ALT ratios can be 
calculated to detect liver disease or 
decreased function and AST/ALT <1.0 
may indicate damage. 
>1.0 5.25 ± 0.84 4.35 ± 0.51 5.55 ± 0.67 5.83 ± 
0.28 
7.09 ± 
0.79 
7.38 ± 1.54 Ratio 
Lactate 
Dehydrogenase 
(LDH) 
High levels of total LDH may be an 
indicator of acute or chronic tissue injury. 
843-3150 2248.7 ± 192.8 2065.6 ± 204.8 2092.5 ± 
105.6 
2100.2 
± 
129.6 
2735.5 
± 
356.9 
2626.7 ± 
429.4 
IU 
Kidney Function          
Blood Urea 
Nitrogen (BUN) 
Increased BUN is suggestive of impaired 
kidney function or excessive catabolism.   
18-29 15.36 ± 0.59 14.50 ± 0.82 13.38 ± 0.63 12.25 
± 0.56 
13.5 ± 
0.62 
14.86 ± 
0.67 
mg/dL 
Serum Creatinine Used in conjunction with BUN to assess 
kidney function.  Combination of blood 
and urine creatinine can be used to 
assess how well kidneys are filtering 
small molecules out of blood. 
0.1-0.4 0.26 ± 0.02 0.25 ± 0.02 0.23 ± 0.02 0.23 ± 
0.02 
0.22 ± 
0.04 
0.24 ± 0.02 mg/dL 
Table 1.  
Enzymatic tests, synopsis of test and normal ranges are indicated in the first three 
columns. Values are presented as the mean ± SEM. *Normal range values are 
acquired from Mazzacara et al [1] and from Iowa State University Clinical 
Pathology. 
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Supplementary Table 1. No elevated biomarkers of liver or kidney damage in 
serum of mice 7 days after injections with polyanhydride nanoparticles. 
Test Synopsis Normal 
Range* 
Treatment 
Results 
(Mean ± 
SEM) 
   Units 
   20:80 
CPH:SA 
20:80 
CPTEG:CPH 
50:50 
CPTEG:CPH 
Saline  
Liver Function        
Total Bilirubin High levels of total bilirubin indicated 
diminished liver function due to liver 
being incapable of sufficiently 
removing bilirubin.    
0.1-0.9 0.56 ± 0.14 0.70 ± 0.13 0.60 ± 0.28 0.64 ± 0.24 Milligrams per 
deciliter 
(mg/dL) 
Alanine Aminotransferase 
(ALT) 
Used to detect liver injury and/or 
diagnose liver disease.  Elevation of 
ALT levels may be elevated when 
exposed to substances that are toxic 
and/or decrease blood flow.   
29-191 73.0 ± 8.4 135.0 ± 38.7 87.0 ± 4.7 103.0 ± 
20.8 
International 
Units per Liter 
(IU/L) 
Albumin Low albumin levels suggest liver 
disease. 
2.5-4.8 1.9 ± 0.20 2.5 ± 0.05 2.6  ± 0.19 2.7 ± 0.08 gm/dL 
Aspartate Aminotransferase 
(AST/)ALT Ratio 
Used in conjunction with ALT 
measurement for diagnosis of 
diminished liver function.  AST/ALT 
ratios can be calculated to detect liver 
disease or decreased function and 
AST/ALT <1.0 may indicate damage. 
>1.0 407 ± 45.6 654 ± 92.8 476 ± 30.7 616 ± 92.0 Ratio 
Lactate Dehydrogenase (LDH) High levels of total LDH may be an 
indicator of acute or chronic tissue 
injury. 
843-
3150 
4885 ± 399.3 7001 ± 643.3 5776 ± 444.6 7116 ± 
794.3 
IU 
Kidney Function        
Blood Urea Nitrogen (BUN) Increased BUN is suggestive of 
impaired kidney function or excessive 
catabolism.   
18-29 17 ± 1.5 19 ± 1.2 17 ± 0.7 16 ± 1.1 mg/dL 
Serum Creatinine Used in conjunction with BUN to 
assess kidney function.  Combination 
of blood and urine creatinine can be 
used to assess how well kidneys are 
filtering small molecules out of your 
blood. 
0.1-0.4 0.4 ± 0.05 0.6 ± 0.06 0.5 ± 0.04 0.6 ± 0.06 mg/dL 
 Liver and kidney tissues were also examined both macroscopically and 
microscopically to identify structural or histological damage. No statistical differences 
in liver and kidney weights were observed for any adjuvant-treated mice as 
compared to controls (Figure 6A and B). Histopathological analysis revealed no 
significant indications of toxicity, inflammation, or necrosis in livers and kidneys from 
nanoparticle-treated mice (Figure 6C and D). While one mouse administered 20:80 
CPTEG:CPH particles did present with focal signs of hepatic necrosis, the 
pathologist interpreted this lesion as being consistent with commonly observed 
Supplementary Table 1.  
Enzymatic tests, synopsis of test and normal ranges are indicated in the 
first three columns. Values are presented as the mean ± SEM.  *Normal 
range values are acquired from Mazzacara et al [1]  and from Iowa State 
University Clinical Pathology. 
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tissue changes within the liver of BALB/c mice. Altogether, tissues analyzed from all 
mice, regardless of treatment group, revealed normal histological features similar to 
those observed in the saline treated controls. 
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Figure 6. Minimal toxicological effects on kidney and liver function 
following immunization with polyanhydride nanoparticles. (A and B) Livers 
and kidneys from immunized mice were weighed at 30 days post-injection; no 
significant differences among treatments were observed. (C and D) Composite 
histopathological scores of liver and kidney tissues from mice administered 
20:80 CPH:SA, 20:80 CPTEG:CPH, 50:50 CPTEG:CPH nanoparticles, Alum, 
IFA, or saline at 30 days post-administration; no significant differences from 
healthy controls were observed.  n = 6-13 per group. 
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4. Discussion 
 Vaccine adjuvants must maintain a delicate balance between eliciting a 
robust antigen-specific immune response and inducing an adverse reaction at the 
site of administration [4, 5, 36-39]. When administered subcutaneously, 
polyanhydride nanoparticles persisted at the injection site, providing an antigenic 
depot similar to that provided by Alum and IFA (Figure 2). However, unlike the 
traditional adjuvants, the nanoparticles provided the added advantage of 
disseminating throughout the body (Figure 1 and 2). Based on companion studies 
and the injection of soluble tracer dye, the distinct biodistribution observed was not a 
result of detecting tracer dye released from the nanoparticles but the dissemination 
of the nanoparticles themselves. Similar to the systemic spread of a pathogen, the 
capacity to distribute or disseminate throughout the body further supports the 
pathogen-mimicking potential of the polyanhydride nanoparticles [19, 23]. Measuring 
the presence of the dye-loaded nanoparticles over time demonstrated that 
polyanhydride nanoparticles persisted for up to 12 weeks in vivo, with polymer 
chemistry influencing the degree of persistence (Figure 2). Additional analyses 
evaluated the biocompatibility of the polyanhydride nanoparticle platform by 
comparing the inflammatory responses, injection site tissue responses, and liver and 
kidney functions from nanoparticle-treated mice to those of mice administered Alum 
or IFA (Figures 3 to 6). No indications of inflammation or adverse reactions 
associated with administration or degradation of the nanoparticles were observed. 
 In combination with our previous reports of nanoparticle-based vaccine 
potency and efficacy [20-22, 24, 30] the reactogenicity profile presented in this work 
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further supports the in vivo use of polyanhydride nanoparticle adjuvants in vaccine 
formulations. Independent of chemistry, the nanoparticles presented unique 
biodistribution characteristics not observed with the microparticles, including their 
ability to disperse from the injection site. We hypothesize that particle size and 
chemistry influences both dissemination to distal tissues and more efficient uptake 
by phagocytic cells that would contribute to tissue distribution and/or persistence of 
the nanoparticles [20, 40]. The observed persistence of the nanoparticles at injection 
sites resembles that of Alum and IFA; however, CPTEG:CPH nanoparticle 
chemistries appear to more readily disperse throughout the body and mimic the 
distribution patterns of pathogens [41-43]. 
 To date, the majority of in vivo immunization studies in murine models 
performed in our laboratories have employed a single 0.5 mg dose of the 
polyanhydride nanoparticles [21, 24]. The data presented herein demonstrated 
negligible inflammatory and adverse biological responses in mice subsequent to the 
administration of 5.0 mg (i.e., 10-fold higher amount) of polyanhydride nanoparticles 
as compared to Alum or IFA. IP-10, thought to be the chemokine primarily 
responsible for the efficacy of the yellow fever vaccine [44], was elevated in the 
nanoparticle-treated mice, indicating monocytic recruitment. Collectively, our results 
indicate that although polyanhydride nanoparticles may mimic pathogens with 
respect to tissue distribution and phagocytic uptake [19, 20, 22], they do not, 
however, induce detrimental tissue destruction caused by extensive inflammatory 
cell infiltrate.  
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 The surface erosion characteristics of the polyanhydride nanoparticles 
enables them to persist in vivo as long or longer than other vaccine formulations. It 
is, therefore, critical that polyanhydride delivery systems be evaluated for the 
induction of both acute and chronic adverse toxicological reactions. In the present 
study, we observed no significant elevation of physiological biomarkers of liver or 
kidney damage in mice administered a 5 mg dose of nanoparticles (Table 1), 
suggesting that neither the nanoparticles nor their degradation products were 
adversely accumulating or altering liver or kidney functions. This finding is in 
agreement with previous studies where liver and kidney functions were fully 
preserved after implantation of a polyanhydride wafer used to treat human brain 
cancer [11, 45]. Together, these results demonstrate the non-toxic and 
biocompatible characteristics of polyanhydride nanoparticle-based vaccine carriers 
and support the hypothesis that their inherent physicochemical properties (e.g., 
degradation kinetics and pathogen-mimicking ability, leading to dissemination and 
persistence) positively affect the immune response by inducing long-lived, protective 
immunity [23]. 
 
5. Conclusions 
 Developing adjuvants that balance enhancing innate and adaptive immune 
responses while simultaneously limiting the induction of non-specific adverse events 
are a challenge for vaccinology. The results of this study indicate that administration 
of larger doses of polyanhydride nanoparticles are more biocompatible than nominal 
doses of traditional adjuvants such as Alum and IFA. The nanoparticles 
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disseminated rapidly into tisssues distal to the administration site, and persisted for 
as long as 12 weeks, potentially providing a basis for the induction of long-lived 
immunity. Furthermore, administration of a 5 mg dose of polyanhydride particles 
resulted in no adverse effects as evidenced by the lack of biomarkers of liver and 
kidney damage and/or dysfunction, affirming the biocompatibility of these materials. 
The data herein also outline the inherent adjuvant activity of polyanhydride 
nanoparticles that stimulates immune responses with minimal lesion development at 
the site of administration. These data offer an initial standard for translating 
polyanhydride nanomaterials into use as a vaccine delivery platform for humans and 
animals.  
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Abstract 
 Vaccination remains the paramount preventive intervention against many 
different pathogens.  Designing new vaccines against pathogens for which there is 
no current vaccine that are efficacious and induce minimal adverse side effects 
associated is one of the greatest challenges in medicine. Recent efforts have been 
focused on the use of biomaterials to enhance immune responses following 
immunization. Recently, polyanhydride nanoparticles have been shown to have the 
ability to provide controlled release of and stabilize protein antigens, enhance innate 
immune activation of antigen presenting cells, and elicit protective immunity against 
a respiratory bacterial pathogen. However, there is limited direct evidence of cell 
mediated immune activation when mice were immunized using polyanhydride 
nanoparticles.  Using the transgenic ovalbumin (Ova) specific T cell (OT) model, we 
report the enhanced expansion of antigen specific cytotoxic CD8+ T cells expressing 
an effector memory phenotype (CD44high CD62Llow) at early time points when 
antigen is encapsulated into polyanhydride nanoparticles. A significant population of 
the Ova-specific CD8+ T cells is maintained at seven days post-injection indicating 
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that controlled and sustained release of Ova contributed to the maintenance of the 
Ova-specific T cell population. Using the high frequency adoptive transfer of 
bioluminescent reporter Ova-specific T cells (3 x 106 cells), it was shown that mice 
vaccinated with Ova-loaded polyanhydride nanoparticles induced the expansion of 
significantly more Ova-specific CD8+ T cells than mice immunized with Alum 
adjuvanted Ova or Ova alone. The CD8+ T cells induced by the polyanhydride 
nanoparticle vaccine were cytotoxic as evidenced by the ability to prevent the growth 
of EG7-Ova tumor cells. A low frequency adoptive transfer model, which better 
represents a naïve antigen specific T cell precursor frequency, was utilized to 
measure induction of CD8+ T cell memory phenotypes following immunization with 
multiple formulations of nanoparticles. Polyanhydride nanoparticles were able to 
significantly (p ≤ 0.05) expand Ova-specific CD8+ T cells that included cells 
characterized as memory effector cells (cell surface markers) and central memory 
(cell surface markers) T cells. These data indicate that subunit vaccine regimens 
designed using the polyanhydride nanoparticle platform can induce cytotoxic cell-
mediated immunity to target antigens using biocompatible and biodegradable 
materials. 
 
 
1. Introduction 
  The use of preventive vaccines to curb disease remains the most effective 
public health intervention strategy to decrease morbidity and mortality associated 
with infectious diseases. Challenges associated with the development of next 
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generation vaccines include eliciting effective cell mediated immune responses 
towards the target antigen and inducing long-lived immunologic memory towards 
that antigen while minimizing severe adverse events (SAEs) following vaccination. 
The yellow fever vaccine remains the most successful vaccine in the human 
population due to its ability to elicit cell mediated (CD4+ and CD8+) T cell responses 
within the first two weeks of immunization and subsequently a long-lived protective 
antibody response that can last 45 years [1-3]. Engagement of multiple pattern 
recognition receptors (PRRs) on antigen presenting cells (APCs) by the antigens of 
yellow fever vaccine leads to pro-inflammatory cytokines IL-1β, TNF-α, and IFN-α/β, 
stimulating migration of mature dendritic cells to the draining lymph nodes and the 
subsequent induction of a robust adaptive immune response.  
The effectiveness of the yellow fever vaccine can be attributed to its 
engagement of the innate immune system as well as its attributes as a live 
attenuated virus establishing a mild subclinical infection, persisting (i.e., replicating) 
for a period of time and effectively establishing immunological memory [3]. Next 
generation vaccine design is subsequently hindered if an organism is unable to be 
attenuated. This hinderence of design is further compounded with concerns 
regarding the presence of the phlogistic components associated with whole cell 
vaccines. Subunit (i.e., recombinant proteins) vaccines are a viable alternative due 
to elimination of phlogistic components and technological capabilities that are readily 
available for the production of recombinant immunogens. However, recombinant 
proteins are often poorly immunogenic requiring the addition of excipients or 
adjuvants to the vaccine formulation in order to enhance immune responses. 
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Altering the kinetics of antigen availability has been a favorable attribute 
associated with generating cellular immunity [4]. Human cytomegalovirus (HCMV) 
infection and the subsequent establishment of cellular immune memory present an 
interesting model for immunologists to consider when designing an efficacious 
vaccine. Low level infection of HCMV and persistent virus presence induces a robust 
T cell population that includes both effector (i.e., cytotoxic) and memory T cells [5]. 
Induction of cytotoxic T cells necessary for mediating immune responses against 
virally infected cells or tumor-specific cells is often difficult to achieve with purified 
subunit vaccines. 
Polyanhydride copolymers based on sebacic acid (SA), 1,6-bis(p-
carboxyphenoxy) hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) have been shown to enhance the stability of encapsulated immunogens 
and provide adjuvant activities that enhance the benefits associated with controlled 
and sustained release of the immunogen [6, 7]. Polyanhydride microparticles also 
enhance in vitro dendritic cell activation and increase cell surface marker 
expression, cytokine production, and proliferation of antigen-specific CD4+ and CD8+ 
T cells [8]. Dosage sparing capabilities of the polyanhydride particle platform have 
been demonstrated in the context of a single parenteral vaccination resulting in 
sustained antibody titers of high avidity (Chapter 3).  
Little analysis has been performed regarding cell-mediated immune 
responses elicited by the polyanhydride platform. Here, we expand our analysis of 
the cell-mediated immune responses elicited by polyanhydride particle vaccination.  
Specifically, we utilize adoptive transfer of ovalbumin (Ova)-specific transgenic T 
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cells to mice receiving a combination vaccine regimen of soluble and encapsulated 
Ova as previously described and a tumor challenge model expressing the model 
antigen Ova [9]. 
We demonstrate that encapsulation of antigen in polyanhydride nanoparticles 
enhances antigen-specific CD8+ T cells in a high frequency adoptive transfer. 
Memory phenotypes of high frequency transfers showed CD8+ effector and central 
memory characteristics. Using an ovalbumin secreting tumor model, we are able to 
show delayed progression of tumor growth using the polyanhydride nanoparticle 
platform as well as significantly increased circulating Ova-specific CD8+ T cells post-
tumor challenge compared to that induced by Ova adjuvanted with Alum. Low 
frequency adoptive transfer was utilized to examine antigen specific T cell responses 
in a less contrived system to capitulate actual naïve T cell precursor frequency. 
CD8+ central effector and central memory phenotypes were examined and show 
that, in low frequency transfer, 20:80 CPH:SA (C:S) and 20:80 CPTEG:CPH (C:C) 
polyanhydride chemistries significantly expand Ova-specific CD8+ T cells leading to 
higher frequencies of memory precursor effector cells and central memory CD8+ T 
cells. 
 
2. Materials and Methods 
2.1 Synthesis and characterization of copolymers 
 Polyanhydrides were synthesized using the chemicals listed: 4-p-
hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, N,N-
dimethylacetamide, and tri-ethylene glycol. All these chemicals and sebacic acid 
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(99%) were purchased from Sigma Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile 
was obtained from Apollo Scientific (Cheshire, UK); potassium carbonate, dimethyl 
formamide, toluene, sulfuric acid, acetic acid, acetonitrile, acetone, acetic anhydride, 
methylene chloride, chloroform, sodium hydroxide, hexane, ethyl ether, and 
petroleum ether were purchased from Fisher Scientific (Fairlawn, NJ). Synthesis of 
CPH and CPTEG diacids was performed as previously described [10, 11] and pre-
polymers of SA and CPH were synthesized using previously described methods [11, 
12]. Copolymers (20:80 CPH:SA (C:S) and 20:80 and 50:50 CPTEG:CPH (C:C)) 
were synthesized using a melt polycondensation process as detailed by Kipper et al. 
and Torres et al.[10, 13] The molecular weight, and polymer purity were determined 
using 1H nuclear magnetic resonance (NMR) spectroscopy (Varian VXR-300 MHz, 
Palo Alto, CA).  
 
2.2 Fabrication and characterization of particles 
Nanoparticles encapsulating ovalbumin (Ova) (Sigma-Aldrich, St. Louis, MO) 
(5.0% w/w loading) were fabricated using the anti-solvent nanoencapsulation 
method outlined in Ulery et al. [7] Briefly, the copolymer was dissolved in methylene 
chloride at a concentration of 20 mg/mL at 4˚C. Lyophilized Ova was added to the 
dissolved copolymer and the solution was sonicated for uniform dispersal of the 
protein within the copolymer. The Ova-loaded copolymer (Ova-loaded) or copolymer 
(blank) solution was poured into chilled pentane (-20°C) at a non-solvent to solvent 
ratio of 250:1, and this suspension was vacuum filtered to recover the nanoparticles. 
Shape and size of the resulting nanoparticles were characterized using scanning 
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electron microscopy (SEM) (JEOL 840 A, JEOL, Peabody, MA). The particle size 
distribution was obtained from SEM images using Image J version 1.46 image 
analysis software[14]. An average of 200 particles per image was analyzed. 
 
2.3 Mice 
 Recipient female C57BL/6 Thy 1.1+, recipient albino C57BL/6, OTI, and OTII 
mice were purchased from Jackson Laboratories (Bar Harbor, MN). C57BL/6 mice 
were obtained from Harlan Laboratories (Indianopolis, IN). T-lux mice were a kind 
gift from the lab of Casey Weaver at University of Alabama.  T-lux breeding colony 
was established at Iowa State University. Heterozygous breeding between T-lux and 
OT mice was established to produce T-lux/OT offspring.  Phenotyping of offspring 
for T cell receptor rearrangement (Vα2 Clone B20.1 Vβ5 Clone MR9-4 (eBioscience 
San Diego, CA)) and luciferase positive status was examined to establish which 
mice were the desired T cell donors (e.g., OT I+:T-Lux+). All mice were housed under 
specific pathogen-free conditions where all bedding, caging, water, and feed were 
sterilized prior to use. Animal procedures were conducted with the approval of the 
Iowa State University Institutional Animal Care and Use Committee. 
 
2.4 Mouse treatments 
2.4.1 Adoptive transfer of antigen-specific T cells 
High frequency adoptive transfer of 3.0 x 106 donor OTI Thy 1.2+ cells was 
performed by tail vein injection on day -1. For in vivo imaging studies, high frequency 
adoptive transfer of 5 x 105 OTI:T-lux cells were transferred into albino C57BL/6 
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recipients performed on day -1.  For the low frequency adoptive transfer studies, 3 x 
103 OTI Thy 1.2+ 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) 
(Molecular Probes/Life Technologies, Grand Island, NY) labeled cells were 
adoptively transferred to each recipient mouse.  
2.4.2 Immunization Regimens 
On day 0 mice were immunized with 1.75 mg of soluble Ova and 5 mg of 
Ova-loaded (5 %) polyanhydride nanoparticles 20:80 CPH:SA, 20:80 CPTEG:CPH, 
50:50 CPTEG:CPH, 2.0 mg of soluble ova (sOVA), or 2.0 mg of Ova adjuvanted 1:1 
with Imject Alum (ThermoFisher, Rockford, IL). 
2.4.3 Tumor challenge 
EG7 ovalbumin expressing tumor cells (2.5 x 106) were subcutaneously 
administered in the left rear flank on day 35 post-immunization.  Tumor 
measurements were recorded using a digital caliper and tumor volume was 
calculated using ellipsoid volume equation where volume = (4/3)* π * length * width * 
height. Per criteria outlined in consultation with the attending veterinarian, animals 
were removed from the study when tumor volume reached 1000 mm3.  Prosense® 
750 was administered (2 nmol) via tail vein injection 7 days post-tumor challenge to 
visualize the inflammation associated with the tumor and to quantify changes in 
tumor size. ProSense® 750 is an activatable fluorescent reagent that is optically 
visible when the dye is cleaved by degradative enzymes, including cathepsin B, L, S, 
or plasminogen, that are common at sites of tumor growth [15]. After 24 h, in vivo 
images were captured while mice were kept under anesthesia using 2 % isoflurane 
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in 100 % O2, at 2.5 L/min. Images were captured using 30 second exposures with an 
excitation filter of 730 nm and an emission filter of 790 nm. 
2.4.4 In vivo imaging of T-lux cells 
Five minutes prior to imaging for the presence of T-lux positive T cells, mice 
were administered D-luciferin (215 µg/g body weight) via intraperitoneal injection. In 
vivo images (Carestream Multispectral FX Rochester, NY) were captured while mice 
were anesthetized as described above. Bioluminescent images were captured using 
10-minute exposures with high amounts of binning for increasing sensitivity. All 
image analyses were performed using Image J software version 1.46 [14]. Raw 
fluorescence images were inverted and background subtracted via a rolling ball 
radius of 150 pixels. The mean luminescence intensity (MLI) of the region of interest 
(ROI) of 0.39 mm x 0.32 mm were quantified via ImageJ and presented thereto. 
Composite images of luminescent channel (lookup table “16 colors” Figure 2 for 
bioluminescence, lookup table “blue ” Figure 4) for bioluminescence, fluorescence 
channel (lookup table “red ”), and white light image were created using Image J 
software.  
 
2.5 Assaying for ex vivo T cell phenotype and activity 
At multiple time points post-immunization, mice were euthanized and draining 
lymph nodes were excised and single cell suspensions were created using a glass 
homogenizer.  Half of the excised spleens were placed in 10 % buffered formalin.  
The other half of spleen was homogenized to prepare single cell suspensions.  Red 
blood cells were lysed using ACK lysis buffer. Cell numbers and phenotype were 
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quantified using flow cytometry (BD FACS Aria III).  For low frequency adoptive 
transfer experiments, positive selection for donor T cells was accomplished using 
biotinylated anti-CD90.2 (Thy 1.2 Clone 53-2.1) (eBioscience, San Diego, CA) and 
streptavidin magnetic microbeads (Miltenyi Biotech, Auburn, CA).  Positive magnetic 
bead selection was performed via methods outlined by Moon et al [16] (AutoMACS 
Pro Milteny Biotech).  Cell suspensions were blocked for non-specific antibody 
binding using 0.1 mg/mL Rat IgG (Sigma Aldrich, St. Louis, MO) and 10 µg/mL 
mouse anti-CD16/32 (eBioscience, San Diego, CA).  For T cell assays, fluorescently 
conjugated antibodies specific for CD4 (PE-Cy7, Clone GK1.5, eBioscience), CD8β 
(APC, Clone eBioH35-17.2, eBioscience), CD62L (PE, Clone 2G8, eBioscience), 
Thy 1.2 (APC-eFluor 780, Clone 53-2.1, eBioscience), Thy 1.1 (PerCP-Cy 5.5, 
Clone HIS51, eBioscience), IL-2 (FITC, Clone JES6-5H4, eBioscience) CD19 
(PerCP-Cy5.5, clone eBio1D3, eBioscience), CD11c (PerCP-Cy5.5, clone N418, 
eBioscience), CD11b (PerCP-Cy5.5, clone M1/70, eBioscience), F4/80 (PerCP-
Cy5.5, BM8, eBioscience), IL-7R (eFluor 450, Clone 4B12, eBioscience), CD197 
(eFluor 450, Clone 4B12, eBioscience), KLRG1 (PE-Texas Red, Clone 145-2C11, 
eBioscience), or CD44 (v500, clone IM7, BD Franklin Lakes, NJ) were diluted in 
FACS buffer and used to label the cells in order to quantify donor antigen-specific 
cell populations. Abs were used in appropriate combination of fluorochromes. 
  
2.6 Analysis of cytokines in serum and culture supernatants  
Serum or cell culture supernatant samples were analyzed using a 32-plex 
chemokine and cytokine antibody array (Millipore, Billerica, MA) measuring the 
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following analytes: Eotaxin, G-CSF, GM-CSF, M-CSF, IFN-γ, IL-10, IL-12p40, IL-
12p70, IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, 
KC, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, LIF, LIX, VEGF, RANTES, and TNF-α. 
Assays were performed according to the manufacturer’s recommendations; data 
were acquired and analyzed using a Bio-Plex 200 (Bio Rad, Hercules, CA). Type I 
interferon was assayed using Verikine Mouse Interferon alpha ELISA kit (PBL, 
Piscataway, NJ) and IL-33 was assayed using IL-33 ELISA Ready-Set-Go 
(eBioscience).  
2.7 Bone marrow macrophage gene changes and cytokine release 
 Bone marrow macrophages were derived via methods outlined in 
Weischenfeldt et al. [17]. Briefly, bone marrow was isolated from long bones of 
donor C57BL/6 mice and plated in 125 x 25 mm plates tissue culture plates in 
complete bone marrow macrophage medium containing dulbelcco’s modified eagle 
medium (DMEM) with L-glutamine supplemented with 40 % fetal bovine serum 
(FBS) and L929 cell conditioned medium from L929 cells serving as a source of GM-
CSF. Cells were incubated for 6 days, and characterized using flow cytometry for the 
expression of macrophage markers CD11b clone: M1/70 (eBioscience, San Diego, 
CA) and F4/80 clone: BM8 (eBioscience, San Diego, CA) After confirming the 
macrophage phenotype of the cells, the cells were harvested and inoculated into the 
wells of a 24 well culture plates at a density of 1.0 x 106 cells/mL in complete tissue 
culture medium consisting of DMEM with L-glutamine supplemented with 10 % FBS. 
Nanoparticles were suspended in complete tissue culture medium at a concentration 
of 0.25 mg/mL translating to 250 µg per well for each treatment, sonicated briefly, 
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and added to the macrophages.  Culture supernatant fluid was collected 8 hours 
after particle addition, aliquoted, and frozen for cytokine analysis.  
 Cells were collected and total RNA isolated using a RNeasy Mini Kit 
(SABiosciences/Qiagen, Valencia, CA) according to manufacturers instructions.  
RNA quality and concentration was analyzed via Agilent 2100 Bioanalyzer (Agilent, 
Santa Clara, CA) and reported RNA integrity numbers (RIN) were above 7.0.   RT2 
cDNA first strand kit (SABiosciences/Qiagen, Valencia, CA) was used for cDNA 
synthesis according to manufacturer’s instructions. Converted cDNA was added to 
RT2 master mix and added to NF-κB signaling pathway PCR array plate 
(SABiosciences/Qiagen, Valencia, CA) and RT-PCR was performed using Applied 
Biosystems 5700 thermocycler.      
2.8 Statistical analysis 
Differences in mean responses among treatment groups were tested with 
either unpaired T test with Welch’s correction or one-way ANOVA F-test followed by 
a post-hoc Tukey’s t-test using Graph Pad Prism version 5. Statistical tests with p 
values ≤ 0.05 were regarded as significant. Data was log transformed when 
variances were not equal. 
 
3. Results 
Induction of antigen specific cell mediated responses to cognate antigen 
happens early after antigen induction. An initial expansion of antigen specific T cells 
occurs and these cells either leave the secondary lymphoid tissue to respond to the 
antigen or are programmed to reside in the lymphoid tissue to respond to antigen 
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later (memory). High frequency adoptive transfer of Ova-specific T cells (OT) was 
utilized to enhance the detection of antigen-specific T cells after immunization. 
Previous studies that have evaluated the use of the polyanhydride platform to 
immunize mice have shown that optimal immune responses are induced using a 
combination of soluble protein administered with protein encapsulated into the 
polyanhydride nanoparticles [9]. Mice were adoptively transferred with 3 x 106 OTI  
(CD8+) T cells prior to immunization. A polyanhydride nanoparticle vaccine 
consisting of 1.75 mg of soluble Ova and 0.25 mg of Ova encapsulated in 50:50 
CPTEG:CPH nanoparticles showed differences in magnitude expansion and 
contraction of Ova-specific T cells compared to soluble OVA alone (Figure 1A). For 
the mice immunized using the nanoparticle regimen, there was a significantly greater 
number of Ova-specific CD8+ T cells observed in the draining lymph nodes at day 3 
post-immunization that was maintained through day 7 (Figure 1B). At day 14 post-
immunization, a small proportion of the Ova-specific T cells was still detectable 
although there was no statistically significant differences.   
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Serum samples obtained at 3 days post-immunization DPI were evaluated to 
determine the monocyte chemokine expression patterns in the nanoparticle 
immunization group as compared to the mice immunized with Ova alone. As can be 
seen in Table 1, there was a statistically significant (P ≤ 0.05) increase in the serum 
Figure 1. Encapsulation of antigen in 50:50 CPTEG:CPH nanoparticles 
expands greater numbers of antigen specific T cells and maintain 
higher numbers of T cells at later time points.  The adoptive transfer and 
immunization schedule showing the time points of tissues obtained (A). 
Representative flow histograms of gated CD8+ T cells at the four time points 
(B).  X-axis represents the recipient congenic marker Thy 1.1 and the y-axis 
represents the donor Thy 1.2 congenic marker.  Quantification of the 
percentage of CD8+ Thy 1.2+ (donor OTI cells) obtained at the four time-
points.  N = 4-5 per group and # indicates a significant difference at p < 
0.05. 
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levels of IP-10, MCP-1 and IFN-γ in the mice immunized with the nanoparticle 
formulation.  
Table 1. Nanoparticle immunization increases monocyte chemokine activity. 
Group IFN-γ (pg/mL) IP-10 MCP-1 
50:50 
CPTEG:CPH 
39.28a 961.36a 696.13a 
sOVA 18.23ab 171.94b 104.18ab 
PBS 3.77b 86.88b 203.62b 
 
 
The activation phenotype of the expanded Ova-specific CD8+ T cell 
populations was examined by measuring the expression levels of cell surface 
markers CD44 and CD62L, as well as, IL-2 production after in vitro antigen 
stimulation. The phenotype of the T cell population induced following immunization 
with the nanoparticle formulation was characterized by the appearance of short-lived 
effector memory T cells (CD44high CD62Llow) at 3 DPI (data not shown). At the 7 DPI, 
Table 1.  
Serum samples from mice immunized with 50:50 CPTEG:CPH, soluble Ova 
(sOVA), or PBS  euthanized at 3 days post-immunization were evaluated for 
monocyte chemokines via 22-plex multiplex assay. IFN-γ, interferon gamma 
inducible protein (IP-10), and monocyte chemotactic protein (MCP-1) show 
statistical differences. Numbers expressed are mean concentrations of the 
analyte in pg/mL. N = 4-5 per group and superscript letters indicate 
significant difference at p < 0.05 using one-way ANOVA with Tukey’s post 
test. 
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a shift in the percentage of effector memory (CD44high CD62Llow) and central 
memory (CD44high CD62Lhigh) was observed in the nanoparticle immunized groups 
(Figure 2A).  When quantified the subtle shift in surface markers was not statistically 
significant (Figure 2B). T cells from the nanoparticle immunized mice that were 
stimulated in vitro with Ova produced a greater amount of IL-2 production than mice 
immunized with Ova alone indicating induction of a central memory T cell population 
in the draining lymph node (Figure 2C-D). PBS immunized mice showed little IL-2 
production (data not shown).   
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In order to efficiently ascertain the capability of multiple polyanhydride 
Figure 2. A greater number of antigen-specific T cells from 
nanoparticle immunized mice demonstrate a central memory 
phenotype.  (A) Representative contour plots showing cell surface marker 
analysis of donor T cells (CD8+ Thy 1.2+) for expression of CD44 and 
CD62L at 7 days post-immunization. (B) Quantified analysis of the 
percentage of donor T cells (Thy 1.2+) expressing a central memory 
phenotype (CD8+, CD44high, and CD62Lhigh). (C) Representative histograms 
of depicting the induction of CD8+ Thy 1.2+ IL-2+ cells following 
immunization.  Dotted histogram indicates isotype control, gray histogram 
indicates Th 1.2+ T cells from sOva immunized mice, and black histogram 
indicates the IL-2 producing cells present in mice immunized with the Ova-
loaded 50:50 CPTEG:CPH. (D)  Percentage of CD8+Thy 1.2+ cells that were 
positive for IL-2. N = 4 to 5 mice per treatment group. P value obtained via 
unpaired T test with Welch’s correction. 
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nanoparticle chemistries to induce CD8+ T cells expressing a memory phenotype, 
we adoptively transferred OTI T cells that also expressed T cell specific luciferase to 
facilitate visualization of Ova-specific T cells in vivo. Mice were immunized with one 
of three separate Ova-loaded polyanhydride nanoparticle formulations. The 
formulations were prepared, namely, 20:80 CPH:SA, 20:80 CPTEG:CPH, and 50:50 
CPTEG:CPH (Figure 3A). Separate groups of mice were also immunized with Ova 
adjuvanted with Alum or soluble Ova (sOVA) alone to examine differences in T cell 
expansion (Figure 3). Antigen release profiles show a release of Ova from the 20:80 
CPH:SA, 20:80 CPTEG:CPH, and 50:50 CPTEG:CPH nanoparticles (Figure 3B). 
After immunization, cohorts from each treatment group were imaged at 1, 3, 5, 7, 
and 10 days. Greater numbers of CD8+ T cell were observed at the site of 
administration and draining lymph nodes for mice immunized with the Ova-loaded 
20:80 and 50:50 CPTEG:CPH nanoparticle formulations (Figure 3C-D).  20:80 
CPH:SA, Alum and sOVA groups also demonstrate expansion of the antigen specific 
T cells although in less magnitude attributable to the high dose of antigen used in 
these studies (Figure 3D).   
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Figure 3. CPTEG:CPH polyanhydride nanoparticle immunized 
groups elicit CD8+ T cell expansion at the immunization site.  (A) 
Scanning electron microscopy images of Ova-loaded nanoparticles of 
the three chemistries (20:80 CPH:SA, 20:80 CPTEG:CPH, and 50:50 
CPTEG:CPH) evaluated. (B) In vitro release kinetics of Ova  from three 
separate formulations of Ova-loaded nanoparticles over time. (C) 
Representative images of albino C57BL/6 mice receiving transfer of 
OTI+ T-lux+ cells from immunized groups (20:80 CPH:SA, 20:80 
CPTEG:CPH, 50:50 CPTEG:CPH, Alum, MPLA, sOVA, or PBS) at 1, 
3, 5, 7, or 10 days post-immunization (DPI) examining bioluminescent 
CD8 T cell activity. (D) Regions of interest of equal area were drawn at 
immunization site to measure intensity of T cell luminescence and 
quantified over time. 
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To test if polyanhydride nanoparticle immunizations were able to elicit 
cytotoxic CD8+ T cells capable of responding to challenge, albino C57BL/6 mice 
receiving adoptive transfer of OTI+ T-lux+ cells and immunized with the regimens 
outlined previously were injected with 2.5 x 106 Ova expressing EG-7 lymphoma 
cells into the right rear flank at 35 DPI. Additionally, at seven days post-tumor 
challenge, Prosense® 750 was administered to cohorts of tumor challenged mice to 
examine fluorescence intensity differences that will indicate differences in tumor size 
and progression. Mice immunized with either Ova-loaded CPTEG:CPH nanoparticle 
formulation effectively inhibited tumor growth resulting from an enhanced Ova-
specific T cell response as evidenced by the decreased fluorescence intensity as 
well as increased luminescence signal at the tumor challenge site, respectively 
(Figure 4A). Mice immunized with Alum, Ova-loaded 20:80 CPH:SA, or sOVA alone 
show little luminescence activity at the challenge site. At eight days post-tumor 
implantation, analysis of peripheral blood samples demonstrated that there was a 
statistically significant increases in V-α2+ V-β5+CD8+ CD44high T cells (i.e., Ova 
specific) in all mice immunized with the polyanhydride nanoparticle formulations 
when compared to cells recovered from mice immunized with Ova adjuvanted with 
Alum, Ova alone, and PBS (Figure 4B).  Quantitative analysis of the T cell response 
(i.e, luminescence intensity) at the site of tumor implantation indicated that the more 
robust CD8+ T cell responses correlated with those mice that demonstrated the 
greatest primary T cell expansion after immunization (Figure 4C). These cells were 
also examined for increases in the surface marker CD107a and intracellular 
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Granzyme B, markers of cytotoxic activity, but no statistical differences between 
polyanhydrides and control immunizations were reported (data not shown). 
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Figure 4. Polyanhydride nanoparticle immunized groups demonstrated 
cellular recall responses capable of controlling tumor growth with 
significant increases in peripheral CTL’s at 8 days post-tumor challenge. 
(A) Representative images of albino C57BL/6 mice receiving transfer of OTI+ T-
lux+ cells from immunized groups (20:80 CPH:SA, 20:80 CPTEG:CPH, 50:50 
CPTEG:CPH, Alum, MPLA, sOVA, or PBS) challenged with EL-7 tumor cells 
visualizing OT-I T-lux cells (Blue) and tumor size (ProSense® 750, Red) at the 
site of tumor implantation. (B) Representative FACS histograms of peripheral 
blood samples were obtained at 8 days post-tumor challenge and the 
percentage of total CD8+ T cells that were V-α2+ V-β5+ CD8ß+ CD44high T cells 
were quantified. (C) Numbers of V-α2+ V-β5+ CD8ß+ CD44high T cells quantified 
via flow cytometry (n = 12 per group). (D) Regions of interest of equal area were 
drawn at the tumor challenge site and luminescent intensity of T cell 
luminescence was quantified post-tumor challenge (n = 4). Mean tumor volume 
measurements of each immunized group recorded over time post-tumor 
challenge (n = 12). Survival curve of immunized groups post-tumor challenge (n 
= 12) (E). # indicates statistical difference from PBS at a p value < 0.05 value 
obtained via one-way ANOVA with Tukey’s post-test. Data presented from one 
experiment.  
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All immunization groups were able to delay tumor progression throughout the 
study.  The passive transfer of a large number of naïve Ova-specific T cells was able 
to provide some protective benefit in regard to tumor progression as evidenced by 
the slower tumor progression compared to naïve animals receiving no adoptive 
transfer of OTI T-lux T cells (Figure 5 A-B).  
High frequency adoptive transfer of OTI T cells allowed us to assess the 
capability of various NP formulations to enhance the activation of Ova-specific CD8+ 
T cells during the early stages of an immune response. In order to more closely 
model a naturally occuring immune response, a low frequency adoptive transfer (3 x 
103 OTI Thy 1.2+ cells) model was utilized to examine the expansion and contraction 
phases of CD8+ T cells early after immunization and the induction of effector versus 
memory phenotypes being elicited. 20:80 CPH:SA or 20:80 CPTEG:CPH 
Figure 5. 20:80 CPTEG:CPH immunized mice slowed tumor 
progression and increased survival (A) Mean tumor volume 
measurements of each immunized group recorded over time post-tumor 
challenge (n = 12). (B) Survival curve of immunized groups post-tumor 
challenge (n = 12). Data presented from one experiment.  
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polyanhydride nanoparticles significantly (p ≤ 0.05) increased the numbers of Ova-
specific CD8+ T cells in the draining lymph nodes at 7 DPI compared to the other 
treatment groups (Figure 5A-B). The donor OTI T cells populations were further 
examined for phenotypic indications of memory precursor effector cells (CD44high 
CD62Lhigh and KLRG1low CD127low) and for central memory phenotypes (CD44high 
CD62Lhigh CCR7+). CCR7 is a lymph node homing integrin that is up-regulated for 
retention in the secondary lymph tissue [18, 19]. The numbers of precursor central 
memory CD44high CD62Lhigh T cells is significantly greater (p ≤ 0.05) in the 20:80 
CPH:SA and 20:80 CPTEG:CPH immunization groups than Alum and sOVA controls 
(Figure 6C-D). These groups show greater numbers of memory precursor effector 
cells (MPEC) as defined by expression of KLRG1low CD127low surface marker 
expression (Figure 6E-F) and evidence of establishing Ova-specific, central memory 
T cells defined by expression of CD44high CD62Lhigh CCR7+ although neither were 
statistically significant.  
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The 20:80 CPTEG:CPH vaccine regimen provided the most consistent T cell 
Figure 6. Polyanhydride nanoparticle immunization expands 
antigen specific T cells early after immunization and promotes 
central memory development. (A) Representative flow cytometric 
histograms of donor OTI Thy 1.2+ (y-axis) CD8+ (x-axis) T cell 
expansion from draining lymph nodes seven days post-immunization 
(DPI). (B) Total CD8+ Thy 1.2+ T cells recovered from the axial and 
brachial LN at seven DPI .  (C) Representative flow cytometric 
histograms of OTI Thy 1.2+ CD8+ T cells analyzed for expression of 
CD44 (y-axis) and CD62L (x-axis). (D) Total numbers of CD8+ Thy 1.2+ 
CD44high CD62Lhigh T cells recovered from the axial and brachial LN at 
seven DPI. (E) Representative flow cytometric histograms of gated OTI 
Thy 1.2+ CD8+ T cells for surface markers CD127 (y-axis) and KLRG1 
(x-axis). (F) Total numbers of CD8+ Thy 1.2+ CD127low KLRG1low 
(MPEC) T cells recovered from the axial and brachial LN. 
Representative flow cytometric histograms of gated OTI Thy 1.2+ CD8+ 
CD44high CD62Lhigh T cells for surface marker CCR7 (x-axis) (G). Total 
numbers of Thy 1.2+ CD8+ CD44high CD62Lhigh CCR7+ T cells quantified 
by gating percentage multiplied by total cell numbers obtained from 
flow cytometric counting beads (H). # indicates statistical difference 
from PBS at a p value < 0.05 value obtained via one-way ANOVA with 
Tukey’s post-test.  Data is from a single experiment. 
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expansion and induction of precursor memory cell formation. This particular 
chemistry is the slowest eroding polyanhydride polymer providing the longest 
bioavailability in vivo (Chapter 4). The in vitro release kinetics of Ova from 20:80 
CPH:SA and 20:80 CPTEG:CPH were largely similar while Ova was released from 
50:50 CPTEG:CPH NPs much more slowly in vitro (Figure 3B). Thus, the burst 
release of Ova from of the 20:80 CPH:SA and 20:80 CPTEG:CPH may have 
contributed to the expanded T cell responses.  
The Ova release kinetics from the particles may contribute to the enhanced T 
cell responses however since the vaccine was administered with such a large dose 
of bolus antigen the more likely contributing factor is the immunomodulatory 
signaling effects of the polyanhydride nanoparticles on APCs. The inflammatory 
cytokine milieu presented by APC’s also contributes to T cell expansion and 
phenotype polarization [20]. The evidence of increases in monocyte chemotactic 
cytokines as well as the dominant macrophage infiltrate at the administration site as 
seen in histopathology (Chapter 4) led us to examine the inflammatory profile of 
macrophages administered polyanhydride nanoparticles. 
The three polyanhydride chemistries were administered to bone-marrow 
derived macrophages and gene changes of those macrophages were analyzed via 
an array examining NF-κB signaling pathways (Table 2).  As hypothesized, the 
CPTEG:CPH containing chemistries led to the largest genetic up-regulation of tnf 
and increases in expression of TNF associated receptors and signaling genes (cd27, 
tnfrsf1a, tnfrsf1b, tnfsf10, and stat1).  The CPTEG:CPH chemistries also up-
regulated expression of pattern recognition receptors (tlr1, tlr2, tlr3, tlr4, tlr6, tlr9 and 
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nod1) and downstream signaling with the greatest increases in tlr3 and nod1. Large 
up-regulation of the co-stimulatory molecule gene cd40 also occurred which is 
consistent with previous work examining dendritic cell and alveolar macrophage 
activation with the polyanhydride particle platform [8, 21, 22].  
 
Table 2. Nanoparticle immunization increases monocyte chemokine activity. 
Gene  
Descriptor (fold regulation above or 
below No Stimulation) 
20:80 
CPH:SA 
20:80 
CPTEG:CPH 
50:50 
CPTEG:CPH 
Agt 
Angiotensinogen (serpin peptidase 
inhibitor, clade A, member 8) 4.05 3.20 1.18 
Akt1 Thymoma viral proto-oncogene 1 1.07 16 9.38 
Atf1 Activating transcription factor 1 -6.41 -1.79 -1.8 
Atf2 Activating transcription factor 2 -5.54 1.36 -1.21 
Bcl10 B-cell leukemia/lymphoma 10 -2.08 10.20 8.11 
Bcl2a1a 
B-cell leukemia/lymphoma 2 related 
protein A1a -1.26 6.02 5.39 
Bcl2l1 Bcl2-like 1 -3.18 4.23 3.66 
Bcl3 B-cell leukemia/lymphoma 3 3.12 177.29 134.36 
Birc3 Baculoviral IAP repeat-containing 3 -2.10 5.54 7.46 
Card10 
Caspase recruitment domain family, 
member 10 4.96 2.38 1.16 
Card11 
Caspase recruitment domain family, 
member 11 3.14 17.88 19.70 
Casp1 Caspase 1 1.60 1.27 5.03 
Casp8 Caspase 8 -78.79 -10.27 -5.54 
Ccl2 Chemokine (C-C motif) ligand 2 (MCP-1) 2.20 2.93 4.56 
Ccl5 
Chemokine (C-C motif) ligand 5 
(RANTES) 51.98 372.22 699.41 
Cd27 CD27 antigen -1.29 7.26 8.57 
Cd40 CD40 antigen 39.67 474.41 729.11 
Cflar 
CASP8 and FADD-like apoptosis 
regulator 1.16 14.12 21.41 
Chuk 
Conserved helix-loop-helix ubiquitous 
kinase -6.32 -2.19 -2.60 
Crebbp CREB binding protein -6.63 1.83 1.72 
Csf1 
Colony stimulating factor 1 (macrophage) 
M-CSF 1.37 16.34 11.71 
Csf2 
Colony stimulating factor 2 (granulocyte-
macrophage) 22.63 491.14 340.14 
Csf3 
Colony stimulating factor 3 (granulocyte) 
G-CSF 5.46 54.19 385.34 
Egfr Epidermal growth factor receptor 1.66 11.08 6.77 
Egr1 Early growth response 1 -4.35 1.77 1.41 
Eif2ak2 
Eukaryotic translation initiation factor 2-
alpha kinase 2 1.59 11.47 12.21 
Elk1 ELK1, member of ETS oncogene family -2.06 7.21 5.28 
F2r Coagulation factor II (thrombin) receptor 1.99 11.31 10.85 
Fadd 
Fas (TNFRSF6)-associated via death 
domain -1.03 7.46 5.24 
Fasl Fas ligand (TNF superfamily, member 6) 2.27 3.05 6.06 
Fos FBJ osteosarcoma oncogene -6.68 3.84 2.04 
Hmox1 Heme oxygenase (decycling) 1 -2.79 6.23 5.17 
Icam1 Intercellular adhesion molecule 1 1.89 61.39 37.53 
Ifng Interferon gamma 8 37.27 140.07 
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Table 2 (Continued) 
Ikbkb Inhibitor of kappaB kinase beta 1.07 14.32 11 
Ikbke Inhibitor of kappaB kinase epsilon -1.13 13.18 13.45 
Ikbkg Inhibitor of kappaB kinase gamma -3.03 -1.66 -1.14 
Il10 Interleukin 10 2.41 17.15 229.13 
Il1a Interleukin 1 alpha -1379.56 -202.25 -56.89 
Il1b Interleukin 1 beta 3.18 35.75 119.43 
Il1r1 Interleukin 1 receptor, type I 1.56 6.15 4.50 
Irak1 Interleukin-1 receptor-associated kinase 1 -1.89 6.11 4.44 
Irak2 Interleukin-1 receptor-associated kinase 2 1.28 27.10 24.76 
Irf1 Interferon regulatory factor 1 2.33 37.27 32.22 
Jun Jun oncogene -1.92 7.01 4.69 
Lta Lymphotoxin A 9.51 73.52 81.01 
Ltbr Lymphotoxin B receptor 1.16 11 5.66 
Map3k1 
Mitogen-activated protein kinase kinase 
kinase 1 -2.57 3.29 1.59 
Mapk3 Mitogen-activated protein kinase 3 -1.80 2.48 2.28 
Myd88 
Myeloid differentiation primary response 
gene 88 9.85 205.07 110.66 
Nfkb1 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 1, p105 -1.03 9.92 10.56 
Nfkb2 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 2, p49/p100 1.44 14.42 19.16 
Nfkbia 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, alpha 1.16 12.30 23.10 
Nod1 
Nucleotide-binding oligomerization 
domain containing 1 4.92 79.89 70.03 
Raf1 V-raf-leukemia viral oncogene 1 -1.25 8.46 7.62 
Rel Reticuloendotheliosis oncogene -2.31 3.73 3.86 
Rela 
V-rel reticuloendotheliosis viral oncogene 
homolog A (avian) 8.82 127.16 81.57 
Relb 
Avian reticuloendotheliosis viral (v-rel) 
oncogene related B 14.83 179.77 111.43 
Ripk1 
Receptor (TNFRSF)-interacting serine-
threonine kinase 1 -2.77 8.34 10.93 
Ripk2 
Receptor (TNFRSF)-interacting serine-
threonine kinase 2 -2.64 1.19 1.95 
Slc20a1 Solute carrier family 20, member 1 -1.62 3.86 2.93 
Smad3 MAD homolog 3 (Drosophila) 1.60 14.62 7.46 
Stat1 
Signal transducer and activator of 
transcription 1 2.95 36 45.25 
Tbk1 TANK-binding kinase 1 -1.62 6.15 7.52 
Tlr1 Toll-like receptor 1 -2.68 5.13 4.66 
Tlr2 Toll-like receptor 2 -2.43 10.78 8.40 
Tlr3 Toll-like receptor 3 18.64 156.50 288.02 
Tlr4 Toll-like receptor 4 -5.66 3.34 2.20 
Tlr6 Toll-like receptor 6 -1.15 7.46 6.36 
Tlr9 Toll-like receptor 9 -1.16 10.63 9.19 
Tnf Tumor necrosis factor 13.55 352.14 433.53 
Tnfaip3 
Tumor necrosis factor, alpha-induced 
protein 3 -227.54 -31.56 -6.82 
Tnfrsf10b 
Tumor necrosis factor receptor 
superfamily, member 10b -1.42 5.28 1.30 
Tnfrsf1a 
Tumor necrosis factor receptor 
superfamily, member 1a 5.86 65.34 27.67 
Tnfrsf1b 
Tumor necrosis factor receptor 
superfamily, member 1b 2.57 50.91 42.81 
Tnfsf10 
Tumor necrosis factor (ligand) 
superfamily, member 10 2.41 32.22 28.05 
Tnfsf14 
Tumor necrosis factor (ligand) 
superfamily, member 14 -3.71 1.56 1.40 
Tollip Toll interacting protein -1.74 4.50 4 
Tradd TNFRSF1A-associated via death domain -2.85 -1.35 -1.41 
Traf2 Tnf receptor-associated factor 2 1.60 11.71 10.06 
Traf3 Tnf receptor-associated factor 3 -1.30 8.46 4.29 
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Table 2 (Continued) 
Traf5 Tnf receptor-associated factor 5 3.25 21.86 19.56 
Traf6 Tnf receptor-associated factor 6 2.17 8.63 9.13 
Zap70 
Zeta-chain (TCR) associated protein 
kinase 3.07 13.36 12.91 
 
In addition to the genetic changes we tested if the treated macrophages 
resulted in increased production of inflammatory cytokines associated with these 
genes. We examined the culture supernatants of the treated bone marrow-derived 
macrophages against a panel of inflammatory cytokines and chemokines. Coinciding 
with the gene expression data presented in Table 2, increases in cytokines TNF-α, 
IFN-γ, IL-1β, IL-10, and chemokines MCP-1, G-CSF, GM-CSF, M-CSF, and 
RANTES (Figure 6 A-J) were observed in the culture supernatant validating the 
gene changes from the PCR array. Because of the MyD88 and stat1 upregulation 
we also examined if type I interferons and IL-33 (an IL-1 cytokine family member) 
were also increased. No type I interferon or IL-33 (an IL-1 cytokine family member) 
secretion was identified by ELISA (data not shown).  
  
Table 2. CPTEG:CPH nanoparticles cause up-regulation of mRNA leading 
to greater NF-κB transcription. RNA changes from bone marrow derived 
macrophages cultured in the presence of 0.25 mg of 20:80 CPH:SA, 20:80 
CPTEG:CPH, or 50:50 CPTEG:CPH nanoparticles as compared to no 
stimulation controls.  Total RNA was harvested 8 hours after addition of 
treatments to the macrophages. Numbers indicated fold regulation above 
(in red) or below (in blue) the non-stimulated controls cells. Array data is 
from a single experiment.  
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Figure 6. CPTEG:CPH nanoparticles cause increased secretion of 
inflammatory cytokines and chemokines coinciding with gene profile 
changes from bone-marrow derived macrophages. Culture supernatant 
fluid was assayed for the secretion of cytokines and chemokines from bone-
marrow derived macrophages stimulated with 0.25 mg of 20:80 CPH:SA, 
20:80 CPTEG:CPH, or 50:50 CPTEG:CPH or MPLA (0.5 µg) and compared 
to supernatant fluid collected from cultures of non stimulated macrophages. 
MCP-1 (A), RANTES (B), M-CSF (C), GM-CSF (D), G-CSF (E), IFNγ (F), IL-
10 (G), IL-1β (H) and TNFα (J) were quantified using multiplex 
immunoassay procedures.  N = 12 for each treatment group. Different letters 
indicate statistical difference at a p value < 0.05 value obtained via one-way 
ANOVA with Tukey’s post-test. 
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4. Discussion: 
Generation of cell mediated immunity in vaccination remains a major obstacle 
in vaccine design especially considering the more stringent purity and safety 
requirements outlined by governmental licensing institutions.  The ability to expand 
cytotoxic T cells and generate memory T cells using immunization is largely biased 
towards replicating viral vectors or DNA vaccines expressing targeted antigens 
which provide both the innate viral stimulatory mechanisms as well as extended 
presence of antigen as would be provided by a replicating viral vector [23, 24].  
Targeting the small number of antigen-specific, naïve T cells that would be available 
for a given T cell epitope, expanding that population of T cells and creating stable 
central memory populations capable of responding to a subsequent pathogen with 
subunit immunizations appears to rely on immunizations capable of recreating the 
aspects of a pathogenic infection and providing shifted or prolonged antigen kinetics 
[25-28]. These principles of pathogen mimicry by imitating size and particulate 
structure of pathogens as well as attempting to continuously provide antigen 
similarly to a replicating pathogen provides the basic principle advantages of the 
polyanhydride nanoparticle vaccine delivery platform. Encapsulation of antigen into 
50:50 CPTEG:CPH nanoparticles provides an enhanced expansion of Ova-specific 
CD8+ T cells that peaked at 3 DPI in the draining lymph node and that T cell 
population shows a delayed contraction compared to that observed in mice 
immunized with soluble Ova alone specific T cell precursor frequency is high (Figure 
1). This enhanced expansion of antigen-specific CD8+ T cells could be attributable to 
the presumed influx of antigen presenting cell precursor monocytes due to increased 
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monocyte chemokines being elicited by the polyanhydride nanoparticle vaccine 
(Table 1 and Chapter 4). We employed a similar combination of soluble Ova with 
encapsulated Ova in this study with the hypothesis being that the soluble protein will 
rapidly drain to the lymph nodes proximal to the injection site and initiate the immune 
response [29, 30]. The encapsulated protein in polyanhydride particles is then 
trafficked to the lymph nodes at later time points (1-3 days) and continues the 
maintenance of the antigen specific immune response started by the soluble protein 
[31].  
Different nanoparticle chemistries can persist from 2-12 weeks in vivo 
depending on copolymer chemistry (Chapter 4). Nanoparticle immunization 
theoretically provides extended antigen kinetics in vivo and this may translate to 
numbers of antigen specific CD8 T cells at 7 DPI as well as promoting a central 
memory phenotype (CD44high CD62Lhigh and increased IL-2 production upon antigen 
restimulation) (Figure 1 and 2). Continued antigen presence is key towards driving 
memory populations as naïve T cells activated as the antigen load is waning acquire 
more central memory characteristics needed for retention in the secondary lymph 
tissue such as decreased ability to down-regulate CD62L and less proliferative 
capacity [32-34]. IL-2 production is also critical for establishing a stable memory pool 
[35]. 
Simultaneous evaluation of antigen-specific CD8+ T cell responses induced 
using vaccine regimen that included one of three different polyanhydride chemistries 
was accomplished using adoptive transfer of a transgenic luciferase reporter mouse 
line (T-lux) under the control of the T cell integrin CD2 promoter [36] crossed with 
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the transgenic OTI antigen specific line.  The three chemistries evaluated showed 
differential antigen release kinetics in vitro with 20:80 CPH:SA and 20:80 
CPTEG:CPH providing a large burst release of antigen while 50:50 CPTEG:CPH 
show a slower and more sustained release (Figure 3B). CPTEG:CPH polyanhydride 
nanoparticles enhance CD8+ T cell expansion at the immunization site based on 
bioluminescence signal increases (Figure 3). Peak expansion of T cells occurred 
early (5 DPI) and contracted to baseline levels by 10 DPI.  Based on anatomical 
location of the bioluminescent signal, magnitude, and dominant effector cell 
phenotype exhibited in Figure 2, it can be postulated that a majority of these cells 
were short-lived effector cells migrating to the immunization site.  The EL-7 Ova 
expressing T cell lymphoma cell line was used to assess the presence of cytotoxic 
effector CD8+ T cells in the immunized mice. In vivo imaging of bioluminescent Ova-
specific T cells showed that MPLA and CPTEG:CPH immunized mice showed 
earlier measurable T cell infiltrate than mice in other immunization groups (Figure 4).  
The T cell infiltrate in all immunizations demonstrates T cell memory as no 
measurable increases in luminescence is detected in sham immunized (PBS) mice 
until 14 days post-tumor challenge time point (Figure 4C). Tumor challenge was 
largely controlled in all groups receiving immunization compared to sham immunized 
mice as well indicating the high frequency adoptive transfer of naïve T cells 
demonstrates a protective advantage against this tumor model (Figure 5 D-E).  The 
kinetics of the response to the tumor challenge and the statistically significant 
amount of antigen specific CD8+ T cells in the periphery are indicative of the levels 
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of memory T cells developed from immunization that were capable of responding 
rapidly to challenge. 
The high frequency adoptive transfer model illuminated the ability of 
polyanhydride nanoparticle immunizations to activate Ova-specific T cells and gave 
indications that an effector memory CD8+ T cell response can be enhanced by the 
inclusion of Ova-containing nanoparticles as part of the vaccine regimen. The high 
frequency transfer model is somewhat unrealistic however, in that the precursor 
frequency of the antigen-specific T cells was skewed in the favor of detecting a 
positive response after administration of a high dose of Ova that would be sufficient 
to stimulate a large number of antigen-specific naïve T cells. To outline the 
capabilities of the polyanhydride nanoparticle-based vaccine regimen to elicit T cell 
responses in an environment more closely resembling the frequency of antigen-
specific naïve T cells while still maintaining the ability to examine an antigen specific 
cell population we utilized a low frequency adoptive transfer technique outlined by 
Moon et al [16]. Examinations of the draining lymph nodes for expansion of Ova-
specific T cells at 7 DPI show that polyanhydride nanoparticle immunizations 
significantly increase the numbers of Ova-specific CD8+ T cells (Figure 6A-B) with 
20:80 CPTEG:CPH demonstrating the greatest ability to expand CD8+ T cells with 
the least variability.  
The kinetics of antigen exposure to naïve T cells entering the draining lymph 
node is crucial in programming memory T cells as this stage in the maturation of the 
antigen-specific response is more likely to occur during the times of limited antigen 
availability [37].  Naïve T cells that arrive later or during reduced antigen lead to a 
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differential programming resulting in the development of more central memory T 
cells rather than a short-lived effector cells (SLEC) [26, 34, 38, 39]. This increased 
memory conversion can be dictated by naïve precursor frequency with increased 
naïve precursor frequency leading to higher memory T cells so it was important to 
both control for that frequency by utilizing low frequency transfer [34, 38]. Longer 
periods of antigen exposure lead to more opportunity for late-coming naïve CD8+ T 
cells to arrive and be programmed. The greater expansion of CD8+ antigen specific 
T cells also leads to higher amounts of precursor memory T cells (MPEC) 
characterized by decreased expression of CD127 (IL-7Rα) and KLRG1 surface 
markers (Figure 6E-F) [19]. KLRG1low CD127low T cells have demonstrated greater 
ability to effectively convert into central memory T cells [19, 40]. Previously MPEC 
definitions of KLRG1low CD127high T cells gave rise to memory T cells [41] but more 
recent evidence supports the concepy/hypothesis that memory precursor cells to be 
focused on the low KLRG1 marker. Nevertheless, the polyanhydride nanoparticle 
immunizations were able to induce greater numbers of the MPEC at 7 DPI. As such, 
greater numbers of central memory T cells are also elicited by the polyanhydride 
nanoparticle immunizations at this early time-point (Figure 6G-H) indicating that in a 
pathogen-like manner, the nanoparticle formulations facilitate the induction of a 
cellular immune response.  
Antigen kinetics appear to play a greater role in memory programming in 
support of the “decreasing-potential model” proposed in Ahmed and Gray [37]. 
Exogenous inflammatory stimuli did not support greater memory population 
generation in a lymphocytic choriomeningitis virus (LCMV) infection model but 
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antigen load dictated memory conversion [19]. Prolonged antigen exposure does not 
increase the memory T cell pool but rather decreases it as more of the MPEC and 
antigen experienced effector cells are programmed to short-lived effector 
phenotypes [42, 43]. Therefore the controlled release kinetics of encapsulation of 
antigen in polyanhydride nanoparticles appears to potentiate the “decreasing-
potential” exposure window leading to more memory precursors and memory T cell 
pools (Figure 2B, Figure 6) 
Inflammation associated with the initiation of the immune response dictates 
aspects of memory pool generation. Increasing amounts of IL-12 drives T-bet 
transcription factor expression leading to larger central memory pools [41]. As such 
we identified changes in gene expression and secretion of cytokines by bone 
marrow derived macrophages treated with the three different polyanhydride 
chemistries. Polyanhydride particles increased the secretion of IL-12p40 and IL-6 
from bone marrow derived dendritic cells indicating the cytokine milieu that may 
drive programming [8]. 
Activation of naïve CD8+ T cells is not only limited to DCs but macrophages 
can also activate naïve CD8+ T cells and influence effector and memory functions 
[44]. The in vivo evidence of enhancing antigen specific T cell expansion (Figure 1, 
3, and 5) as well as increases in monocyte chemokines and cytokines (Chapter 4 
and Table 1) and the dominant monocyte/macrophage infiltrate at the administration 
site (Chapter 4), led us to examine the genetic and inflammatory chemokine/cytokine 
profile of macrophages administered nanoparticles in vitro. We observed the 
CPTEG:CPH polyanhydride chemistries to induce the largest NF-κB associated 
	  	   183	  
signaling gene changes as well as the greatest inflammatory cytokine production as 
compared to 20:80 CPH:SA which seemed similar in genetic changes to un-
stimulated cells (Table 2). The genetic up-regulation of stat1 has been shown to be 
critical for IP-10 production from macrophages [45] which may be a major indicator 
of the polyanhydride specific IP-10 production in vivo (Chapter 4 and Table 1). The 
increases in transcription of intracellular PRRs TLR3 and NOD1 and to a lesser 
extent TLR9 all indicate that nanoparticles are perceived as intracellular pathogens 
by the BM-MØ [46-49].  Most relevant to the expanded T cell responses, however, 
was the large up-regulation of CD40 (Table 2). CD40-CD40L ligation is needed for 
optimal expansion of T cell responses and one can theorize that sustained antigen 
presentation occurring from APCs continually processing slowly eroding 
nanoparticles benefits from sustained expression of CD40 for greater increases in T 
cell expansion.  We speculated that the 20:80 CPTEG:CPH chemistry would be the 
most immunomodulatory in these in vitro assays based on the in vivo inflammatory 
response induced at the site of injection (Chapter 4). However, the 50:50 
CPTEG:CPH chemistry appeared the most immunomodulatory according to the 
genetic profiles and cytokines secreted. This could be a function of timing of the 
assay as these in vitro data reported were examined at 8 hours. The 20:80 
CPTEG:CPH polymer is the slowest eroding polymer and, therefore, may provide 
stronger signals later and/or more sustained immunomodulatory signals leading to 
the best in vivo responses. This data, the T cell activation data, and the T cell 
localization data correlates with observations that macrophages are more capable of 
activating naïve CD8+ T cells and forming multiple immunological synapses than are 
	  	   184	  
DCs. These BM-MØ:naive T cell interactions may occur at the administration site as 
well as within the draining lymph tissue [50]. 
The data reported herein coincides with meta-analysis of previous 
publications examining the immunomodulatory potential of the polyanhydride 
platform indicating that the CPTEG:CPH chemistries appear “pathogen-like” in the 
ability to induce innate immune functions [8, 51, 52]. These “pathogen-like” 
properties most likely are a synergistic combination of the particulate structures of 
the nanoparticles mimicking pathogen size, the controlled release of encapsulated 
antigen mimicking the antigen kinetics of replicating pathogen being resolved by the 
immune system leading to immune memory, and interaction of conserved innate 
immune receptors responding to the polymeric strands of degrading particles and 
the oxygenated hydrophobic backbones of the polymers. Therefore, the 
polyanhydride nanoparticle platform performs as both an effective particulate 
vaccine delivery system as well as a potent immunopotentiator capable of activating 
APCs leading to enhanced CD8 T cell immunity.  
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CHAPTER 6: HUMORAL IMMUNE RESPONSES ELICITED BY THE 
POLYANHYDRIDE PARTICLE VACCINE PLATFORM ARE FACILITATED BY 
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Abstract: 
 
 
 The polyanhydride nanoparticle vaccine platform provides innate 
immunomodulatory activity while also controlling antigen release kinetics to enhance 
humoral immunity. The increased humoral responses by adjuvanting vaccines with 
polyanhydride nanoparticles is indicative of activating T helper cell responses early 
after immunization that provide the necessary help for B cells to secrete antibody. 
Here we identify the mechanisms of CD4+ T cell expansion and phenotypes 
observed after immunizing with three different polyanhydride nanoparticle 
formulations using the transgenic Ovalbumin specific T cell (OTII) system. 
Statistically increased expansion of CD4+ T cells occurs with 20:80 CPH:SA and 
20:80 CPTEG:CPH chemistries. These T cells show T follicular helper cells 
(CXCR5high PD-1high) phenotypes important for initiating and maintaining germinal 
centers in similar percentages as traditional Alum and MPLA adjuvants. The 
polyanhydride nanoparticle vaccines display enhanced IgG1 antibody responses as 
compared to antigen alone and the mice were effectively primed to respond with 
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robust IgG1 and IgG2c isotype antibody after antigenic challenge 35 days post 
immunization. The polyanhydride nanoparticles show enhanced amounts of Vα2+ 
Vβ5+ CD4+ T cells of the Tfh phenotype as well as enhanced PNA+ activated B cells 
indicative germinal centers.   
 
1. Introduction 
 
 Protective humoral immunity elicited by preventive immunization is provided 
by long-lived plasma cells and memory B cells, leading to the production of antibody 
that inhibits bacterial growth or colonization, provides immune exclusion, opsonizes 
bacteria, activates complement activation, or neutralizes toxins or viral entry into 
cells [1]. Germinal centers are elegant B cell training grounds where initial activation 
of B cells occurs as well as affinity maturation of the antibody response, and 
development of memory B cells that ultimately maintain humoral immune responses. 
Competition of high affinity antigen receptors against immune complexes of antibody 
and antigen maintained by follicular dendritic cells occur in the germinal center [2]. 
Subsequent studies into germinal center formation have shown that competition for 
cytokines provided by a unique CD4+ T cell phenotype, namely T follicular helper 
cells (Tfh), is an important cellular mechanism for optimal B cell responses after 
immunization [3-5]. In particular, Tfh cells are critical sources of cytokines IL-4 and 
IL-21 which are important for B cell activation, proliferation, and isotype switching [3]. 
Co-stimulatory ligation of CD40, T cell co-stimulatory molecule-ligand (ICOSL), and 
CD80/86 are also critical components of T cell help that augment B cell activation 
during germinal center formation.   
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Biodegradable polyanhydride biomaterials represent a unique next generation 
vehicle delivery platform that can be used to design efficacious vaccine regimen for 
poorly immunogenic subunit (i.e., recombinant) proteins [6, 7]. Polyanhydride 
copolymers based on sebacic acid (SA), 1,6-bis(p-carboxyphenoxy) hexane (CPH), 
and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) formed into particulate 
carriers can be tailored to meet the desired controlled release profile of 
encapsulated immunogens as well as providing innate immunomodulatory functions 
such as activating dendritic cells [8-11]. A polyanhydride nanoparticle vaccine 
regimen was used to induce protective immunity against Yersinia pestis. The 
resultant antibody response was characterized by the presence of avid high titer F1-
V-specific IgG1 after a single intranasal immunization consisting of soluble 
recombinant F1-V and polyanhydride nanoparticles encapsulating F1-V [12].  
Herein, we identify the cellular responses important in generation of the high 
titer antibody responses elicited by vaccine regimen incorporating the polyanhydride 
nanoparticle vaccine platform by utilizing transgenic CD4+ T cells (OT II) responsive 
to ovalbumin (Ova). Immunization with Ova-loaded polyanhydride nanoparticles after 
high frequency adoptive transfer of OTII T cells induced the expansion and 
contraction kinetics of OTII T cells that was similar to soluble antigen alone. In 
contrast, a more significant expansion of OTII T cells was observed when mice were 
immunized with Ova adjuvanted with Alum. Following high frequency transfer of OTII 
T cells, the induction of Ova-specific IgG1 antibody responses at 14 days post-
immunization (DPI) was greater in mice immunized with Ova-loaded 50:50 
CPTEG:CPH nanoparticles. To mimic the in vivo environment where antigen-specific 
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naïve T cell precursor frequency ≥ 0.1 % , a low frequency adoptive transfer of OTII 
T cells was utilized and the polyanhydride nanoparticle platform exhibited expanded 
CD4+ T cells highlighted by increases in CD4+ T cells with a Tfh phenotype. Antibody 
responses in the low frequency adoptive transfer model also indicate augmentation 
of antibody responses when antigen is encapsulated in each of the three 
polyanhydride nanoparticle chemistries examined compared to unadjuvanted Ova. 
Strong IgG1 antigen specific antibody was generated and these nanoparticle 
immunized mice were primed to respond strongly with IgG1 when antigenically 
challenged 35 DPI. Polyanhydride nanoparticle vaccine regimens show statistically 
increased numbers of V-α2+ V-β5+ CD4+ Tfh at 42 DPI as well as increased 
percentage of B220+ CD23high PNA+ B cells. These early indications of GC formation 
outline the cellular mechanisms responsible for the immune phenotype observed 
after immunization with vaccines utilizing the polyanhydride nanoparticle platform.  
 
2. Materials and Methods  
 
2.1 Synthesis and characterization of copolymers 
 CPH and CPTEG monomers were synthesized using the chemicals listed: 4-
p-hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, and tri-
ethylene glycol. All these chemicals and sebacic acid (99%) were purchased from 
Sigma Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile was obtained from Apollo 
Scientific (Cheshire, UK); potassium carbonate, dimethyl formamide, toluene, 
sulfuric acid, acetic acid, acetonitrile, acetic anhydride, methylene chloride, and 
petroleum ether were purchased from Fisher Scientific (Fairlawn, NJ). Synthesis of 
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CPH and CPTEG diacids was performed as previously described [13, 14] and pre-
polymers of SA and CPH were synthesized using previously described methods [14, 
15]. Copolymers (20:80 and 50:50 CPH:SA and 20:80 and 50:50 CPTEG:CPH) were 
synthesized using a melt polycondensation process as detailed by Kipper et al. and 
Torres et al [6, 13]. The degree of polymerization, molecular weight, chemical 
structure, and polymer purity were determined using 1H nuclear magnetic resonance 
(NMR) spectroscopy (Varian VXR-300 MHz, Palo Alto, CA).  
 
2.2 Fabrication and characterization of particles 
Nanoparticles encapsulating Ova (Sigma-Aldrich, St. Louis, MO) (5.0% w/w 
loading) were fabricated using the anti-solvent nanoencapsulation method outlined 
in Ulery et al [9]. Briefly, the copolymer was dissolved in methylene chloride at a 
concentration of 20 mg/mL at 4˚C. Ova was added to the dissolved copolymer and 
the solution was sonicated for uniform dispersal of the protein within the copolymer. 
The dissolved ova loaded copolymer (ova-loaded) or copolymer (blank) solution was 
poured into chilled pentane (-20°C) at a non-solvent to solvent ratio of 250:1, and 
was vacuum filtered to recover the nanoparticles. Shape and size of the resulting 
nanoparticles were characterized using scanning electron microscopy (SEM) (FEI 
Quanta 250, FEI, Hillsboro, OR). The particle size distribution was obtained from 
SEM images using Image J version 1.46 image analysis software [16]. An average 
of 200 particles per image was analyzed. 
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2.3 Mice 
 Recipient female C57BL/7 Thy 1.1, recipient albino C57BL/6, OTII mice were 
purchased from Jackson Laboratories (Bar Harbor, MN). All mice were housed 
under specific pathogen-free conditions where all bedding, caging, water, and feed 
were sterilized prior to use. Animal procedures were conducted with the approval of 
the Iowa State University Institutional Animal Care and Use Committee. 
 
2.4 Mouse treatments 
2.4.1 Adoptive transfer of antigen-specific T cells 
For the high frequency adoptive transfer experiments, 3.0 x 106 donor OTII 
Thy 1.2+ cells were transferred by tail vein injection on day -1. For the low frequency 
adoptive transfer experiments, 3 x 103 OTII Thy 1.2+ cells were transferred via the 
tail vein on day -1. For in vivo imaging studies, low frequency adoptive transfer of 3.0 
x 103 OTII cells was performed on day -1.   
2.4.2 Immunization Regimens 
On day 0, mice were immunized subcutaneously (SC) with 1.75 mg of soluble 
Ova and 5 mg of 5 % Ova loaded polyanhydride nanoparticles (20:80 C:S, 20:80 
C:C, 50:50 C:C), 2.0 mg of soluble Ova (sOVA), or 2.0 mg of Ova adjuvanted 1:1 
with Imject Alum (Alum) (ThermoFisher, Rockford, IL). For the low frequency 
adoptive transfer experiments, 25 µg of Ova was administered as an antigenic 
challenge at 37 DPI. 
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2.5 Assaying for ex vivo T cell phenotype and activity 
At three, five, seven, fourteen, and forty-five days post-immunization (DPI), 
draining lymph nodes were excised and single cell suspensions were created using 
a glass homogenizer. Half of each spleen was homogenized to prepare single cell 
suspensions and the red blood cells were lysed using ACK lysis buffer. The numbers 
of T cells recovered from the splenic tissue and their phenotype were quantified 
using flow cytometry (BD FACS Aria III). For low frequency adoptive transfer 
experiments, positive selection for donor T cells was accomplished using 
biotinylated anti-CD90.2 (Thy 1.2 Clone 53-2.1) (eBioscience, San Diego, CA) and 
streptavidin conjugated magnetic microbeads (Miltenyi Biotech, Auburn, CA). 
Positive magnetic bead selection was performed via methods outlined by Moon et al 
(AutoMACS Pro Milteny Biotec) [17]. Prior to the addition of the monoclonal 
antibodies used for selection or cell surface marker analysis, cell suspensions were 
blocked for non-specific antibody binding using 0.1 mg/mL Rat IgG (Sigma Aldrich) 
and 10 µg/mL mouse anti-CD16/32 (eBioscience). For T cell assays, fluorescently 
conjugated antibodies for CD4 (PE-Cy7, Clone GK1.5, eBioscience), CD8ß (APC, 
Clone eBioH35-17.2, eBioscience), CD62L (PE, Clone 2G8, eBioscience), PD-1 
(eFluor 450, Clone 4B12, eBioscience), Thy 1.2 (APC-eFluor 780, Clone 53-2.1, 
eBioscience), Thy 1.1 (PerCP-Cy 5.5, Clone HIS51, eBioscience), CD19 (PerCP-
Cy5.5, clone eBio1D3, eBioscience), CD11c (PerCP-Cy5.5, clone N418, 
eBioscience), CD11b (PerCP-Cy5.5, clone M1/70, eBioscience), F4/80 (PerCP-
Cy5.5, BM8, eBioscience), CXCR5 (PE, clone 2G8, BD, Franklin Lakes, NJ), and 
CD44 (v500, clone IM7, BD) were used to label the cells, to establish analytical 
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gates, and to quantify donor Thy 1.2+ cells. Abs were used in appropriate 
combination of fluorochromes. The population of B cells was analyzed using 
fluorescently conjugated antibodies for CD19 (PerCP-Cy5.5, clone eBio1D3, 
eBioscience), B220 (PE-eFluor 780, clone RA3-682, eBioscience), and CD23 (PE-
Cy7, clone B384, eBioscience), and FITC PNA (Vector Labs, Burlingame, CA) to 
quantify germinal center responses.  
   
2.6 Serum cytokine analysis 
Serum samples obtained from C57BL/6 Thy 1.1 recipient mice were analyzed 
using a 22-plex chemokine and cytokine antibody array (Millipore, Billerica, MA) 
measuring the following analytes: G-CSF, GM-CSF, IFN-γ, IL-10, IL-12p70, IL-13, 
IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC, MCP-1, MIP-1α, 
RANTES, and TNF-α. Assays were performed according to the manufacturer’s 
recommendations; data were acquired and analyzed using a Bio-Plex 200 (Bio Rad, 
Hercules, CA). 
 
2.7 Antigen Specific Antibody Analysis 
Serum was generated from blood samples taken from saphenous vein bleeds 
or collected by cardiac puncture after the mice were euthanized. Serum was clarified 
by centrifugation at 1000 x g for 10 minutes. The serum samples were then stored at 
-20 °C until used.  ELISA plates (Costar Catalog # 3590, EIA/RIA high binding) were 
coated overnight with 0.5 µg/well Ova. Plates were washed with phosphate buffered 
saline (PBS, 0.05 M, pH 7.4) containing 0. 5 % Tween 20 at a (PBST). Plates were 
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blocked for two hours with 2 % fish gelatin (Difco) in PBST. Plates were washed and 
serial dilutions of individual serum samples in PBST supplemented with 1% heat 
inactivated normal goat serum (GIBCO) were incubated overnight at 4 oC. Plates 
were washed again with PBST and alkaline phosphatase-conjugated goat anti-
mouse IgG (H&L), IgG1, or IgG2c (Jackson ImmunoResearch Laboratories, West 
Grove, PA) diluted 1:1000 in 1 % heat inactivated normal goat serum in PBST was 
incubated for 2 h. Plates were washed and p-nitrophenyl phosphate (Sigma) 
substrate (1 mg/mL) in 50 mM Na2CO3 and 2 mM MgCl2 buffer (pH 9.3) was added 
to each well. Changes in optical density (OD) were measured at 405 nm using a 
spectrophotometer (Spectra Max 190, Molecular Devices, Sunnyvale CA).  
The avidity of the Ova-specific IgG1 was measured as described previously to 
determine antibody binding strength in the presence of a chaotropic agent that 
disurpts antibody-antigen binding interactions [6]. The relative avidity percentage 
was calculated by dividing the OD405 nm of 1:3000 diluted serum treated with 0.625 
M NaSCN by the OD405nm of 0 M NaSCN treated wells and the percentage was 
reported.  
2.8 Statistical analysis 
Differences in mean responses among treatments were tested with one-way 
ANOVA F-test followed by a post-hoc Tukey’s t-test using Graph Pad Prism version 
5. Values were log transformed for equal variance where needed. Statistical tests 
with p values ≤ 0.05 were regarded as significant. 
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3. Results 
3.1 Nanoparticle immunization in high frequency adoptive transfer expands less 
CD4+ antigen specific T cells compared to Alum 
Measures of vaccine efficacy for vaccines designed with the polyanhydride 
nanoparticle platform exhibit high titer IgG1 antibody of high avidity [7]. Little 
evidence of T cell recall responses were observed in these studies other than the 
protection from challenge. We hypothesized that encapsulation of antigen in 
polyanhydride nanoparticles leads to an expansion of T helper cells that exceeds 
soluble antigen and would be similar to traditional adjuvants such as Alum. C57BL/6 
Thy 1.1 recipients were adoptively transferred high amounts of purified OTII CD4+ T 
cells and immunized with 2.0 mg of Ova as a soluble dose (sOVA), encapsulated 
regimen of 1.75 mg of soluble Ova and 0.25 mg encapsulated in 50:50 CPTEG:CPH 
particles or adsorbed to Alum. The expansion of antigen specific T cells was 
quantified via the donor specific congenic marker Thy 1.2. The expansion kinetics of 
polyanhydride nanoparticle immunizations mimicked the expansion and contraction 
of a soluble dose immunization alone (Figure 1). The main differences observed 
were in the heightened expansion of antigen specific CD4+ T cells at five DPI with 
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the Alum adjuvanted immunization.  
 
3.2 Nanoparticle immunization elicits less serum inflammatory in a high frequency 
adoptive transfer model 
We hypothesized that the lower amounts of inflammation associated with a 
nanoparticle regimen as compared to Alum contributed to differences in expansion 
of antigen specific CD4+ T cells (Chapter 4). Examining the serum cytokine and 
Figure 1. Nanoparticle immunization regimen leads to less CD4+ antigen specific 
T cell expansion compared to Alum. High frequency adoptive transfer of OTII Thy 
1.2+ T cells (3 x 106 cells/mouse) was performed one day prior to immunization with 
Ova-loaded 50:50 CPTEG:CPH nanoparticles, adsorbed to Alum, or soluble Ova 
(sOVA) alone. Percentages of Thy1.2+ T cells present in the draining lymph nodes were 
examined at the time points indicated and donor T cells were identified by donor 
congenic marker Thy 1.2+ compared to Thy 1.1+ recipient markers.  Each time point is 
mean percentage of CD4+ Thy 1.2+ cells for cohorts of 4 to 5 mice per time point (N ≥ 
4).  # indicates a significant difference from other groups at p < 0.05. 
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chemokine responses from mice at one DPI shows an increase in the neutrophil 
chemotactic pro-inflammatory cytokine KC (mouse analog of IL-8) (Figure 2A). IL-6 
was also increased in the serum of immunized mice although there was no 
significant differences between groups observed (Figure 2B).   
 
3.3 Nanoparticle immunization leads to greater Ova-specific antibody 
We hypothesized that the Alum adjuvanted groups, because of the increased 
expansion of CD4+ T cells at 5 DPI, would exhibit enhanced Ova-specific antibody 
as compared to the 50:50 CPTEG:CPH and sOva groups. At 14 DPI, the Thy 
1.2+CD4+ T cells had all but contracted to baseline levels in the mice receiving 3 x 
106 Thy 1.2+ OTII T cells. (Figure 1). The IgG1 Ova-specific antibody response was 
enhanced in the polyanhydride nanoparticle groups at 14 DPI (Figure 3). no Ova-
specific IgG2c antibody was observed at this time point (data not shown).  
Figure 2. Inflammatory cytokines IL-6, KC, and GM-CSF are increased after 
immunization. Concentrations of (A) KC, (B) IL-6, and (C) GM-CSF in the serum of 
mice immunized with the polyanhydride nanoparticle vaccine (50:50 CPTEG:CPH, 
soluble Ova (sOVA), Alum adjuvanted Ova (Alum), or saline one day post-
immunization. Treatment groups marked with # are significantly different from those 
mice treated with saline at p < 0.05. n = 4-5 mice per group.  
 
	  	   202	  
  
3.4 Nanoparticle immunizations expand CD4+ T cells in low precursor frequency 
adoptive transfer 
The high frequency adoptive transfer model allowed us to enhance and 
magnify the in vivo expansion kinetics of CD4+ T cells after polyanhydride 
nanoparticle adjuvanted vaccines. The high frequency adoptive transfer model is 
unconventional in that it artificially inflates the pool of naïve antigen-specific CD4+ T 
cells. To examine antigen-specific T cell responses while maintaining a more natural 
level of naïve antigen-specific T cells, 3 x 103 Thy1.2+ OTII T cells were adoptively 
Figure 3. Nanoparticle vaccine enhances antigen specific IgG1 antibody 
responses following high frequency adoptive transfer of OTII T cells. Ova 
specific antibody responses were quantified via ELISA at 14 days post-
immunization with 50:50 CPTEG:CPH nanoparticles, soluble Ova (sOVA), Ova 
adsorbed to Alum, or PBS.  IgG1 isotype specific secondary antibody was used 
to identify isotype specific antibodies.  N = 4-5 mice per group. # indicates a 
significant difference from other groups at p < 0.05. Data presented from one 
experiment. 
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transferred into recipient mice. The expansion and the phenotype of OTII T cells was 
monitored after immunization by flow cytometry. 
 Adoptive transfer was performed one day prior to immunization. 
Immunizations consisted of three formulations of polyanhydride nanoparticles, 20:80 
CPH:SA, 20:80 CPTEG:CPH, and 50:50 CPTEG:CPH, as well as two positive 
control vaccines consisting of Ova adsorbed to Alum or co-administered. Statistically 
significant antigen specific CD4+ T cell expansion was observed in the mice 
receiving the 20:80 CPH:SA, and 20:80 CPTEG:CPH, vaccine formulations (Figure 
4A-B).  The phenotype of these antigen experienced (CD4+ CD44high) expanded T 
cells shows a shift in Tfh cell phenotype (PD-1high CXCR5high) in percent and total 
cell numbers when the antigen is adjuvanted by encapsulation into polyanhydrides 
or by Alum (Figure 4C-E).   
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3.5 Nanoparticle immunizations enhance antibody responses in low frequency 
adoptive transfer models by sustaining germinal centers 
To test the hypothesis that an increase in Tfh cells would correlate with a 
greater humoral immune responses, the kinetics of the Ova-specific antibody 
response was evaluated for a period of 35 DPI (Figure 5A-D).  We observed that 
enhanced IgG1 antibody responses were generated by all adjuvanted vaccines as 
compared to sOva alone.  Higher sustained IgG1 antibody titers were maintained, as 
compared to the titers induced by sOVA, through 35 DPI (Figure 5A-D). There was 
no evidence that Ova-specific IgG2c and IgG3 was induced by any vaccine 
Figure 4. Nanoparticle vaccines expand 
antigen specific CD4 T cells and generate T 
follicular helper cells. Donor OTII T cells were 
quantified at 7 DPI following immunization of 
mice with Ova-loaded polyanhydride 
nanoparticle formulations (20:80 CPH:SA, 20:80 
CPTEG:CPH, and 50:50 CPTEG:CPH), Ova 
adjuvanted with Alum  or soluble Ova alone 
(sOVA). Representative FACS histograms of 
CD4+ Thy 1.2+ populations from draining lymph 
nodes (A) and quantified cell numbers (B). 
Representative FACS histograms of gated CD4+ 
Thy 1.2+ CD44high cells gated for PD-1high 
CXCR5high populations (Tfh cells) (C), quantified 
cell numbers (D) and percentage of gated cells 
(E). N = 5 to 6 mice per group. # indicates a 
significant difference from PBS groups at p < 
0.05.  
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formulation after the initial immunization (data not shown).  At 37 DPI, a 25 µg 
antigenic challenge was administered to the immunized groups to examine the 
anamnestic Ova specific antibody responses. All groups receiving antigen were 
effectively primed and displayed robust IgG1 responses (Figure 5D). Antigen 
specific IgG2c responses were also expanded in all groups receiving antigen though 
no statistical differences were identified  
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Figure 5. Nanoparticle vaccines expand antigen specific antibody responses 
similar to common adjuvants Alum. Ova specific antibody responses elicited from 
mice receiving low frequency transfer of OTII T cells and Ova immunizations 
adjuvanted with 20:80 CPH:SA, 20:80 CPTEG:CPH, 50:50 CPTEG:CPH 
polyanhydride nanoparticles, Alum, or soluble Ova (sOVA) were quantified to 
examine IgG1 isotype. A 25 µg antigenic challenge of Ova was administered on 37 
DPI. Antibody titers reported as mean titer values at 14 (A), 21 (B), 35 (C), and 45 
(D) N = 9 mice per group. Different letters above indicate significant difference at p < 
0.05. Results are from one experiment   
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To examine if the enhanced antibody responses observed were due to 
sustained Ova specific T cells, the draining lymph nodes from the immunized mice 
were examined for CD4+ T cells (Vα2+, Vβ5+) that displayed the Tfh phenotype 
(Figure 6A). OTII T cells recovered from mice immunized with polyanhydride 
nanoparticle vaccines showed a greater numbers of Tfh Vα2+ Vβ5+ T cells.  The 
presence of larger numbers of Tfh cells also correlated with larger germinal center B 
cell populations (B220+ CD23high PNA+) with polyanhydride nanoparticle vaccines 
(Figure 6C).  MPLA adjuvanted vaccines show high CD4 T+ cell responses early 
(Figure 4) however T cell populations are not identified later (Figure 6A) and 
correlating PNA+ B cell populations were not identified (Figure 6B). The strength of 
the antibody responses at this late time point indicated that immunization with the 
polyanhydride nanoparticles facilitated the maintenance of germinal center cell 
populations and more avid antigen-specific antibodies.  
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 4. Discussion 
 Induction of protective immune responses via immunization is one of the most 
effective preventive medicinal measures for decreasing infectious disease in at-risk 
populations. Designing efficacious vaccines while minimizing safety and purity 
Figure 6. Nanoparticle vaccines maintain Tfh cell populations correlating to 
more sustained germinal centers at 45 days post-immunization. Single cell 
suspensions of draining lymph nodes of mice immunized with Ova adjuvanted 
with 20:80 CPH:SA, 20:80 CPTEG:CPH, or 50:50 CPTEG:CPH polyanhydride 
nanoparticles, Alum, or soluble Ova (sOVA) protein at 45 DPI were labeled with 
anti-CD4, anti-CD44, anti-PD-1, anti-CXCR5, anti-Vα2, and anti-Vβ5. 
Representative FACS histograms of CD4+ CD44high CXCR5high PD-1high cells that 
are V-α2+ (x-axis) and V-β5+ (y-axis) (A). Percent of CD4+ CD44high CXCR5high 
PD-1high cells that are V-α2+ V-β5+ (Ova specific) in the draining lymph nodes (B). 
Lymph node cells labeled with anti-B220, anti-CD23, and PNA. Representative 
FACS histograms of gated B220+ CD23high  with PNA on the x-axis (C). Quantified 
B220+ CD23high PNA+ percent of total cells in the spleen of immunized mice (D). 
Relative avidity percentage (OD405nm at 0.625M NaSCN divided by 0M NaSCN) 
of Ova specific IgG1 antibody at 45 DPI (E). N = 9 mice per group. Different 
letters above histograms indicate significant differences between groups at p 
<0.05. Data is from one experiment. 
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concerns by implementing the use of subunit immunogens (e.g., recombinant 
proteins) is a foundation of next generation vaccine design. Adjuvants are often 
employed to boost immunostimulatory activity and skew antigen availability to 
bolster the efficacy of subunit vaccines.  
 Polyanhydride particles provide a particulate context for APCs for optimal 
phagocytosis as well as increases in the expression of co-stimulatory molecules 
(e.g., CD86, CD40) on APC [9, 10, 12, 18]. Encapsulation of antigen in 
polyanhydride particles enhances humoral immune responses with low doses of 
antigen while eliciting less inflammation in vivo than traditional adjuvants such as 
alum or Freund’s incomplete adjuvant (Chapter 3 and 4). Designing vaccines 
consisting of a soluble portion of antigen as well as a portion of F1-V antigen 
encapsulated in polyanhydrides nanoparticles led to high-affinity IgG1 antibody 
induction and protection from Yersinia pestis challenge utilizing a single dose 
regimen [7, 12]. We hypothesized that the polyanhydride nanoparticles may 
augment antigen-specific CD4+ T cell expansion similar to that described for Alum. 
In contrast, the results of the present study indicated that the expansion and 
contraction kinetics of Ova-specific CD4+ OTII T cells followed the kinetics of that 
induced by immunization with soluble Ova alone compared to an Alum adjuvanted 
vaccine in mice receiving 3 x 106 naïve OTII T cells by adoptive transfer (Figure 1). 
These observations would be consistent with the decreased inflammation induced 
following administration of the various polyanhydride nanoparticle formulations 
(Chapter 4) and measured in the serum may contribute to the differential expansion 
and contraction kinetics (Figure 2). Antigen-specific IgG1 antibody responses were 
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enhanced in mice immunized with the polyanhydride vaccines compared to those 
vaccinated with Ova adjuvanted with Alum (Figure 3) indicating that the increased 
CD4 expansion at 5 DPI was not sufficient to enhance IgG1 antibody secretion. No 
measurable antigen specific IgG2c was identified at this time point. What is evident 
is that the magnitude of CD4+ T cell expansion did not directly translate to more 
antibody production. How naïve T cells are influenced during antigen presentation to 
commit to a lineage important for B cell help and antibody production appears to be 
of vital importance.    
 Optimal high-affinity antibody responses are dependent on CD4+ T cell help in 
the context of cytokines and co-stimulatory ligation towards antigen-specific B cells 
in the germinal centers formed in the secondary lymphoid tissue [4, 19-23]. The 
CD4+ T cell subset critical for germinal center formation and maintenance are the T 
follicular helper cells defined by increased expression of CXCR5, allowing for follicle 
localization, and PD-1 [4, 19, 24]. We employed low frequency adoptive transfer 
techniques to examine the Ova-specific CD4+ T cells of the Tfh phenotype 
(CXCR5high PD-1high) at an early time point post-immunization of polyanhydride 
nanoparticle vaccines. All polyanhydride nanoparticles induced a shift towards Tfh 
lineage commitment compared to soluble antigen alone both in a percentage of 
gated donor CD4+ T cells as well as total Tfh cell numbers (Figure 4). Alum 
adjuvanted vaccines, although demonstrating robust T cell expansion in the high 
frequency transfer model (Figure 1), show little difference from soluble antigen 
groups in terms of CD4+ T cell expansion, as well as Tfh commitment (Figure 4), 
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most likely due to the differences in naïve precursor frequency between the two 
models.   
 T follicular helper cell differentiation is largely dependent on cytokine 
influence and prolonged antigen presentation by APCs. Disruption in type I IFNs, IL-
6, and IL-12 leads to impaired Tfh cell generation as well as impaired humoral 
immune responses [20, 21, 25-27]. Prolonged antigen presentation either by 
continuous dendritic cell presentation in cases of abundant antigen or by B cells in 
the T-B border of the germinal center in cases of sparse antigen drive the 
differentiation of Tfh [22, 24]. Interesting hypotheses emerge when relating the 
controlled release antigen kinetics of the polyanhydride nanoparticles and how that 
controlled release of antigen may be allowing for continuous DC presentation or by 
providing a continuous antigen immune complex directly ligating B cells in the 
follicle. The latter hypothesis may also answer why the humoral phenotype of 
polyanhydride nanoparticle vaccines show a dominant antigen specific IgG1 isotype 
with lesser amounts of IgG2c (Figure 5) indicating greater amounts of IL-4 than IFN-
γ [28]. Tfh cells produce abundant amounts of IL-4 again reinforcing the Tfh lineage 
commitment of CD4+ T helper cells by polyanhydride nanoparticle vaccines [23].  
These antigen specific CD4+ Tfh cells are present in the secondary lymphoid tissue 
in greater amounts at 45 DPI in those mice receiving nanoparticle regimens 
translating to greater and more sustained activated (CD23high) B cells that are PNA+ 
(Figure 6). These sustained T cell and B cell GC interactions translate to stronger 
IgG1 antibody populations post-primary immunization (Figure 5 and 6C) as 
compared to equivalent protein unadjuvanted. The antibody avidity of the 
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polyanhydride nanoparticle vaccines was greater at 45 DPI, indicating stronger and 
longer GC kinetics and a better quality of antibody generated from polyanhydride 
nanoparticle vaccines.  
 
5. Conclusions  
The work presented herein outlines the CD4+ T cell responses that are 
modulated by the polyanhydride nanoparticle platform leading to the long-lived IgG1 
antibody titers characteristic of the polyanhydride platform.  These mechanistic 
understandings of the platform will translate to improved vaccine design when 
utilizing the polyanhydride nanoparticle platform for vaccines against viral and 
bacterial pathogens.    
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Abstract 
Influenza virus infections remain one of the most common and costly illnesses 
throughout the world. Because of the high mutation rates and possibilities for co-
infections with different strains of influenza virus leading to genetic reassortment, 
global pandemics of influenza infection are an alarming possibility. One potential 
influenza strain that could lead to global pandemics, due to the human naivety to the 
virus, is H5N1. Therefore, development of efficacious vaccines designed against 
H5N1 which are safe and induce protective immunity are of incredible import. Bio-
erodible polyanhydride nanoparticles provide a particulate structural context for 
delivery of encapsulated subunit immunogens as well as innate immunomodulatory 
activities in vivo. Herein, we characterize H5-specific humoral and cellular immune 
responses induced following vaccination with polyanhydride nanoparticles based 
vaccines. Immunizations consisted of combinations of soluble and encapsulated 
recombinant trimeric H5 (influenza A/Whooper Swan/Mongolia/244/05) protein and 
encapsulated synthetic innate immunostimulatory ligands to activate the 
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inflammasome pathway (poly dA:dT) or TLR 3 (Poly I:C). The results of these 
studies show that vaccines utilizing encapsulated H5-Trimer with encapsulated Poly 
I:C generated viral neutralizing antibody titers as well as significant H5-specific CD4+ 
T cell recall responses when administered subcutaneously or intranasally.  
Collectively, these studies demonstrate the successful design of a polyanhydride-
based  anti-H5 nanoparticle vaccine with balanced humoral and cellular immune 
efficacy.   
 
1. Introduction 
 The 2009 H1N1 influenza pandemic demonstrated that a novel influenza virus 
can efficiently spread worldwide by unwittingly infected international travelers [1]. 
Less than a year after identification of the novel triple re-assortment (human, swine, 
and avian) H1N1 virus, it had spread to 215 countries and resulted in 18,000 
reported deaths [2]. Epidemiological studies following the pandemic reinforced the 
impact that efficacious preventive therapies, mainly immunization, have in controlling 
spread and severity of infections [3, 4]. The CDC estimates seasonal influenza 
infections leads to $10 billion in direct healthcare costs annually [5]. 
 Highly pathogenic avian influenza (HPAI) H5N1 has long been monitored 
because of its potential as a pandemic influenza strain to which humans are 
relatively immunologically naïve. HPAI H5N1 is an avian virus demonstrating 
hemagglutinin (HA) binding specificity to α 2-3 sialic acid receptors found in high 
density in the avian respiratory tract and very low density in the human respiratory 
tract (mostly α 2-6 sialic acid receptors present). The greater concern with HPAI is 
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the clinical severity of humans with confirmed infection. Hyper-cytokinemia as well 
as viral replication in tissue sites beyond the lung are attributes of the pathogenesis 
associated with human infection with H5N1 influenza [6-8].  
Although the immune-pathology of HPAI infected individuals is severe 
mammalian viral transfer does not occur. Currently, mammalian viral transfer has 
only been demonstrated in ferret models driving the adaptation of H5N1 virus [9, 10]. 
However, if sufficient pressure to push the virus to evolve towards mammalian viral 
transfer occurs, the pandemic potential of HPAI H5N1 dramatically increases. 
Therefore, great emphasis has been placed on the development and implementation 
of pre-pandemic therapeutic interventions against H5N1, in particular, safe and 
efficacious vaccines [11-21]. 
 Polyanhydrides based on copolymer combinations of aromatic 
polyanhydrides 1,6-bis(p-carboxyphenoxy) hexane (CPH), and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) are unique biomaterials that can 
provide a protein stablizing amphiphilic environment as well as provide for the 
controlled release of protein immunogens [22-25]. These materials can be tailored to 
generate particulate structures for optimizing uptake by innate phagocytic cells [26-
28]. The polyanhydride particles exhibit inherent immunomodulatory activity in vitro 
by activating antigen presenting cells (APCs) [27, 29] and in vivo by increasing 
monocyte chemotactic cytokine production (MCP-1 and IP-10) as well as by 
inducing mild inflammatory reactivity while minimizing tissue damage at the 
administration site (Chapter 4). Encapsulation of antigen into polyanhydride 
microparticles resulted in an enhanced  antibody titer when vaccinating with an 
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otherwise suboptimal dose of protein (Chapter 3) and increased the antibody titer 
and antibody avidity to tetanus toxoid [30]. The use of a single dose nanoparticle 
vaccine induced protective immunity from Yersinia pestis challenge after intranasal 
(IN) administration of soluble plus encapsulated F1-V antigen [31]. In addition, 
studies using the model antigen ovalbumin (Ova) and transgenic T cells specific for 
Ova (OTI and OTII) revealed the ability to significantly increase the numbers 
antigen-specific cytotoxic T cell (Chapter 4) as well as T follicular helper cells 
(Chapter 6) when mice were immunized with vaccine formulations containing 
antigen-loaded polyanhydride nanoparticles. 
 Herein, we outline the evaluation of nanoparticle vaccine regimen using a 
stabilized trimeric form of the recombinant H5 hemagglutinin from the A/Whooper 
Swan/Mongolia/244/05 strain of influenza virus (Wu et al., Appendix). The 
adaptability of the platform is demonstrated by the ability to increase CD4+ and CD8+ 
T cell memory populations in the draining lymph nodes by including pattern 
recognition receptor (PRR) ligands in the vaccine formulation. Viral neutralizing anti-
H5 antibody responses were elicited using single and multiple dose immunization 
strategies. These data indicate the effectiveness of the polyanhydride nanoparticle 
platform to enhance both antigen-specific cellular immune responses as well as elicit 
viral neutralizing antibody against a potentially pandemic strain of influenza virus.  
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2. Materials and Methods 
2.1 Synthesis and characterization of copolymers 
 CPH and CPTEG monomers were synthesized using the chemicals listed: 4-
p-hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, and tri-
ethylene glycol. All these chemicals and sebacic acid (99%) were purchased from 
Sigma Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile was obtained from Apollo 
Scientific (Cheshire, UK); potassium carbonate, dimethyl formamide, toluene, 
sulfuric acid, acetic acid, acetonitrile, acetic anhydride, methylene chloride, and 
petroleum ether were purchased from Fisher Scientific (Fairlawn, NJ). Synthesis of 
CPH and CPTEG diacids was performed as previously described [24, 32]. 20:80 
CPTEG:CPH was synthesized using a melt polycondensation process as detailed by 
Kipper et al. and Torres et al., [24, 30] respectively. The degree of polymerization, 
molecular weight, and polymer purity were determined using 1H nuclear magnetic 
resonance (NMR) spectroscopy (Varian VXR-300 MHz, Palo Alto, CA). 
2.2  Particle fabrication and characterization 
Antigen-loaded nanoparticles (4.0 % w/w) were fabricated using a modified  
anti-solvent nanoencapsulation method outlined in Ulery et al [28].  Particles 
functionalized with poly I:C or poly dA:dT (Invivogen San Diego, CA) were loaded at 
(1.0 % w/w). Briefly, H5-T was concentrated into 100 µL of nanopure water (20 
mg/mL) and homogenized for 90 seconds with the copolymer dissolved in methylene 
chloride at 4˚C. The copolymer solution was rapidly transferred into chilled pentane 
(-20 °C) at a non-solvent to solvent ratio of 250:1, and the suspension of 
nanoparticles was vacuum filtered to recover the nanoparticles. Shape and size of 
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the resulting nanoparticles were characterized using scanning electron microscopy 
(SEM) (FEI Quanta 250, FEI, Hillsboro, OR). The particle size distribution was 
obtained from SEM images using Image J version 1.44 image analysis software [33]. 
An average of 200 particles per image was analyzed.  
2.3  Mice and immunization procedures 
BALB/c mice were purchased from Harlan Sprague Dawley (Frederick, MD). 
All animal procedures were conducted with the approval of the Iowa State University 
Institutional Animal Care and Use Committee. To evaluate the serum antibody 
responses to H5-T induced by administration of polyanhydride nanoparticle vaccines 
and control vaccines adjuvanted with MPLA or unadjuvanted sH5-T diluted in 
pyrogen-free saline. H5-T is a recombinant protein of the full length H5 (A/Whooper 
Swan/Mongolia/244/05)  hemagluttinin (HA) minus the cytoplasmic tail. This 
construct was stabilized with an isoleucine zipper motif as described in Wu et al 
(Appendix). Prior to administration, nanoparticles were sonicated briefly to generate 
a uniform suspension. A total volume of 250 µL was administered at the 
subcutanous (SC) injection site (nape of the neck) and a total volume of 50 µL was 
administered intranasally (IN). Separate groups of mice (n=12, multiple 
immunizations n=6 and single immunizations n=6) were immunized as outlined in 
Table 1. Control animals received saline alone (n=8). Blood samples were collected 
from the left saphenous vein prior to immunization and at indicated time points 
thereafter. Serum was collected after centrifugation and stored at -20 °C until 
assayed for H5-T-specific antibody as described below.  At termination of the study, 
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bronchioalveolar lavage fluid (BAL) was collected via methods outlined in Chavez-
Santoscoy et al [34].  
2.4 Flow cytometric bead assay for antigen specific antibody 
Carboxylated xMAP magnetic beads (Luminex, Austin, TX) were conjugated 
with 10 µg of H5-T per 1.25 x 106 (037 fluorescent signature) beads according to 
manufacturer’s instructions.  Serum samples were diluted 1:200 in blocking-storeage 
buffer supplemented with Tween 20 (BST) (PBS with 1% bovine serum albumin, 
0.05% sodium azide, 0.05% Tween 20). BAL protein concentrations were 
normalized to 0.5 mg/mL with PBS supplemented with 0.05 % Tween 20 prior to 
assay and this was considered a “neat” concentration.  Diluted serum samples or 
neat BAL (50 µL) was then incubated for 1 h at RT with 6000 beads conjugated with 
H5-T per well.  Beads were washed with BST and incubated for 1 h at RT with 0.5 
µg/well of biotinylated anti-mouse IgG antibody or biotinylated anti-mouse IgA heavy 
chain (eBioscience, San Diego, CA) antibody diluted in BST. Beads were washed 
and incubated for 30 min at RT with 0.5 µg/mL of streptavidin-phycoerythrin 
(eBioscience). Beads were washed once more and then fluorescence was quantified 
using the Bio-Plex Pro 200 (Bio-Rad, Hercules, CA).  
2.5 Assaying for memory T and B cell proliferative populations 
Draining lymph nodes (e.g., brachial and axilary) from individual mice were 
harvested at 63 days post-immunization and homogenized into single cell 
suspensions. Single cell populations were labeled with 2.5 µM 5-(and-6)-
carboxyfluorescein diacetate, succinimidyl ester (5(6)-CFDA, SE) (CFSE) (Life 
Technologies, Grand Island, NY). Cells (2.5 x 105/well) were incubated for 96 h at 37 
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°C in 5 % CO2 in 96 well U-bottom plates along with 0.5 µg/well of H5-T . Cells were 
aspirated and lymphocyte proliferation was quantified using flow cytometry (BD 
FACScanto). Cell suspensions were blocked to prevent non-specific antibody 
binding using 0.1 mg/mL rat IgG (Sigma Aldrich, St. Louis, MO) and mouse anti-
CD16/32 (10 µg/mL , eBioscience, San Diego, CA).  Fluorescently conjugated 
antibodies for CD4 ((PE-Cy7, Clone GK1.5, eBioscience), CD8ß (APC, Clone 
eBioH35-17.2, eBioscience), and CD19 (PerCP Cy5.5, eBio H35-17.2, eBioscience), 
to delineate T cells and B cells, were used to stain in FACS buffer, gate, and 
quantify specific cell populations.  
2.6   Neutralizing antibody quantification using pseudovirus 
Influenza H5-pseudotyped retroviral vectors carrying a luciferase (Luc) 
reporter gene were produced in 293T cells by co-transfecting 5 µg of pEV-53B and 
5.5 µg of plgSIN6.1Luc with 1 µg of HA expression plasmid DNA containing the H5 
gene from H5N1 influenza strains A/Vietnam/1203/2004 (clade1) or A/Whooper 
Swan/244/Mongolia/ 05 (clade 2.2). At 18h post-transfection, cells were fed with 
fresh medium containing 7 mU/ml of bacterial nucleic acid (Vibrio cholera Type II, 
Sigma, St. Louis, MO) and 1M NaB to induce the release of H5-pseudovirions (H5-
VietnamLuc and H5-WhooperLuc).Supernatants were collected 48 h post-
transfection, clarified by centrifugation at 3000 rpm for 10 min, and the viral stocks 
were then stored frozen at −80oC.  
 Sera samples were heat inactivated at 56oC  for 30 min, serially diluted 
threefold in culture medium containing 16 µg/ml of polybrene (Sigma, St. Louis, MO), 
and mixed with an equal volume of diluted pseudoviruses containing 5 × 104 relative 
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light units (RLU)/mL. After incubation at 37°C for 1h, virus and serum mixtures were 
added into 96-well plates containing 2 x 104 293T cells per well. Infectivity was 
evaluated 48 h after infection using One-Glo Luciferase assay system (Promega, 
Fitchburg, WI).   
2.7  Statistical analysis 
Longitudinal data were analyzed using repeated measure analysis of variance 
(ANOVA) models (with Graphpad Prism 5.0). Treatment and time were fixed effects 
in the statistical model, whereas mouse was the subject of repeated measures. 
Cross-sectional data were analyzed using one-way ANOVA models with treatment 
as the explanatory variable. Differences in mean responses among treatments were 
compared by using Tukey’s T-test. Log10 transformation was applied to responses 
with skewed distributions before analyses. Statistical tests with p ≤ 0.05 were 
regarded as significant. 
 
3.  Results  
3.1 Neutralizing antibody responses are elicited following single dose and 
prime/boost immunization regimens administered subcutaneously.  
Using polyanhydride nanoparticles encapsulating either poly dA:dT or poly 
I:C, three formulations of an H5N1 influenza subunit vaccine were fabricated using a 
stable trimer of recombinant H5 HA. The nanoparticles were loaded with the H5-T at 
0.4 % (w/w) The immunization regimens (Table 1) were designed based on the 
protection results elicited by a ratio combination soluble antigen and encapsulated 
regimen demonstrated in a Yersinia pestis challenge model [31]. Additional particles 
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encapsulating poly I:C and poly dA:dT were included to evaluate the benefits 
associated with increased innate signaling relative to enhancing the induction of 
neutralizing serum antibody response with a single primary immunization as 
compared to the multiple dose regimens (primary dose day 0, second immunization 
day 21, third immunization day 42). As a positive control, mice were immunized with 
10 µg H5-T adjuvanted with MPLA given as a single dose or administered as a 
multiple dose regimen consistent with previously published reports [35] .   
Table 1. H5N1 polyanhydride and control vaccine formulations. 
Group Abbreviation 
Total 20:80 
CPTEG:CPH 
Nanoparticles 
(µg) 
Soluble 
antigen 
dose 
(H5-T in 
µg) 
Encapsulate
d antigen 
dose (H5-T) 
PRR 
Ligand 
PRR 
Ligand 
Dose 
(µg) 
Soluble H5-T + H5-T 
encapsulated in 20:80 
CPTEG:CPH + 250 µg 
unloaded 20:80 
CPTEG:CPH 
20:80 C:C 300 8.0 2.0 ----------- ----------- 
Soluble H5-T + H5-T 
encapsulated in 20:80 
CPTEG:CPH + 250 µg 
1% Poly I:C loaded 20:80 
CPTEG:CPH 
20:80 C:C 
Poly I:C 300 8.0 2.0 Poly I:C 2.5 
Soluble H5-T + H5-T 
encapsulated in 20:80 
CPTEG:CPH + 250 µg 
1% Poly dA:dT loaded 
20:80 CPTEG:CPH 
20:80 C:C 
Poly dA:dT 300 8.0 2.0 
Poly 
dA:dT 2.5 
Soluble H5-T + MPLA MPLA ----------- 10 ----------- MPLA 10 
Soluble H5-T sH5-T ----------- 10 ----------- ----------- ----------- 
PBS PBS ----------- ----------- ----------- ----------- ----------- 
    
Following a single immunization, the 20:80 CPTEG:CPH polyanhydride 
nanoparticle platform alone significantly enhanced the induction of H5-specific 
Table 1.  
Table describes the details of the immunization regimens designed using 
the polyanhydride nanoparticle platform and control immunzations MPLA, 
sH5-T, and PBS.  
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antibody at 42 DPI (Figure 1A) when compared to the response induced by  soluble 
H5-T alone (sH5-T). Inclusion of poly I:C encapsulated particles in the vaccine 
regimen also enhanced antibody to near equivalent levels to those induced in mice 
immuniced with H5-T adjuvanted with MPLA. At day 63 post-primary immunization 
the same trends in antibody responses were observed as compared to the day 42 
data (Figure 1C). Multiple dose immunization regimens provided strong serum 
antibody responses throughout all groups at 42 days post-immunization (Figure 1B) 
with little statistical differences between groups other than MPLA providing the best 
response. The same results were observed at 63 DPI with no statistical differences 
between immunization groups other than statisical differences above the sham 
(PBS) vaccine (Figure 1D). 
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Figure 1. Subunit anti-H5 influenza vaccines show strong antibody 
responses in multiple dose regimens. H5-T specific antibody 
quantified using Luminex based system expressed in mean fluorescence 
intensity of bead at day 42 post subcutaneous immunization (A-B) and 
day 63 (C-D). Serum was diluted 1:200 in PBS-T prior to assay. Mice 
were immunized with immunization regimens described in table 1: 20:80 
CPTEG:CPH, 20:80 CPTEG:CPH Poly I:C, 20:80 CPTEG:CPH Poly 
dA:dT, MPLA, sH5-T, and PBS. Six mice per group were immunized with 
a single dose and followed for antigen specific antibody responses at 42 
days post-immunization (A) and 63 DPI (B). Six mice per group were 
immunized with multiple immunizations at day 0, 21, and 42 DPI and 
followed for antigen specific antibody responses at 42 DPI (C) and 63 
DPI (D). Values were log transformed for statistical analysis. Different 
letters above each set of data points indicates statistical difference from 
groups at a P value < 0.05 value obtained via one-way ANOVA with 
Tukey’s post-test. Results are from a single experiment. 
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 Viral neutralizing titers were assayed via pseudovirus expression system 
using homologous HA. The multiple dose immunizations show generally higher 
antibody responses in magnitude and neutralizing antibody titers at day 42 than 
were induced by the single dose regimen (Figure 2A-B). Little neutralizing antibody 
titers were elicited from any single dose immunization regimen other than MPLA at 
day 42 and day 63 (Figure 2A and C). By day 63 after multiple immunizations, all 
groups have effectively mounted robust neutralizing antibody titer (Figure 2D).  
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Figure 2. Subunit anti-H5 influenza vaccines show strong 
neutralizing antibody responses in multiple dose regimens. H5-T 
specific neutralizing antibody responses were evaluated using a H5 HA 
pseudotyped reporter virus and results reported as the inverse serum 
dilution that neutralized 50% of virus infectivity (ID50). Mice were 
immunized with immunization regimens described in table 1: 20:80 
CPTEG:CPH, 20:80 CPTEG:CPH Poly I:C, 20:80 CPTEG:CPH Poly 
dA:dT, MPLA, sH5-T, and PBS. Six mice per group were immunized with 
a single dose and followed for antigen specific antibody responses at 42 
days post-immunization (A) and 63 DPI (B). Six mice per group were 
immunized with multiple immunizations at day 0, 21, and 42 DPI and 
followed for antigen specific antibody responses at 42 DPI (C) and 63 
DPI (D). Values were log transformed for statistical analysis. Different 
letters above each set of data points indicates statistical difference from 
groups at a P value < 0.05 value obtained via one-way ANOVA with 
Tukey’s post-test. Results are from a single experiment. 
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3.2 CD4+ T cell memory is enchanced by prime/boost immunization of anti-H5N1 
with Poly I:C encapsulated in polyanhydride nanoparticles 
On day 63, draining lymph nodes were extracted from the immunized mice, 
homogenized to a single cell suspension, labeled with CFSE, and incubated with 
H5-T antigen for 96 hours to measure antigen-specific proliferative responses 
indicative of memory populations. We identified that multiple immunizations induced 
more robust T cell memory responses, but more CD4+ T cells capable of 
proliferating to the cognate antigen were observed in the T cell populations 
recovered from H5-T immunized mice also treated with the 20:80 C:C poly I:C 
multidose polyanhydride vaccine (Figure 3A).  Similar antigen-specific proliferative 
responses were demonstrable when assessing CD8+ T cell recall responses in the 
20:80 C:C Poly I:C multidose group as well (Figure 3B).   
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Figure 3. Robust cellular memory responses are obtained by inclusion 
of encapsulated Poly I:C in anti-H5 influenza polyanhydride 
nanoparticle vaccines. Single cell suspensions of draining lymph nodes 
cells were CFSE labeled and incubated with H5-T antigen for 96 hours.  
Cells were then aspirated and labeled with anti-CD4, anti-CD8, and anti-
CD19 antibodies for FACS analysis.  Representative FACS histograms 
draining lymph node cells labeled with cell marker (CD4, CD8, or CD19) on 
y-axis and of CFSE on x-axis of mice immunized with single dose 
immunizations (A) or multiple dose immunizations (B). Histograms are mean 
results of CFSE low gated cell populations indicating proliferation of single 
immunized groups (open histogram) or multiple dose immunizations (black 
histograms).  Mean CFSE low populations of gated CD4+ T cells (A), CD8+ T 
cells (B) and CD19+ B cells (C). Different letters above indicates statistical 
difference between the treatment groups (n = 6) within the single dose (upper 
case letter) or multiple dose (lower case letters) treatment groups. Data was 
analyzed using a one-way ANOVA with Tukey’s post-test and significance 
was defined as P ≤ 0.05. Results are from a single experiment. 
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3.3 Single dose intranasal adjuvanted vaccine formulations show strong short-lived 
antibody responses  
After evaluating the immune responses following administration of the various 
H5 vaccine formulations by the subcutaneous route, the efficacy of these same 
vaccine formulations following intranasal (mucosal) administered was evaluated. 
Previously our group has demonstrated the ability to induce protective immunity 
against Yersinia pestis using an intranasal vaccine based on the polyanhydride 
nanoparticle platform [31]. It was hypothesized that the antibody responses of the 
H5 vaccine designed using the 20:80 CPTEG:CPH nanoparticles would be 
enhanced by immunizing via a mucosal route in comparison to a systemic route.  
The same vaccine regimen were employed as outlined in Table 1 with the 
only change being the route of administration. In the absence of poly I:C or poly 
dA:dT nanoparticles, a single administration of the H5 polyanhydride nanoparticle 
formualtion alone failed to induce a demonstrable anti-H5 specific antibody response 
(Figure 4A and C). All other single dose immunizations show strong antibody 
responses compared to sham vaccines in contrast to subcutaneous immunizations 
(Figure 1 and 2) which show little induction of antibody with single doses. For the 
single dose vaccine regimen used, the peak antibody responses occurred at 42 DPI 
with antibody magnitude waning at 63 DPI. While not optimal, the multiple dose 
regimen of the H5-loaded nanoparticles did induce measurable HA-specific antibody 
at 42 DPI and remained strong at 63 DPI (Figure 4B and D). Little differences in 
magnitude of the antibody responses were elicited by adjuvanted and non-
adjuvanted vaccines other than the 20:80 CPTEG:CPH group showing lower 
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antibody responses either in single doses (Figure 4A and C) or multiple doses 
(Figure 4B and D).  
  
Figure 4. Single dose intranasal immunizations induce strong 
short lived antibody responses. H5 specific antibody quantified using 
Luminex based system expressed in mean fluorescence intensity of 
bead at day 42 post intranasal immunization (A-B) and day 63 (C-D). 
Serum was diluted 1:200 in PBS-T prior to assay. Mice were 
immunized with immunization regimens described in table 1: 20:80 
CPTEG:CPH, 20:80 CPTEG:CPH Poly I:C, 20:80 CPTEG:CPH Poly 
dA:dT, MPLA, sH5-T, and PBS. Six mice per group were immunized 
with a single dose and followed for antigen specific antibody responses 
at 42 days post-immunization (A) and 63 DPI (B). Six mice per group 
were immunized with multiple immunizations at day 0, 21, and 42 DPI 
and followed for antigen specific antibody responses at 42 DPI (C) and 
63 DPI (D). Values were log transformed for statistical analysis. 
Different letters above each set of data points indicates statistical 
difference from groups at a P value < 0.05 value obtained via one-way 
ANOVA with Tukey’s post-test. Results are from a single experiment. 
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 H5-specific cellular immune responses were evaluated using lymphocytes 
recovered from the cervical and mediastinal lymph nodes following intranasal 
immunization.  Contrary to the results observed following SC immunization  (Figure 
2), there was little evidence of enhanced T cell memory was identified (Figure 5A-B). 
H5-T-specific proliferation of B cells was demonstrated in lymphocytes recovered 
from mice immunized with MPLA plus H5-T and sH5-T alone.   
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Figure 5. Intranasal H5 polyanhydride nanoparticle formulations elicit 
little cellular memory in cervical and mediastinal lymph nodes. Single cell 
suspensions of draining lymph nodes cells were CFSE labeled and incubated 
with H5-T antigen for 96 hours.  Cells were then aspirated and labeled with 
anti-CD4, anti-CD8, and anti-CD19 antibodies for FACS analysis. 
Representative FACS histograms draining lymph node cells labeled with cell 
marker (CD4, CD8, or CD19) on y-axis and of CFSE on x-axis of mice 
immunized with single dose immunizations (A) or multiple dose immunizations 
(B). Histograms are mean results of CFSE low gated cell populations 
indicating proliferation of single immunized groups (open histogram) or 
multiple dose immunizations (black histograms).  Mean CFSE low populations 
of gated CD4+ T cells (A), CD8+ T cells (B) and CD19+ B cells (C). Different 
letters above indicates statistical difference between the treatment groups (n = 
6) within the single dose (upper case letter) or multiple dose (lower case 
letters) treatment groups. Data was analyzed using a one-way ANOVA with 
Tukey’s post-test and significance was defined as P ≤ 0.05. Results are from 
a single experiment.  
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3.4 Multiple dose vaccine regimens elicit mucosal IgA in bronchioalveolar 
lavage fluids Bronchioalveolar lavage (BAL) fluids were evaluated for the presence 
of antigen-specific IgA. Single dose regimens elicit no demonstrable H5-T-specific 
antibody in BAL at 63 DPI (Figure 6A).  Multiple dose IgA magnitude correlated with 
systemic antibody magnitude from Figure 3 (Figure 6B).  
 
 
 
Figure 6. Multiple dose vaccine regimens elicit significant 
levels of mucosal IgA in bronchioalveolar lavage fluids. 
H5-T specific antibody quantified using Luminex based system 
expressed in mean fluorescence intensity of bead at day 63 
post single intranasal immunization (A) and multiple dose 
regimens (B). BAL protein concentrations were normalized to 
0.1 mg/mL using PBS prior to sample evaluation. Values were 
log transformed prior to statistical analysis. Data was analyzed 
using a one-way ANOVA with Tukey’s post-test and 
significance was defined as P ≤ 0.05. Results are from a single 
experiment. 
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4. Discussion 
The need for novel vaccine formulations that increase purity and safety 
requirements while simultaneosly maintaining or increasing immune efficacy is 
paramount for next generation vaccine design. The polyanhydride nanoparticle 
platform combines favorable and unique attributes of adjuvanticity, materials based 
engineering, and vaccinological design of subunit vaccines. The polyanhydride 
chemistries used in these studies are readily producible from inexpensive “off the 
shelf” materials [36]. These polyanhydride biomaterials create a protein favorable 
environment that maintains immunogenicity of encapsulated protein (subunit) 
antigens and provides controlled release of those antigens [24, 25, 37-42]. 
Fabrication techniques of these materials can be altered to create particulate 
structures that mimic pathogen size crucial for providing a particulate antigenic 
structure needed for phagocytic antigen presenting cells or bystander cells to take 
up particles and initiate antigen presentation [27-29, 43]. In vivo profiles of three 
formulations of polyanhydrides indicate differential inflammation between 
chemistries with CPTEG:CPH. CPTEG:CPH containing chemistries are more 
inflammatory as well as being able to elicit more monocyte chemokine activity 
(Chapter 4 and 5) [44].  
Nanoparticles consisting of 20:80 CPTEG:CPH copolymers, which exhibit the 
slowest in vitro and in vivo degradation kinetics, also elicit inflammatory cytokine 
secretion in vivo (Chapter 4 and 5). Polyanhydride nanoparticle designed vaccines 
based on the 20:80 CPTEG:CPH chemistry including the viral PAMP poly I:C were 
able to elicit neutralizing antibody responses with single doses (Figure 1); however, 
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these responses were not statistically different from those induced when mice were 
subcutaneously immunized with H5-T adjuvanted with MPLA. We also examined 
multiple dose immunization strategies to further expand the cellular and humoral 
immune responses elicited by the nanoparticle vaccines as the literature and clinical 
trial data indicate that this regimen is necessary due to the relatively immunologically 
naivety of the population to the H5 influenza hemagglutinin [7, 8, 45, 46]. The HA 
immunogen when administered subcutaneously was a weak immunogen and 
multiple dose regimens were needed to elicit strong neutralizing antibody (Figure 2). 
The nanoparticle platform release kinetics and immunomodulatory effects were not 
able to overcome this deficit in single doses. Increased dosages of immunogen and 
particles should be evaluated. When employing the prime/boost/boost strategy, 
neutralizing antibody responses were strong throughout all immunized groups 
(Figure 1 and 2). The best neutralizing antibody responses at 42 DPI (prime/boost) 
were generated from the 20:80 CPTEG:CPH Poly I:C group and MPLA (Figure 2). At 
63 DPI (prime/boost/boost) no difference in antibody and neutralizing antibody 
between groups was identified. 
The greatest changes in adaptive immune responses occurred when 
examining the T cell recall responses to antigen in the polyanhydride nanoparticle 
subcutaneous immunization groups that included poly I:C.  Statistically significant 
increases in CD4+ T cell recall responses were observed (Figure 3) as well as 
significant increases in CD8+ T cell recall responses demonstrating stronger T cell 
memory populations being elicited from the 20:80 CPTEG:CPH Poly I:C vaccine 
formulation. The other subcutaneous immunization regimens also show strong CD4+ 
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T cell proliferation so the differences may be slight. Therefore, the benefits of 
encapsulation of antigen in the polyanhydride platform had more effects on cellular 
immunity while eliciting strong neutralizing antibody responses when administered 
subcutaneously.   
When evaluating the response profile induced by these polyanhydride 
vaccines given via a mucosal route (intranasal) the advantages of adjuvanting the 
protein either with the polyanhydride nanoparticle formulations or with MPLA 
seemed to have been lost.  Interestingly, the 20:80 CPTEG:CPH formulations 
induced the poorest response especially when compared to soluble H5-T antigen 
alone. This observation could be the result of high levels of IL-10 elicited by the 
20:80 CPTEG:CPH nanoparticles (Chapter 4) and introducing this immune 
modulation into the lung which is already a highly regulated environment may have 
resulted in little adaptive immune responses being elicited.  The inclusion of PAMPs 
in the polyanhydride nanoparticle regimens overcame the regulatory effect. The 
beneficial attributes of enhanced cellular immunity from adjuvanting with 
polyanhydride nanoparticles appears to be dependent on parenteral routes of 
immunization (Chapter 4, Figure 3 and 6).   
The practical design of subunit influenza vaccines using the polyanhydride 
platform shown herein demonstrates the malleability of the platform to be adapted to 
increase immune responses. The H5 influenza vaccines designed for this study 
showed little differences from adjuvanted vaccines and un-adjuvanted vaccines 
(sH5-T) though. Encapsulating the antigen into polyanhydride nanoparticles did not 
lead to detrimental effects as compared to soluble antigen.  Alum adjuvanted H5-T 
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vaccines induced lower antibody responses compared to soluble antigen (Wu et al 
Appendix). Follow up studies examining dose titrations of antigen and adjuvants 
need to be performed to truly examine if variable immune responses can be elicited 
using the nanoparticle platform. Future work should focus on examining efficacy of 
these designed vaccines within influenza challenge models to truly examine the 
protective effect of the balanced humoral and cellular responses identified here. 
Boosting efficacy of influenza vaccines by using inexpensive novel biocompatible 
technologies can have profound epidemiological effects in controlling pandemic 
influenza outbreaks worldwide.  The platform examined here benefits from being 
openly accessible to any recombinant antigen or other synthetic patterns needed for 
optimizing the immune response output. The studies presented herein provide a 
base evaluation of influenza vaccines designed using the polyanhydride platform 
even though little differences between designed vaccines were observed. Past work 
has shown the platform to enhance protein stability, further studies need to examine 
the glycosylated hemagglutinin protein particle interactions to better understand the 
platform’s capabilities to improve vaccine design. 
 
5. Conclusions:  
Influenza vaccines designed using the polyanhydride nanoparticle platform 
were able to elicit viral neutralizing antibody titers and cellular immunity in multiple 
dose immunization regimens given subcutaneously. No strong differences from un-
adjuvanted protein were identified however. Single dose intranasal immunizations 
show stronger responses as compared to subcutaneous regimens however the 
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antibody response waned at later time points. Further evaluation of dosages of these 
designed vaccines are warranted in conjunction with influenza challenge models.   
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CHAPTER 8: CONCLUSIONS 
 
Lucas Huntimer 
Conclusions: 
 The polyanhydride particle vaccine platform displays characteristics 
associated with efficacious adjuvanted vaccines.  The particle platform provides a 
particulate context facilitating phagocytosis by antigen presenting cells (APCs) [1-­‐4]. 
The encapsulation of protein in the polyanhydride materials results in a profile that 
can be tuned using chemistry to increase or decrease rate of protein release [5-­‐11]. 
Polyanhydride materials possess abilities to non-specifically activate APCs leading 
to inflammatory cytokine secretion and costimulatory receptor upregulation [1-­‐4, 11-­‐14].   Those innate activating abilities could theoretically be attributed to repetitive 
structures of the copolymer materials used to fabricate the materials [15]. The 
platform also exhibits depot effects after parenteral administration in vivo allowing for 
extended persistence (Chapter 4). 
 Those requisites of vaccine design have evolved in parallel with biomaterials 
applicability for vaccine delivery options.  Refinement in fabrication techniques have 
allowed for fabrication of particles of various sizes and diameters ranging from 
micrometers to nanometers (Chapter 3 and 4).  Unless specifically prepared, these 
particle preparations are generally polydispersed populations relative to particle 
diameters. Monodisperse particles may provide a tighter phagocytosis target for 
APCs. Monodisperse populations will allow for greater insight into the in vivo 
intracellular and extracellular dynamics. Ongoing efforts in the laboratory to refine 
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monodisperse fabrication processes and study these particles in the context of 
intranasal delivery are ongoing. Efficacy studies comparing monodisperse versus 
polydisperse particle preparations are needed to determine if polydisperse sizes 
contribute to increased cellular and humoral immune responses or if monodisperse 
size populations do. Specifically testing the hypothesis of different sizes and 
chemistries affecting uptake allowing for generation of cellular immunity (Chapter 5) 
compared to chemistries with less uptake (50:50 CPTEG:CPH) leading to greater 
humoral immunity to do ability to persist in extracellular environments and ligate 
surface receptors in the lymph node (Chapter 6). 
 The aspect of repetitive structure between polydispersed and monodispersed 
particle preparations also needs to be examined. As of yet, all repetitive structure 
aspects associated with the particles have been theoretical.  Dependent on molar 
combinations, that the copolymer combinations of CPH, SA, and CPTEG would 
create a particle of repetitive structure. Combined with that principle is the aspect of 
antigen encapsulation and surface modifications creating a repetitive structure that 
may lead to increased receptor ligation thus translating to phagocytosis by APCs or 
activation of B cells via crosslinking of surface B cell receptors. Additionally, 
scanning electron microscopy of degrading particles and visualizing the surface is 
needed 
 Design of vaccines incorporating the encapsulation of subunit (I.e., 
recombinant) immunogens in polyanhydride nanpoparticles needs to be refined. 
Early studies examining the immune response of vaccines with the total amount of 
antigen encapsulated into the nanoparticles revealed that the onset and peak titer of 
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the resultant antibody response was delayed [16, 17].  For studies involving design 
of an efficacious vaccine against Yersinia pestis, the most efficacious vaccines were 
combination vaccines of soluble antigen plus encapsulated antigen at a ratio of 4:1, 
respectively This ratio dictated design of the vaccines in this thesis.  When designing 
vaccines, the pathogenesis of the target pathogen and the antigen should be the first 
factors in dictating dosages. Host factors such as age, health, and population 
susceptibility also need to be considered. The inclusion of encapsulated portions of 
the antigen dose and how encapsulation may reduce dosages after that needs to be 
examined both in model antigens and pathogen antigens. In turn, exact antigen 
availability in vivo must be identified using sensitive protein labeling techniques.  The 
studies outlined in Chapter 4 demonstrate the presence of particles in vivo and how 
the different chemistries influence degradation in vivo. This does not account for 
antigen encapsulated in the particles, however.       
 Enhancement of immune responses from nanoparticle vaccines is most likely 
due to multiple attributes of the particles.  While encapsulation of the antigen will 
alter the kinetics of the interaction between the host and the antigen and persistence 
in vivo, the particles also possess innate immunomodulatory activity associated with 
activation of dendritic cells and macrophages (Chapter 5 and [1-­‐3, 13, 14, 18]). The 
contribution of the immunomodulation of the innate immune system and how this 
influences cellular and humoral immune responses should be characterized with 
experiments involving multiple doses of particles in a fixed antigen regimen.  These 
experiments can also involve examining gene changes at the sites of administration 
using multiple gene arrays to correlate with the in vitro gene changes in 
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macrophages presented in Chapter 5. Specifically the innate immune receptor 
interactions that are upregulated (TLRs) and STAT1 signaling that may contribute to 
understanding of how innate immune cells interact with particles in vivo.  
 Particulate antigen delivery and how the particles are trafficked to draining 
lymph nodes also warrant examination as improving or dictating trafficking can be a 
mechanism of improving immune responses to polyanhydride particle 
immunizations. Preliminary microscopy studies attempting to stain for antigen in the 
lymph nodes at different time points early after immunization provided insight into 
particle localization within the structure of the lymph node but those experiments 
need refinement although staining for donor congenic receptors verified the antigen 
specific T cell expansion identified by FACS (Chapter 5 and 6) and thus allowing for 
localization in the context of overall structure in the lymph node. Also having built 
genetic reporter populations of mice (Chapter 5) and using those animals to examine 
localization of T cells to particles in vivo using multi-photon microscopy or confocal 
microscopy will provide answers to hypothesis posed involving particle and antigen 
availability allowing test hypothesis regarding antigen persistence being increased in 
the lymph nodes by polyanhydride particles, interactions of APCs to the particles in 
the lymph nodes, and further expansion of antigen specific populations following 
polyanhydride particle immunizations in secondary lymphoid organs.   
 In summation, the data presented within this dissertation describes the 
adaptive immune responses, cellular and humoral, elicited by vaccines designed 
using the polyanhydride particle platform as the delivery system.  Using those 
principles, we designed H5 influenza nanoparticle-based vaccines containing the 
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recombinant H5 hemagglutinin from the influenza virus (H5 A/Whooper 
Swan/244/Mongolia/05 and characterized the resultant immune responses induced 
by these vaccine regimen. Humoral responses were strong throughout all groups 
including unadjuvanted antigen vaccines suggesting the polyanhydride particles 
show the ability to elicit humoral immunity while simultaneously increasing cellular 
immunity following parenteral administration with a TLR receptor agonist (Chapter 
7). Finally, challenge studies involving influenza virus expressing heterologous and 
homologous hemagglutinin sequences are warranted to fully examine the protection 
elicited from the polyanhydride nanoparticle vaccines. The studies here and future 
studies will build the portfolio needed for this platform to be used in translational 
medicine.   
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APPENDIX 
Harvesting Alveolar Macrophages and Evaluating Cellular 
Activation Induced by Polyanhydride Nanoparticles  
Ana V. Chavez-Santoscoy, Lucas M. Huntimer, Amanda E. Ramer-Tait, Michael 
Wannemuehler, and Balaji Narasimhan 
Published in the Journal of Visualized Experiments 
Abstract: 
Technological aspects of vaccine design are undergoing a revolution.  New 
information regarding the molecular and cellular processes of innate immune cells is 
providing important insight as to how immune responses towards pathogens are 
generated.  In order to elucidate the mechanisms regulating the activation of innate 
immunity following intranasal mucosal vaccination, one must evaluate alveolar 
macrophage responses.  These cells are a critical antigen presenting cell type in the 
lung [1].  Alveolar macrophages are frontline innate defenders of the pulmonary 
mucosa and are highly efficient in clearing the lungs of microbial pathogens and cell 
debris[2, 3].  In addition, alveolar macrophages transport microbial antigens to the 
draining lymph nodes, which is an important first step in the initiation of an adaptive 
immune response[4]. 
In this context, biodegradable nanoparticles have emerged as a versatile platform for 
the design and implementation of new intranasal vaccines against respiratory 
infectious diseases. Specifically, polyanhydride nanoparticles composed of the 
aliphatic sebacic acid (SA), the aromatic 1,6-bis(p-carboxyphenoxy)hexane (CPH), 
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or the amphiphilic 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) display 
unique bulk and surface erosion kinetics [5, 6].  These particles can be exploited to 
slowly release functional biomolecules (e.g., protein antigens, immunoglobulins) in 
vivo [7-9].  Alveolar macrophages are highly phagocytic, have increased amounts of 
innate pattern recognition and scavenger receptors, and secrete pro-inflammatory 
mediators when engaged[2, 10].  The population of alveolar macrophages is greater 
than 80% of the total cells obtained by lung lavage.  Resident alveolar macrophages 
harvested from immune competent animals provide a representative macrophage 
phenotype of the cells that will encounter the particle-based vaccine in vivo.  Herein, 
we describe the protocols used to harvest and culture alveolar macrophages from 
mice and examine the phenotype of the macrophages after treatment with 
polyanhydride nanoparticles in vitro with the purpose of evaluating the cellular 
activation of these cells.  
 
 
 
Figure 2. Flow cytometric analysis of harvested alveolar macrophages labeled 
with (A) Alexa Fluor 700 anti-CD11b and the PE-Cy7 FMO Control, (B) Alexa 
Fluor 700  FMO Control and the PE-Cy7 anti-F4/80 and (C) Alexa Fluor 700  anti-
CD11b and PE-Cy7 anti-F4/80.  The number in the top right corner represents the 
percentage of double-positive cells. 
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Combinatorial Evaluation of In Vivo Distribution of Polyanhydride 
Particle-based Platforms for Vaccine Delivery 
Latrisha K. Petersen, Lucas Huntimer, Katharine Walz, Amanda Ramer-Tait, 
Michael J. Wannemuehler, and Balaji Narasimhan 
Submitted to Nanomedicine 
Abstract 
Several challenges are associated with current vaccine strategies, including 
repeated immunizations, poor patient compliance, and limited approved routes for 
delivery, which may hinder induction of protective immunity. Thus, there is a need for 
new vaccine adjuvants capable of multi-route administration and prolonged antigen 
release at the site of administration by providing a depot within tissue. In this work, 
we designed a combinatorial platform to investigate the in vivo distribution, depot 
effect, and localized persistence of polyanhydride nanoparticles as a function of 
nanoparticle chemistry and administration route. Our observations indicated that the 
route of administration differentially affected tissue residence times. All nanoparticles 
rapidly dispersed when delivered intranasally but provided a depot when 
administered parenterally. When amphiphilic and hydrophobic nanoparticles were 
administered intranasally, they persisted within lung tissue. These results provide 
insights into the chemistry- and route-dependent distribution and tissue-specific 
association of polyanhydride nanoparticle-based vaccine adjuvants. 
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Figure 5. Chemistry played an important role in nanoparticle distribution 
throughout the body.  ROI analysis is depicted in Figure 4 for (A) nasal passage, 
(B) neck, (C) chest, and (D) abdomen. The 20:80 CPH:SA nanoparticles show 
significantly greater fluorescence in the lower abdomen at initial time points (3 h). 
MFI values for all treatment groups were normalized to the saline control (saline 
normalized MFI = 1). Letters indicate statistical significance between each 
treatment group and asterisks indicate statistical significance (p-value < 0.05) 
from the saline control, n = 3 for all groups. 
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Impact of antibiotics on the susceptibility to inflammatory insults: 
lessons from defined and conventional microbiota mice 
Anne-Marie C. Overstreet, Amanda E. Ramer-Tait, Jesse Hostetter, Chong Wang, 
Lucas M. Huntimer, Michael J. Wannemuehler	  
 
Abstract 
 The gastrointestinal tract harbors bacteria on which the body depends on for 
a variety of functions such as vitamin production and energy storage. This 
community is susceptible to changes from environmental factors such as antibiotics. 
The effect of the antibiotic on the microbial community lasts longer than the duration 
of treatment and in some cases the community may never fully re-establish itself. 
When the community deviates from normal it becomes dysbiotic, which may lead to 
the development of diseases such as inflammatory bowel disease. We report here 
the study of two intestinal microbial communities to identify differences in disease 
severity in response to a DSS-induced model of murine colitis. ASF and CONV mice 
were given 4 mg/mL of ampicillin for nine days. Mice were then colonized with 
Helicobacter bilis for two weeks. Then either a 1.5 % (ASF) or 2.5 % (CONV) 
dextran sulfate sodium solution was added to their drinking water for five days 
followed by a 4 day restitution period. The results of this study revealed major 
differences in the inflammatory response after the induction of colitis. The 
administration of ampicillin caused the ASF mice to gain significantly less weight 
during the study compared to their CONV counterparts. Macropscopic and 
microscopic lesions within the two communities showed no change in score when 
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comparing ampicillin H. bilis DSS (AhbD) and H. bilis DSS (Hbd). Ampicillin 
administration modulated the microbiota of the ASF mice much more drastically 
compared to the CONV mice. In the ASF mice, 4 of the 8 species present in the 
community were significantly reduced at the end of the study. ASF mice produced 
significantly higher levels of pro-inflammatory cytokines compared to the CONV mice 
and also produced significantly more antibody against members of the microbiota. 
CONV mice had an increased concentration of several diabetes biomarkers, 
something not seen in the ASF mice.  
 The results of this study reveal that the severity of the immune response to 
colitic insults is microbiota specific. Mice with a simplified microbiota had increased 
antibody responses to the microbiota and increased pro-inflammatory 
cytokine/chemokine production. CONV mice, which had only a minimal inflammatory 
response, had an increase in diabetic biomarkers indicating that these mice were 
entering into a metabolic syndrome-like state. 
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The effects of Prunella vulgaris and Hypericum gentianoides whole 
extract on DSS induced colitis in C3H/HeN mice   
Anne-Marie C. Overstreet, Amanda E. Ramer-Tait, Jesse Hostetter, Lucas M. 
Huntimer, Cathy Hauck, Pat Murphy, Michael J. Wannemuehler	  
 
Abstract 
The morbidity and expense of traditional inflammatory bowel disease (IBD) 
treatments have led patients to explore alternative therapeutic options. Over 50 % of 
IBD patients have used alternative or complementary prebiotic treatments. Botanical 
supplements represent a subset of alternative therapies of potential value for IBD 
patients. Additional research is needed to identify the potential biological activity and 
Figure 6. Both ASF and CONV mice have increased inflammation when given the 
colitic insult of H. bilis and DSS. Giving ampicillin preceding the inflammatory 
insult increases inflammation in the ASF mice only.This is revealed by increased 
fluorescence intensity present only in the cecum of the ASF mice given ampicillin, 
colonized with H.bilis and treated with DSS. 
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safety of these products. Ethanolic extracts of the botanicals Prunella vulgaris and 
Hypericum gentianoides possess anti-inflammatory and/or anti-microbial activities; 
however, limited information exists regarding its efficacy as a treatment for IBD. 
Using mice with a defined microbiota (the altered Schaedler flora or ASF), we have 
established a colitis model that mimics human IBD and enables us to elucidate the 
roles of both the host and its microbiota in the progression of disease and the 
response to nutraceutical treatment. Despite the purported anti-inflammatory effects 
of P. vulgaris and H. gentianoides, neither extract was able to significantly lessen 
disease severity. There was no significant difference in microscopic lesion scores 
between any of the treatment groups. Use of an inflammatory probe to measure 
inflammation in situ also revealed no significant difference between the groups, but 
there was a decrease in the fluorescence intensity in mice treated with H. 
gentianoides indicating the potential for an anti-inflammatory effect with that 
botanical. Increased production of the pro-inflammatory cytokines and chemokines, 
KC, IL-5, LIX, and RANTES in mice given P. vulgaris was not observed in the mice 
treated with H. gentianoides. Mice administered H. gentianoides did have a 
substantial modulation of their gastrointestinal microbial community as H. 
gentianoides treatment resulted in a significant decrease in four of the eight 
members of the ASF. P. vulgaris had no effect on the bacterial population. In 
summary, there was no significant amelioration of disease severity in this mouse 
model of colitis. The presented data do suggest, however, that there may be benefit 
to the use for H. gentianoides in the modulation of the gastrointestinal microbial 
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community. Further studies are warranted to determine the specific compounds 
associated with this anti-bacterial activity.  
 
 
 
 
Untitled project involving antibiotic delivery using the 
polyanhydride nanoparticle delivery platform 
 
 Antibiotics effective in combating Brucella infection were encapsulated into 
polyanhydride nanoparticles as well as a fluorescent marker to track tissue 
Figure 3. Mice treated with botanical have no difference in cecal inflammation 
compared to H. bilis DSS mice. A) Fold increase of mean fluorescence intensity of 
treatment compared to naïve control who received no treatment. B) Ex vivo 
images of representative ceca from the three treatment groups analyzed during 
the study. Data are expressed as mean + SEM. Dissimilar letters indicate p < 
0.05, while similar letter indicate no significant difference. 
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distribution in vivo.  At time of necropsy we utilized in vivo imaging of ex vivo tissues 
to quantify biodistribution of the particles given in therapeutic regimens in mice 
infected with Brucella.  
 
 
 
 
Figure 1. Ex vivo liver 
images of co-
administration of antibiotic 
with Rhodamine Red either 
given in a soluble form or 
encapsulated in 
polyanhydride 
nanoparticles. Mice 
infected with Brucella were 
given high doses of 
doxycycline antibiotic 
either in a soluble form 
(Images 11-20), 
encapsulated in multiple 
polayanhydride 
nanoparticle chemistries 
(21-55). Livers were 
excised and imaged using 
in vivo imaging techniques.  
Fluorescence was 
spectrally unmixed from 
negative controls. 
Fluorescent images were 
overlayed onto white light 
images for localization.   
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Untitled project involving dual hit model of colitis using H. bilis or 
E. coli and DSS to examine inflammation in distinct tissues 
 A dual hit model of colitis was developed utilizing colonization of mice with E. 
coli and then adding an inflammatory insult of an epithelial toxin.  These mice were 
administered an inflammatory probe that was optically active in sites of inflammation.  
Excised cecum and colon tissues at 3 weeks or 12 weeks post colonization were 
examined using in vivo imaging to localize points of inflammation at the end points of 
the study.   
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Recombinant trimeric influenza hemagglutinin elicits high level 
neutralization antibody 
Wuwei Wu, Lucas Huntimer, Kathleen Ross, Balaji Narasimhan, Michael 
Wannemuehler, and Susan Carpenter 
Immunization against the influenza virus remains the paramount preventive 
therapeutic measure to decrease morbidity and mortality in a population while 
minimizing economic impact at the same time [11, 12]. Influenza A virus is a single 
stranded, segmented, negative sense RNA virus that is highly susceptible to genetic 
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drift of its surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) due to 
low fidelity RNA polymerase proofreading [13]. Therefore seasonal influenza A virus 
vaccines consist of multiple antigenic preparations of stains of virus that are 
predicted to be predominant in the upcoming influenza season [14]. Influenza 
viruses also possess the ability to genetically shift genetic components when 
different strains of virus co-infect a susceptible mammal. This particular genetic shift 
scenario presents global health implications in novel recombinations of influenza 
virus that the human population is naïve to as compared to traditional seasonal 
strains of the virus.  In particular, human infection with highly pathogenic avian 
influenza virus (HPAI) H5N1 in which nearly 60% of hospitalized cases resulted in 
mortality attributed to hypercytokinemia [15-17].  Debate wages on the exact lethality 
of human infections with this predominantly avian circulating virus as proper immune 
surveillance of exposed humans in the areas where H5N1 is present is still 
incomplete [18]. Human to human transmission of the virus is limited due to the 
receptor fidelity towards the α 2-3 linked sialic acid motifs of avian species where the 
HA of influenza binds.  Multiple passages of HPAI in a ferret model can lead to 
sufficient evolutionary pressure to force the virus to mutate towards ferret to ferret 
transmission [19, 20]. 
The surface glycoproteins HA and NA are the key antigenic targets of the 
immune response wherein an appropriate humoral response directed towards these 
targets can result in protective immunity. The lack of preexisting immunity against 
H5N1 as well as the potential morbidity and mortality of the virus point to the 
importance of efficacious vaccine preparations against the virus to prevent pandemic 
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spread.  Typical seasonal influenza vaccine preparations require prediction of 
seasonal H1 and H3 strains that may be the most prominent during the particular 
influenza season.  The viruses used for antigen are often propagated in 
embryonated eggs which require multiple passages as well 3- 6 months of lead time 
to prepare [21]. The efficacy of these vaccines are reliant on both preexisting 
immunity to previous H1 and H3 strains as wells as being the correct strains. The 
luxury of predicting which strains of H5N1 virus that would be dominant during a 
pandemic is difficult to gauge as the virus is predominantly of avian origin.  
Recombinant production of the key HA antigens of H5N1 can effectively limit 
the production time of antigen production depending on scaling factors.  Mammalian 
and insect cell culture production systems also add the benefit of glycosylation of the 
proteins important for neutralizing epitope generation [22].  Recombinant production 
of antigens also allows for ease in manipulation of antigens to create the proper 
context of the antigens that would recapitulate the structures identified by the 
immune system during a pathogenic infection.  In particular HA exists as trimer on 
the virion surface of influenza therefore creating a complex where antibodies can be 
generated.  Herein we identify production of a stabilized trimeric form of the HA of 
H5 A/Whooper Swan/244/Mongolia/ 05 (clade 2.2) in a baculovirus insect cell 
expression system using the GCN isoleucine zipper motif.  The stabilized H5 trimer 
was successfully able to elicit neutralizing antibody titers using common human 
approved adjuvants in both a parenteral and a mucosal immunization route 
indicating efficacy of this antigenic production method for stockpiling of H5N1 
pandemic vaccines.    
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Figure 5. Serum neutralizing antibody titer from mice vaccinated with 
recombinant H5-T proteins through intranasal (IN) or subcutaneously (SC) at 
different days post-immunization (DPI) Pseudoviruses H5-WhooperLuc were used 
to titrate the serum neutralizing antibodies (NAbs) from vaccinated mice. A. 
Neutralizing antibody titer of serum NAbs from mice vaccinated with H5-T protein 
without adjuvant.  B. Neutralizing antibody titer of serum NAbs from mice 
vaccinated with H5-T protein with MPLA adjuvant. C. Neutralizing antibody titer of 
serum NAbs from mice subcutaneously vaccinated with H5-T protein and different 
adjuvants.  
 
	  	   268	  
Next Generation Pulmonary Adjuvants Integrating Biological 
Principles with New Technology for Improving Vaccines 
Shannon Haughney, Tim Brenza, Lucas Huntimer, Michael Wannemuehler, Amanda 
Ramer-Tait, and Balaji Narasimhan 
Abstract 
Beginning vaccine design by Edward Jenner is centered on the principle of 
introducing or mimicking a mild pathogenic infection to train the immune system to 
protect against a subsequent severe pathogenic infection. As such, the optimal 
training regimen for the immune system against pathogens of different tissue 
tropisms is to mimic a pathogenic infection in that same tissue site.  Respiratory 
pathogens remain the number one target to design preventive therapeutics against 
because of their ease of transmission, population dynamics of infection, and the 
social and economic impact. Constructing pulmonary vaccines that elicit immune 
responses in respiratory tissues while minimizing reactogenicity remains a lofty goal 
of biomedical research. Adjuvants provide the enhanced immune function against 
the antigen of interest but must straddle the line between engaging the immune 
system without over engagement leading to detrimental immunopathology. Insight 
into immunological mechanisms of innate and adaptive immunity has led to a myriad 
of different applications in pulmonary adjuvant design.  Herein we attempt to outline, 
albeit non-exhaustively, and review advances in pulmonary adjuvants. 
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